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ABSTRACT OF DISSERTATION 
 
 
 
 
FUNCTIONAL PROPERTIES OF L-GLUTAMATE REGULATION IN 
ANESTHETIZED AND FREELY MOVING MICE 
 
 L-glutamate (Glu) is the predominant excitatory neurotransmitter in the 
mammalian central nervous system with involvement encompassing learning and 
memory, cognition, plasticity, and motor movement.  Dysregulation of the 
glutamatergic system is implicated in several neurological disorders including 
Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and amyotrophic 
lateral sclerosis.  The mechanisms underlying these neurological disorders are 
not clear, but evidence suggests that abnormal Glu neurotransmission plays a 
role.  Elevated levels of Glu in the synaptic cleft overstimulate the N-methyl-D-
aspartate receptor leading to excitotoxicity, which causes neuronal loss in 
chronic neurological diseases.  What is less understood is the source for the 
elevated Glu levels.  One hypothesis involves alterations in either activity or 
concentration of Glu metabolizing enzymes.  To study this, two transgenic mouse 
models were developed that increase levels of Glu pyruvate transaminase 
(GPT), responsible for Glu degradation, and Glu dehydrogenase (GLUD1), 
responsible for Glu synthesis.  Our laboratory is interested in studying stimulus-
evoked Glu release and re-uptake dynamics in these mice using an enzyme-
based multisite microelectrode array (MEA) capable of subsecond 
measurements with low detection limits.  Our main finding indicates that GLUD1 
mice have increased release of Glu.   The GLUD1 mice show spontaneous motor 
neuron degeneration of the hind limbs that could be correlated to an excitotoxic 
effect from the increased release of Glu.  We wanted to study these GLUD1, 
motor deficient mice without the affects of anesthesia.  First, we needed to 
modify the current MEAs for use in the awake, freely moving mouse.  In these 
studies we measured resting Glu levels as well as MEA viability with local 
application of 1 mM Glu in both the striatum and prefrontal cortex of C57BL/6 
mice.  No change in MEA sensitivity for Glu was observed on days 3 through 7 
post-implantation.  Resting Glu levels are examined in the striatum of the freely 
moving mouse by locally applying an uptake inhibitor or a sodium-channel 
blocker.  Our studies indicate the resting Glu levels are partially neuronally 
derived and not from reversal of the high-affinity transporters. This 
 
characterization has laid the foundation to study behavioral alterations of Glu in 
the GLUD1 mice. 
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Neurodegeneration 
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Chapter One: Introduction 
 
Intracranial Electrode Applications  
 The idea behind merging technology with the human brain for improving 
quality of life is not a new concept.  In fact, the first documented human cortical 
stimulation was conducted over a century ago (Barthlow, 1874).  When human 
stereotactic devices were developed in the later 1940s, neurosurgeons were able 
to investigate the effects of stimulating deeper brain structures (Spiegel et al., 
1947).  The concept of treating neurological disorders with chronic stimulation 
emerged in the 1960’s, but this was used mainly to pinpoint surgical lesions 
(Perlmutter and Mink, 2006).  Sterotaxic thalatomy and pallidotomy were popular 
neurosurgical techniques for treating disabling tremor until levodopa therapy 
emerged in the 1970s.  Unfortunately, researchers discovered that prolonged 
levodopa therapy resulted in drug related complications for advancing the very 
symptoms the drug was intended to treat.  At this same time, it was discovered 
that chronic stimulation could be used for treating pain (Hosobuchi et al., 1973), 
movement disorders, or epilepsy (Cooper, 1973).  In an effort to find alternative 
therapies for levodopa, pacemaker technology was merged with chronically 
implanted deep brain electrodes for long-term deep brain stimulation (DBS) 
(Benabid, et al., 1991, 1996).  Researchers discovered that a high-frequency 
electrical current can have the same affects as a lesion without the need for 
destroying brain tissue.  Since this time, DBS has been used to treat a variety of 
neurological disorders including essential tremor, Parkinson disease (PD), 
dystonias, tourette syndrome, pain, and obsessive compulsive disorder 
(Perlmutter and Mink, 2006).  Technology has emerged to not only treat patients 
with electrical stimulation, but rather create brain-machine interfaces (BMIs) that 
can translate the electrical activity of neuronal populations and perform the 
desired motor movement.  This would essentially return motor control to severely 
disabled patients suffering from amyotrophic lateral sclerosis (ALS), spinal cord 
injury, stroke, cerebral palsy, and amputees (Lebedev and Nicolelis, 2006). 
  2
 Clearly, intracranial electrode applications such as DBS and BMI hold a 
great deal of promise but much more research is needed to fully understand how 
these devices effect chemical signaling within and between neuronal subregions.  
Neuroscientists have become interested in coupling these techniques with the 
ability to monitor specific neurotransmitters.  Since neurotransmitters such as 
dopamine (DA), L-glutamate (Glu), γ-aminobutyric acid (GABA), and 
acetylcholine (to name a few) are the key chemicals for neuronal signaling 
(Cooper, Bloom, and Roth, 2003) techniques have developed to better 
understand their role in neuronal communication.  The most widely used 
technique for studying neurotransmitters, microdialysis, has several limitations as 
discussed below.  Our laboratory has spent the past 15 years developing an 
enzyme-based microelectrode array (MEA) that is capable of recording specific 
neurochemicals.  These devices have been routinely used in rats, mice, and 
monkeys (both anesthetized and freely moving) to better understand the 
glutamatergic system in relation to various neurological disorders including, but 
not limited to, PD and epilepsy.  The goal is to move this technology into the 
operating room, either by itself or coupled with DBS and BMI, to further enhance 
the quality of life for patients suffering from movement disorders. 
  
An Overview of L-Glutamate Neurotransmission in the Mammalian Central 
Nervous System 
 Glu is the predominant excitatory neurotransmitter in the mammalian 
central nervous system (CNS) existing in all main afferent fibers ascending to the 
brain cortex and in excitatory nerves (Boksha, 2004).  Glu is involved in most 
aspects of normal brain function including cognition, memory and learning, 
plasticity, and motor movement.  As a neurotransmitter, Glu is found in 
glutamatergic neurons, which are defined by the presence of vesicular glutamate 
transporters (VGLUT).  This protein is responsible for loading Glu into synaptic 
vesicles through a proton-dependent electrochemical gradient across the vesicle 
membrane that is created by a vacuolar-type ATPase (Takamori, 2006).  When 
these vesicles dock with the pre-synaptic plasma membrane and release Glu into 
  3
the synaptic cleft there are two different classes of receptors that Glu can 
activate; (a) ionotropic and (b) metabotropic.  Their localizations are shown in 
figure 1.1. 
  Ionotropic Glu receptors (iGluRs) contain three major types, all named 
after the agonists that were originally used to selectively activate them; N-methyl-
D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid 
(AMPA), and 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine (Kainate; KA).  
Table 1.1 outlines some of the agonists and antagonist for NMDA, AMPA, and 
KA receptors.  All three iGluRs are ligand-gated ion channels that are 
predominantly associated with modulating postsynaptic excitability and plasticity 
(Kew and Kemp, 2005; Swanson et al., 2005).  They are also found pre-
synaptically to modulate the release of Glu and other neurotransmitters 
(Engelman and MacDermott, 2004; Galvan et al., 2006).  AMPA and KA 
receptors are believed to be responsible for fast, excitatory neurotransmission 
(Greene and Greenamyre, 1996). Upon Glu binding, both AMPA and KA 
receptors change conformation to allow sodium influx into the post-synaptic 
neuron and depolarize the membrane.  The NMDA receptor is unique in that it 
binds two ligands  (Glu  and  the  coagonist  glycine)  as  well as  being  a  
voltage-sensitive ion channel.  At resting membrane potential, the ion channel is 
blocked by extracellular magnesium which prevents calcium influx irregardless of 
agonist binding.  Since this blockade is voltage-dependent, post-synaptic 
depolarization facilitates NMDA receptor activation.  Upon Glu binding to AMPA 
or KA receptors, sodium enters the post-synaptic neuron leading to membrane 
depolarization.  This removes the magnesium block found in the NMDA channel.  
Upon Glu and glycine binding to the NMDA receptor, the pore opens allowing an 
influx of calcium (Swanson et al., 2005; Gardoni and Di Luca, 2006).  This 
mechanism for receptor activation underlies the fundamental physiological 
function of learning and memory; however, it is also the means by which 
excitotoxicity occurs; in both acute and chronic neurodegeneration (Albin and 
Greenamyre, 1992; Beal, 1992; Greene and Greenamyre, 1996).   
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Figure 1.1:  Glutamate Synapse Schematic 
 
Schematic representation of a typical glutamatergic synapse.  Glu is loaded into vesicle by 
vGluTs and upon depolarization, the vesicles fuse and release the neurotransmitter into the 
synaptic cleft.  Once in the synaptic cleft, Glu can induce downstream signaling by postsynaptic 
neurons through mGluRs and iGluRs.  Sodium-dependent, high-affinity transporters located on 
both glia and neurons are responsible for uptake of Glu with the majority of Glu transported into 
glia and astrocytes.  Gamma aminobutyric acid (GABA) neurons can also be regulated by mGluR 
Groups II and III, which can affect downstream glutamatergic signaling.  Adapted from Schoepp 
et al., 2001.   
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Table 1.1:  Ionotropic Glutamate Receptors  
 
  
(R,S)-2-amino-3-(3-carboxy-5-methyl-4-isoxazolyl)propionic acid (ACPA); 5-tert-butyl-4-
isoxazolepropionic acid (ATPA); (2S,4R) 4-methyl glutamic acid (SYM2081); (2S,4R,6E)-2-
amino-4-carboxy-7-(2-naphthyl)hept-6-enoic acid (LY339434); (±)-cis-4-phosphonomethyl-2-
piperidine carboxylic acid (CGS 19755); (2S*,3R*)-1-(phenanthrene-2-carbonyl)piperazine-2,3-
dicarboxylic acid (PPDA); (R)-2-amino-5-phosphonopentanoate (D-AP5); 2,3-dihydroxy-6-nitro-7-
sulfamoyl-benzo(F)quinoxaline (NBQX); [2,3-dioxo-7-(1H-imidazol-1-yl)-6-nitro-1,2,3,4-
tetrahydro-1-quinoxalinyl]-acetic acid (YM872); [1,2,3,4-tetrahydro-7-morpholinyl-2,3-dioxo-6-
(trifluoromethyl)quinoxalin-1-yl] methylphosphonate (ZK200775); (3S,4aR,6S,8aR)-6-(4-
carboxyphenyl)methyl-1,2,3,4,4a,5,6,7,8,8a-decahydroxyisoquinoline-3-carboxylate (LY382884); 
(R,S)-3-(2-carboxybenzyl)willardiine (UBP296); 5-carboxyl-2,4-di-benzamido-benzoic acid 
(NS3763); (R-(R*,S*)-α-(4-hydroxyphenyl)-β -methyl-4-(phenylmethyl)-1-piperidine propanol (Ro 
25-6981); 1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol (Ro 63-1908/Co 
101244/PD 174494); 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine 
(GYKI 52466); (R)-1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-4,5-dihydro-3-
methylcarbomyl-2,3-benzodiazepine (GYKI 53784/LY303070); (R)-7-acetyl-5-(4-aminophenyl)-  
 
Ionotropic Receptors (iGluRs) 
 
NMDA AMPA Kainate 
Receptor 
Subunits 
NR1, NR2A, NR2B NR2C, 
NR2D NR3A, NR3B 
GluR1, GluR2, GluR3, 
GluR4 
GluR5, GluR6 
GluR7, KA-1 KA-2 
Signal 
Transduction 
Ca2+, Na+ Na+ (Ca2+) Na+ (Ca2+) 
Agonists 
NMDA, Quinolinate 
Homocysteate 
AMPA, ACPA 
L-Quisqualic acid 
Kainic Acid, ATPA 
SYM2081 
LY339434 
Allosteric 
Potentiators 
Glycine, D-Serine 
D-Cycloserine, Spermine, 
Spermidine 
CX516, CX546, CX614 
Cyclothiazide, IDRA-
21, PEPA, LY404187 
LY392098, LY503430 
Concanavillin A  
Antagonists 
CGS 19755, PEAQX PPDA, 
D-AP5 
NBQX, YM872  
ZK200775 
LY382884, 
UBP296   
Allosteric 
Antagonists 
Dizocilpine, Ifenprodil 
Memantine, Ro 25-698 
(+)-CP-101,606 
Ro 63-1908  
Benzimidazole  
Benzamidines 
GYKI 52466 
(R)-LY303070  
(R)-LY300164  
CP-465,022 
CP-526,427 
NS3763 
Channel 
Blockers 
Phencyclidine 
Dizocilpine, Ketamine 
Jorospider toxin N/A 
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Table 1.1:  (continued) 
 
8,9-dihydro-8-methyl-7H-1,3-dioxolo(4,5-h) (2,3) benzodiazepine (GYKI 53773/LY300164); 3-(2-
Chloro-phenyl)-2-[2-(6-diethylaminomethyl-pyridin-2-yl)-vinyl]-6-fluoro-3H-quinazolin-4-one      
(CP-465,022); 2-{2-[3-(2-Chloro-phenyl)-6-fluoro-4-oxo-3,4-dihydro-quinazolin-2-yl]-vinyl}-
nicotinonitrile (CP-526,427); 1-(quinoxalin-6-ylcarbonyl)-piperidine (CX516); 5-carboxyl-2,4-di-
benzoamido-benzoic acid, (NS3763) 1-(1,4-benzothiadiazine 1,1-dioxide (CX546); 2H,3H,6aH-
pyrrolidino[2”,1”-3’2’]1,3-oxazino[6’5’-5,4]benzo[e]1,4-dioxan-10-one (CX614); 7-chloro-3-methyl-
3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide   (IDRA-21); (4-[2-
(phenylsulphonylamino)ethylthio]-2,6-difluorophenoxyacetamide (PEPA); (R,S)-N-2-(4-(3-
thienyl)phenyl)propyl-2-propanesulfonamide (LY392098); N-2-[4-(4-cyanophenyl)phenyl]propyl 2-
propanesulphonamide (LY404187); (R)-4-[1-fluoro-1-methyl-2-(propane-2-sulphonylamino)-
ethyl]-biphenyl-4-carboxylic acid methylamide (LY503430)  
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 Metabotropic Glu receptors (mGluRs) are G-protein coupled receptors that 
regulate Glu release and modify postsynaptic excitability to Glu, high-affinity Glu 
transporters, and vGluTs (Swanson et al., 2005).  Since mGluRs rely on second 
messenger responses, they are generally slower than iGluRs.  These receptors 
contain seven alpha-helical transmembrane domains with a ligand binding site 
located on the extracellular N-terminus (Kew and Kemp, 2005).  mGluRs are 
classified into three groups.  Group I (mGlu1 and mGlu5) are excitatory receptors 
localized on glial and post-synaptic, glutamatergic neurons.  Group II (mGlu2 and 
mGlu3) receptors are inhibitory.  mGlu2 is located primarily on pre-synaptic 
glutamatergic terminals, while mGlu3 is expressed on both glial and pre- and 
post-synaptic glutamatergic neurons.  Finally, Group III (mGlu4, mGlu6, mGlu7 
and mGlu8) are also inhibitory receptors, but they are not as specific for 
glutamatergic neurons.  mGlu4 and mGlu7 receptors are located both pre- and 
post-synaptically on both glutamatergic and other neurotransmitter synapses.  
mGlu8 is localized primarily on pre-synaptic glutamatergic and other 
neurotransmitter terminals, while mGlu6 expression is only confirmed on retinal 
cells.  (Refer to Table 1.2 for further information regarding mGluRs).   
  Proper activation of Glu receptors requires that extracellular 
concentrations of Glu be kept low for a high signal-to-noise ratio in synaptic 
transmission, thus allowing for stimulation with low levels of neurotransmitter 
release.  No extracellular enzymes for Glu metabolism have been identified, so 
Glu clearance from the extracellular space is achieved by means of sodium-
dependent, high-affinity transporters located primarily on glial cells.  These 
transporters are more commonly known as excitatory amino acid transporters 
(EAATs).   The uptake process is electrogenic and is therefore stimulated by a 
negative membrane potential, which is maintained by the sodium/potassium 
adenosine triphosphatase (Na+/K+ ATPase).  Sodium is required for Glu binding 
while potassium is required for net transport of Glu through the EAATs.  To be 
precise, for every 1 molecule of Glu transported into the cell, 3 sodium ions and 1 
hydrogen ion are cotransported, while one potassium ion is transported out of the 
cell (Takahashi et al., 1997; Danbolt, 2001; Kanai and Hediger, 2004; Grewer 
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Table 1.2:  Metabotropic Glutamate Receptors  
 
 Receptor G-Protein Glutamatergic Localization and Functions Agonist Antagonist 
mGluR1 Post-synaptic; activation enhances excitability 
DHPG  
ACPD  
quisqualate 
LY393675 
LY367385 
G
ro
up
 I 
mGluR5 
Gq; 
increase 
PLC Post-synaptic; also found in 
glia; indicated in synaptic 
plasticity 
DHPG 
quisqualate
CHPG 
MPEP 
 
mGluR2 Pre-synaptic; linked to LTD 
G
ro
up
 II
 
mGluR3 
Go; 
decrease 
AC 
Pre- and post-synaptic; found 
on glia where it is linked to 
neurotropin release 
DCG-IV 
APDC 
ACPD 
LY354740 
LY379268 
EGLU 
LY404039 
LY341495 
mGluR4 Pre- and post-synaptic; linked to motor learning 
L-SOP 
ACPT-1 
L-AP4 
MSOP 
MAP4 
CPPG 
mGluR6 Expression localized to retinal tissue 
 
mGluR7 
Pre- and post-synaptic; 
autoreceptor 
L-SOP 
L-AP4 
G
ro
up
 II
I 
mGluR8 
Go; Gi 
decrease 
AC 
Pre-synaptic; regulation of 
lateral perforant path 
L-SOP 
L-AP4 
DCPG 
MSOP 
MAP4 
 
3,5-dihydroxyphenylglycine, DHPG; (1S,3S)-1-aminocyclopentane-1,3-dicarboxylic acid, ACPD; 
2-(S)-amino-2-(3-cis-carboxycyclobutyl)-3-(9H-thioxanthen-9-yl) propionic acid, LY393675; [(+)-2-
methyl-4-carboxyphenylglycine], LY367385; (RS)-2-chloro-5-hydroxyphenylglycine, CHPG; 2-
methyl-6-(phenylethylnyl)-pyridine, MPEP; (2S, 2’R,3’R)-2-(2’,3’-dicarboxycyclopropyl)glycine, 
DCG-IV; 2R,4R-4-aminopyrrolidine-2,4-dicarboxylic acid, APCD; (1S,2S,5R,6S)-2-
aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate, LY354740; (-)-2-oxa-4- 
aminobicyclo[3.1.0]hexane-4,6-dicarboxylate, LY379268; (S)-α-ethylglutamic acid, EGLU; (-)-
(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid, LY404039; L(+)-2-
amino-4-phosphonobutyric acid, LY341495; S-serine-O-phosphate, L-SOP; (1S,3R,4S)-1-
aminocyclo-pentane-1,3,4-tricarboxylic acid, ACPT-1; L(+)-2-amino-4-phosphonobutyric acid, L-
AP4, (RS)-alpha-methylserine-O-phoshate, MSOP; (S)-2-amino-2-methyl-4-phosphonobutanoic 
acid/alpha-methyl, MAP4; (RS)-4-phosphonophenyl glycine, CPPG; (S)-3,4-
dicarboxyphenylglycine, DCPG 
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and Rauen, 2005).   To date, five Glu transporters have been cloned and 
numbered EAAT1-5.  EAAT1 (Glu-Aspartate Transporter (GLAST) in rodents) 
and EAAT2 (Glu Transporter (GLT-1) in rodents) are responsible for the majority 
of Glu uptake in the mammalian CNS and both are located exclusively on glial 
cells.  Glu transporters differ in brain localization; EAAT1 predominates in the 
cerebellum, while EAAT2 is the major Glu transporter of the forebrain.  EAAT3 
(Excitatory Amino Acid Carrier (EAAC1) in rodents) is expressed in the lowest 
concentration compared to the others and thought to account for a small 
percentage of Glu uptake.  It has a wide expression throughout the mammalian 
brain, located primarily on neurons.  EAAT4 is found in Purkinje cells of the 
cerebellar molecular layer, while EAAT5 is found in the retina.  For a 
comprehensive review on Glu transporters, refer to Danbolt, 2001.   
 
Excitotoxicity 
 While Glu normally functions as a neurotransmitter; excessive stimulation 
of Glu receptors can cause neuronal degeneration by a mechanism termed 
excitotoxicity (Olney, 1978).  Olney and colleagues defined this process as “a 
phenomenon whereby the excitatory action of Glu and related excitatory amino 
acids becomes transformed into a neuropathological process that can rapidly kill 
CNS neurons.”  Excitotoxic cell death involves prolonged depolarization of 
neurons, changes in intracellular calcium concentrations, and the activation of 
enzymatic and nuclear mechanisms of cell death (Doble, 1999).  In the classical 
model of excitotoxicity, post-synaptic depolarization is initiated by activation of 
AMPA receptors and voltage-dependent sodium channels, leading to sodium 
entry and further depolarization.  To maintain ionic equilibrium, chloride ions 
enter the cell along with water that is following the osmotic gradient.  Entry of 
water causes osmotic swelling of the cell, but the process is reversible and 
therefore is not the final mechanism of excitotoxicity (Choi, 1987).  Instead, the 
calcium-dependent part of the cascade seems essential for toxicity and cellular 
death.   Depolarization of the membrane by sodium leads to opening of voltage-
sensitive calcium channels as well as removal of the magnesium block on the 
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NMDA receptor.  These are the two primary sources for calcium entry into the 
cell.  This appears to be the irreversible step and the ability of the neuron to 
survive this calcium influx may depend on intracellular organelles, such as the 
mitochondria or endoplasmic reticulum, to buffer the influx of calcium (Doble, 
1999).  If the neuron is unable to buffer the large quantities of calcium entering 
the cell, calcium can overstimulate proteases, protein kinases, and nitric oxide 
synthetases.  This leads to production of free radicals or apoptotic mechanisms 
and eventually cell death (Nicholls and Budd 2000; Sattler and Tymianski, 2000).   
 During the time course of excitotoxicity, the extracellular concentrations of 
Glu rise for three main reasons.  First, influx of calcium leads to vesicular release 
of Glu from pre-synaptic neurons.  Second, more Glu is being released into the 
extracellular space due to cell lysis. Finally, since Glu transport is electrogenic, 
membrane depolarization can slow down or even reverse these transporters 
keeping Glu in the extracellular space for prolonged periods of time (Doble, 
1999).  This increase in extracellular Glu can diffuse to nearby neurons, thus 
propagating and amplifying cell death.   
 The above process is most commonly seen in stroke, ischemia, and 
traumatic brain injury and referred to as acute excitotoxicity.  Evidence exists for 
a slower, indirect form of excitotoxicity involved with chronic neurodegenerative 
diseases.  In this form of excitotoxicity, mitochondria become damaged leading to 
energy impairment and subsequent decrease in intracellular ATP levels (Beal, 
1992; Greene and Greenamyre, 1996; Doble, 1999).  As ATP levels decrease, 
the Na+/K+ ATPase, responsible for maintaining the resting membrane potential 
slows down leading to depolarization.  This can relieve the magnesium block on 
NMDA channels as well as open voltage-gated calcium channels.  With the 
magnesium block removed, the NMDA receptor is more susceptible to activation 
by ambient or even slightly elevated levels of extracellular Glu (Beal, 1992; 
Greene and Greenamyre, 1996; Doble, 1999). Over prolonged periods of time 
(years) this process becomes similar to what is seen in acute excitotoxicity.  For 
this reason, it has been postulated that slow, indirect excitotoxicity is partly 
responsible for the neuronal loss seen in several neurodegenerative disorders 
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including amyotrophic lateral sclerosis (ALS).  ALS is characterized by 
progressive muscular weakness leading to paralysis and eventual death due to 
respiratory failure (Williams and Windebank, 1991).  This neurodegenerative 
disease has the largest body of evidence supporting excitotoxicity contributes to 
the progression of symptoms (Doble, 1999).  Several studies have suggested 
that there is a defect in Glu metabolism (Heath and Shaw, 2002; Rao and Weiss, 
2004) causing elevated levels of the neurotransmitter Glu in the cerebrospinal 
fluid (Rothstein et al., 1990; Shaw et al., 1995; Spreux-Varoquaux et al., 2002) of 
ALS patients compared to control patients.  The failure to properly metabolize 
Glu may result in raised extracellular Glu levels that overtime could contribute to 
excitotoxic and motorneuron degeneration described above. 
 
L-Glutamate Metabolism 
 Metabolic compartmentation in the brain was first demonstrated by Lajtha 
and colleagues (1959) when they injected [14C] Glu into the rat brain and found 
that glutamine was the predominant molecule containing the isotope.  They 
interpreted this data as glutamine was formed exclusively from a “small” pool of 
Glu that rapidly accumulates Glu and synthesizes glutamine (Hertz, 2004).  
Computer simulation studies over the next decade by Van den Berg and 
Garfinkel (1971) showed the flow of Glu from a “large” compartment where it was 
degraded to glutamine in a “small” compartment and an identical flow of 
glutamine in the opposite direction.  This process became known as the 
Glutamate-glutamine cycle (Benjamin and Quastel, 1975).  But, it wasn’t until the 
selective localization of glutamine synthetase that the “small” pool was 
determined to be astrocytes (Norenberg and Martinez-Hernandez, 1979). Since 
glutamine synthetase is absent in neurons, this meant all neuronal constituents 
constitute the “large compartment.”   
 Today, the Glutamate-glutamine cycle is a well understood mechanism.  
Upon depolarization and vesicular release of Glu, it is taken up into astrocytes by 
high affinity transporters (Danbolt, 2001).  Once in the astrocytes, Glu is 
aminated into glutamine by glutamine synthetase that is localized only in 
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astrocytes.   Glutamine is not neurotoxic and therefore it can be safely 
transported out of the astrocytes through System N located on astroglial cells. In 
the extracellular space, glutamine is transported into neurons through System A 
(Bak et al., 2006).  When returned to the neuron, glutamine is converted back 
into Glu by posphate-activated glutaminase (PAG), which is located on the inner 
mitochondrial membrane (Kvamme et al., 2000).  The Glu formed is returned to 
the cytosol and subsequently packaged into vesicles for future neurotransmitter 
signaling.   
 Since neurons are incapable of net synthesis of Glu from glucose 
(Waagepetersen et al., 2005), the Glutamate-glutamine cycle was previously 
thought to provide neurons with all the Glu necessary for neurotransmitter 
signaling.  Because of this theory, the Glutamate-glutamine cycle was originally 
thought to operate in a stoichiometric one-to-one ratio.  For every Glu released, 
one glutamine was transported into neurons to replenish the neurotransmitter 
pool of Glu.  However, recent evidence suggests this process is oversimplified 
and other enzymes must be responsible for replenishing the neurotransmitter 
pool of Glu (Fonnum, 1993; Peng et al., 1993; Broman et al., 2000; 
Waagepetersen et al., 2000; Danbolt, 2001; Waagepetersen et al., 2005).  It is 
now known that Glu is metabolically closely related to the tricarboxylic acid (TCA) 
cycle (Waagepetersen et al., 2005).  For example, when Glu is transported into 
astrocytes, it can be metabolized into glutamine by glutamine synthetase or 
transaminated into α-ketoglutarate.  Alpha-ketoglutarate can then enter the TCA 
cycle where it is eventually metabolized into malate, and malate can be 
decarboxylated into pyruvate and reduced to lactate.  Lactate can be transported 
out of astrocytes and into neurons by monocarboxylate transporters (Gladden, 
2004; Pierre and Pellerin, 2005).  Once in the neurons, lactate can be oxidized to 
pyruvate and either re-enter the TCA cycle or it can be transaminated back into 
Glu for neurotransmitter packaging and signaling.  (Please refer to Figure 1.2).  
This example highlights one of the many possible fates of Glu and is used to 
show the complicated competition for Glu between cellular energy demands and 
neurotransmitter signaling.  Furthermore, Hassel and Bråthe (2000) 
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Figure 1.2:  The Glutamate-Glutamine Cycle Revisited 
 
Schematic representation of Glu synthesis between astrocytes and neurons.  The classic 
Glu/glutamine cycle is highlighted in the purple, dashed box.  All enzymes are shown in RED, 
while dashed arrows indicate multiple metabolic steps that are not shown due to size limitations.  
The terms “mito” and “cyt” indicate either mitochondrial or cytoplasmic localization, respectively.  
Figure modified from Waagepetersen et al., 2000.    
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demonstrated that it is possible to obtain Glu formation independent of glutamine.  
This implies that enzymes other than PAG and glutamine synthetase are 
responsible for de novo synthesis or degradation of Glu.  Two such Glu 
metabolizing enzymes found in neurons are glutamate pyruvate transaminase 
(GPT) and glutamate dehydrogenase (GLUD1). 
 
Glutamate Pyruvate Transaminase 
 GPT exists as a dimer with a molecular mass of approximately 100 kDa in 
most species (Saier and Jenkins, 1967).  The enzyme catalyzes a reversible 
transaminase reaction using pyruvate as a co-substrate to form alanine and α-
ketoglutarate (Figure 1.3A).  Biochemical studies show GPT activity in both the 
cytosol and mitochondria of astrocytes and neurons (Balazs and Haslam, 1965; 
Erecińska et al., 1994), but the greatest activity is found in astrocytes of the 
cerebral cortex (Westergaard et al., 1993).  It is debated throughout the literature 
whether GPT favors Glu degradation (Saier Jr. and Jenkins, 1967; Ruščák et al., 
1982; Erecińska et al., 1994) or synthesis (Peng et al., 1991, 1993; Schousboe et 
al., 2003).  This process most likely depends on the amount of 
substrates/products available.  However, Matthews and colleagues (2000, 2003) 
demonstrated that GPT is an active Glu degrading enzyme that acts as an 
effective neuroprotectant in cell culture models of exogenous and endogenous  
Glu excitotoxicity.  Unfortunately, GPT does not exist in the extracellular space 
and, due to its large size, is unable to cross the blood-brain barrier.  This makes 
it an unsuitable candidate for excitotoxicity thereapeutics; nevertheless these 
studies demonstrate the propensity for GPT to metabolize Glu.   
 
Glutamate Dehydrogenase 
 Similar to GPT, GLUD1 catalyzes a reversible reaction; however, this 
reaction favors Glu formation from ammonia and α-ketoglutarate, using NAD(P)+ 
as co-factors as shown in figure 1.3B (Yudkoff et al., 1991; Kanamori and Ross, 
1995; Bak et al., 2006).  GLUD1 is composed of six identical subunits, each with 
a molecular mass of 56 kDa (Mastorodemos et al., 2005).  Biochemical and 
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Figure 1.3:  Glutamate Metabolic Pathways 
 
A) Glu metabolism by Glutamate Pyruvate Transaminase.  B) Glu synthesis by Glutamate 
Dehydrogenase. 
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histochemical studies show GLUD1 is localized to the inner mitochondrial 
membrane of neurons (Toledano et al., 1979; Rothe et al., 1990; McKenna et al.,  
2000), while immunohistochemical studies show astrocytic localization (Kaneko 
et al., 1987).  This suggests that GLUD1 is ubiquitously expressed in 
mitochondria throughout the mammalian brain (Madl et al., 1988).  Recently, 
however, two isoforms of Glu dehydrogenase (GLUD1 and GLUD2 have been 
identified in humans and primates (Burki and Kaessmann, 2004), which may 
account for the discrepancies in localization.  GLUD1 is considered a 
housekeeping gene ubiquitously expressed throughout mammals while GLUD2 
is a brain-specific isotype found in primates and humans (Plaitakis and Zaganas, 
2001; Burki and Kaessmann, 2004; Mastorodemos et al., 2005; Kanavouras et 
al., 2007).  Burki and Kaessmann (2004) demonstrated that GLUD2 formed by 
retroposition of GLUD1 to the X chromosome in primates 23 million years ago 
and may be indicative of higher thought processes.  In humans, these two 
isoforms are homologous differing in only 16 amino acids (Kanavouras et al., 
2007).  Because the retroposition occurred in primates, rodents only have the 
GLUD1 copy. 
  GLUD1 is thought to be controlled by cellular energy demands since it is 
allosterically stimulated by ADP and inhibited by ATP (Smith, 1979; Plaitakis and 
Zaganas, 2001).  This indicates that the activity of the enzyme can operate in the 
direction of oxidative deamination when cellular supplies of ATP are low. By 
converting Glu to α-ketoglutarate the mitochondria is provided with essential 
reducing equivalents, through NAD(P)H, for synthesis of ATP.  In addition, the α-
ketoglutarate formed can be metabolized in the TCA cycle for further production 
of ATP.  This has been supported by studies examining pancreatic beta cells and 
modulation of GLUD1 to regulate insulin release (Gylfe, 1976; Stanley et al., 
1998).   
 Several studies examining post-mortem CNS tissue have determined that 
increases in GLUD1 activity are associated with several different neurological 
disorders.  Malessa and colleagues (1991) found that GLUD1 activity was 
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significantly increased in the ventral white matter and in the dorsal horn of the 
spinal cord in ALS patients compared to control.  It is well documented that Glu 
levels are increased in the CSF of ALS patients (Rothstein et. al, 1990; Doble, 
1999; Heath and Shaw, 2002; Spreux-Varoquaux et al., 2002).  Since the 
GLUD1 reaction favors Glu formation, this finding by Malessa and colleagues, 
suggests a causative relation for the increased levels of Glu.  These CSF Glu 
levels may be high enough to cause excitotoxicity and damage the lower motor 
neurons—a hallmark of ALS.  Burbaeva and colleagues (2005) determined that 
GLUD1 was increased in brain tissue homogenate from the prefrontal cortex 
(PFC) of Alzheimer’s disease (AD) patients compared to control patients.  
Additionally, the same group (Burbaeva et al., 2003, 2007) determined that 
GLUD1 activity was increased in the PFC of schizophrenic patients compared to 
control patients.  In both studies this group concludes that alterations in Glu 
metabolizing enzymes may be responsible for changes in the extracellular 
concentration of Glu.  The results of all of these independent studies strongly 
suggests that increased GLUD1 activity is involved in three different neurological 
disease states. 
 
Techniques for Measuring L-glutamate: Microdialysis 
 Microdialysis is a technique that utilizes semipermeable membranes to 
restrict the diffusion of extracellular molecules or neurotransmitters along their 
concentration gradients. (Ungerstedt, 1984; Di Chiara et al., 1996). A 
microdialysis probe consists of a cylindrical dialysis membrane with inlet and 
outlet tubes.  These probes have a diameter of 150-400 µm with an average 
length of 1-4 mm (Kennedy et al., 2002).  Dialysis probes are stereotaxically 
compatible and therefore have been used in both anesthetized and awake 
animal models.  Once implanted, dialysate samples are collected every 5 to 20 
minutes and experiments can last from hours up to 3 or 4 days (Westerink, 
1995).  Collected fractions are generally analyzed using analytical chemistry 
techniques. High performance liquid chromatography coupled with 
electrochemical or fluorescence detection is often used due to their sensitivity 
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and ability to handle small sample sizes (< 10 µl) (Westerink, 1995).  The high 
sensitivity of the analytical techniques allows for detection of low concentration of 
analytes in the femtomolar range (Kennedy et al., 2002).  Another advantage of 
microdialysis is the ability to measure multiple analytes simultaneously thus 
allowing the researcher to study several neurotransmitter systems at once.  
Despite how commonplace the technique has become in the laboratory, there 
are several large disadvantages that make microdialysis unsuitable for 
measuring Glu.   
 Due to the high-affinity transporters, Glu neurotransmission lasts on the 
order of milliseconds to seconds (Kinney et al., 1997).  Since dialysate samples 
are collected over minutes, Glu release and re-uptake is often missed or grouped 
together into larger pools within the samples, which makes it exceptionally 
difficult to study behavioral paradigms.  Recent advances in the collection and 
analyzing methods have increased the time resolution into the range of seconds.  
Lada and colleagues (1997) showed that using capillary electrophoresis coupled 
with laser-induced fluorescence detection resulted in sample collection every 12 
seconds.  That same year, Tucci and colleagues (1997) demonstrated a similar 
method with samples collected every 6 seconds.  However, the fastest collection 
time published was by Rossell and colleagues (2003) that demonstrated a 1-
second collection method.  For these methods, dialysate samples are collected in 
a tube and this tube is cut into specific lengths corresponding to the desired 
collection time (Kennedy et al., 2002).  This is a controversial method because 
diffusion through the tubing (band broadening) can affect concentration values in 
different time intervals, if the tubing is not cut immediately (Rossell et al., 2003).  
Also, the flow rates and dead volume can drastically change the temporal 
response, which suggests band broadening is responsible for a sluggish 
response to analyte in the fractions collected (Lada et al., 1997).  In this paper, 
Lada goes onto explain that band broadening within the dialysis probe or tubing 
prevents this method from achieving faster than a 10 second temporal response.  
This brings into question the validity of the Rossell study claiming 1 second 
response times. 
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 The large size of the microdialysis probe causes substantial short- and 
long-term trauma, which is evidenced by histological, physiological, and 
biochemical changes in nearby CNS tissue (Bungay et al., 2003).  During the first 
hours after implantation the blood-brain barrier is disrupted, blood flow to the 
tissue surrounding the probe is decreased and release of neurotransmitters is 
altered (Westerink, 1995).  Positron emission tomography (PET) imaging has 
revealed that glucose metabolism is drastically and irreversibly altered by chronic 
implantation of a microdialysis cannula/probe (Schiffer et al., 2006).  Three days 
after implantation a glial barrier is observed and may account for probe blockage 
(Benveniste and Diemer, 1987).  This glial barrier is markedly increased if 
nonfunctional microdialysis probes are removed and functional probes are 
reinserted in an attempt to continue freely moving studies within the same animal 
(Georgieva et al., 1992). Clapp-Lilly and colleagues (1999) demonstrated that 
ultrastructural damage occurs up to 1.4 mm away from a microdialysis probe 
implant site.  In addition, perfusion and removal of material by the probe may 
produce concentration gradients that can further damage tissue up to several 
millimeters away from the implant site (Bungay et al., 1990).  The implantation 
damage caused by microdialysis probes has drastic effects on local 
neurotransmitter dynamics. Carbon fiber microelectrodes coupled with 
voltammetric techniques were used to demonstrate that evoked dopamine 
release is attenuated up to 220-250 µm from the microdialysis probe implant site 
(Yang et al., 1998; Borland et al., 2005).  If this probe-induced trauma along with 
glial barrier formation is not taken into account for microdialysis analysis, the 
estimation of extracellular concentrations and clearance of neurotransmitters 
such as DA and Glu can be underestimated (Lu et al., 1998; Yang et al., 1998; 
Bungay et al., 2003).  Furthermore, Frumberg and colleagues (2007) 
demonstrated that rats implanted with microdialysis probes performed 
significantly worse in object recognition tasks despite no change in locomotor 
activity.  These studies demonstrate the excessive damage caused by a dialysis 
probe as well as question the physiological validity of dialysis samples. 
  20
 Finally, previous microdialysis studies indicate that resting Glu levels are 
virtually tetrodotoxin (TTX) and calcium-independent (Timmerman and 
Westerink, 1997).  This does not fulfill the classical criteria for excytotoxic release 
thus raising doubt as to the vesicular origin of Glu.  Several laboratories have 
also demonstrated that increases in neurotransmitters due to stress are largely 
TTX-independent as well.  These studies indicate that physiological release of 
Glu, whether it be resting or stimulated, is from non-neuronal sources such as 
reversal of the high-affinity transporters (Kanai and Hediger, 2004). However, 
little data supports this hypothesis.  Instead, since Glu released from neuronal 
pools is rapidly cleared and has limited diffusion, it has been hypothesized that 
microdialysis fails to reliably sample synaptic pools of Glu (Drew et al., 2004).   
Drew and colleagues claim that the current microdialysis probes sample from too 
large of an area to reliably measure changes close to the synapse.  For this 
reason, the relevance of using microdialysis to study Glu neurotransmission is 
uncertain.   
 
Techniques for Measuring L-glutamate: Amperometric Detection with 
Microelectrode Arrays 
 The poor temporal and spatial resolution as well as the severe damage on 
CNS tissue due to implantation has warranted more reliable techniques that are 
less invasive for the study of Glu.  Within the past decade several groups have 
developed Glu selective microelectrodes to address the above inconsistencies 
with microdialysis studies on glutamatergic physiology (Hu et al., 1994; Rahman 
et al., 2005) and some studies utilizing these microelectrodes have shown that 
Glu is TTX-dependent (Kulagina et al., 1999; Day et al., 2006; Oldenziel et al., 
2006). Our laboratory has developed an enzyme-based multisite microelectrode 
array (MEA) that uses amperometric recording techniques with subsecond 
measurements (Burmeister et al., 2000; Burmeister and Gerhardt, 2001; 
Burmeister et al., 2002; Nickell, et al., 2004; Day et al., 2006; Nickell et al., 2007).  
These MEAs have 4 platinum (Pt) recording sites each measuring 333 X 15 µm, 
and because of the small size, the MEAs have been shown to cause minimal 
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damage to surrounding CNS tissue and are viable for at least one week post-
implantation (Rutherford et al., 2007).  Furthermore, through a specific coating 
technique that is referred to as self-referencing, our laboratory is able to 
selectively measure resting Glu levels and consistently demonstrate that resting 
Glu levels are TTX-sensitive (Day et al., 2006).  For a thorough explanation 
regarding the MEAs and self-referencing, please refer to Chapter Two: Materials 
and Methods. 
 
Mouse Models 
 The mouse model has many advantages as an experimental animal 
model.  They have a unique adaptation and ability to survive inbreeding (Joyner 
and Sedivy, 2000), they have a short generation turnover and low maintenance 
cost for breeding, housing, and drug administration (Cryan and Holmes 2005; 
Jacobson and Cryan, 2007).  More importantly, mouse and humans share close 
metabolic and anatomical similarities.  Genes between the two species are 
greater than 99% conserved (Consortium, 2002).  This provides the researcher 
with a model system to study human diseases including diabetes, cancer, 
immunological, and neurological disorders.    
 Inbred mice strains offer several additional advantages to those already 
mentioned including genetic and phenotypic uniformity.  This uniformity reduces 
the number of animals needed for experiments, because variability is limited to 
extragenetic or varying controllable environmental factors.  In particular, the 
inbred mouse is a valuable tool for studying the aforementioned human diseases.  
Since inbred strains trace back to a common ancestor, they are considered 
isogenic and homozygous at all loci. (Beck et al., 2002), which indicates that 
differences between mouse strains as well as genetically modified mice and 
wildtype (WT) littermates is a function of the change in genotype (Crabbe et al., 
2002; Lesch, 2004; Festing, 2004).    
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Thesis Outline 
 The present studies address the use of these MEAs to study Glu 
dynamics in both anesthetized and awake, freely moving mice.  For our 
anesthetized studies, we studied the importance of GPT and GLUD1 on the 
neurotransmitter pool of Glu.  Since no specific modulators for either of these 
enzymes exist, we used transgenic mouse models that were developed at the 
University of Kansas by Dr. Elias K. Michaelis’s group.  The remainder of the 
work addresses the adaptation and validation of the MEAs for use in awake, 
freely moving mice.  It serves to develop and characterize a new technique as 
well as expand upon the current knowledge regarding resting Glu levels in the 
freely moving mouse.  The long-term goal is to incorporate the freely moving 
technology with the GPT and GLUD1 transgenic mouse models, so we can 
determine if altering Glu metabolizing enzymes has any effect on behavior.  
 In Chapter Three, we investigated how upregulation of GLUD1 affects 
stimulus-evoked Glu release and uptake as well as exogenously applied Glu in 
the striatum (Str) of two inbred mouse strains: C57BL/6 and BALB/C.   We 
examined two different mouse strains due to histochemical data acquired at the 
University of Kansas that revealed C57BL/6 mice have endogenously higher 
levels of GLUD1 protein compared to BALB/C mice.  Local application of 70 mM 
KCl resulted in a significant increase in Glu release in both strains of GLUD1 
transgenic mice compared to WT littermates.  Furthermore, uptake of 70 mM 
KCl-evoked Glu release as well as clearance of 5 mM Glu was similar for the 
GLUD1 transgenic mice compared to WT littermates in both mouse strains.  At 
16 months of age, the C57BL/6 GLUD1 transgenic mice developed lower limb 
atrophy that resulted in severe gait disorders and righting problems.  Histological 
data conducted at the University of Kansas revealed severe atrophy of Betz cells 
within the motor cortex and atrophy of lower motor neurons in the spinal cord.  To 
our knowledge, this is the first animal model that displays a late onset 
neurodegeneration, similar to what is observed in patients suffering from ALS. 
 In Chapter Four we examined how upregulation as well as knockout (KO) 
of the GPT gene affects Glu neurotransmission in C57BL/6 mice.  Similar to 
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studies in Chapter Three, we investigated stimulus-evoked Glu release and 
uptake as well as clearance of exogenously applied Glu in the Str.  In the GPT 
transgenic mice, we did not observe any differences in stimulus-evoked Glu 
release, but did observe significantly slower uptake dynamics of both stimulus-
evoked Glu and exogenously applied Glu.  In the GPT KO mice, homozygous 
mice released significantly more Glu compared to WT littermates.  We also 
observed that GPT homozygous KO mice cleared exogenously applied Glu 
slower compared to WT.  Despite these differences, we have not observed any 
noticeable phenotypic or behavioral alterations due to upregulation or KO of the 
GPT gene.  
 In Chapter Five we wanted to study the GLUD1 motor deficient mice in an 
awake, freely moving mouse model.  Before we could do this, we had to develop 
and characterize our current freely moving technology for a mouse model.  We 
adapted our current technology for freely moving rats to make the recording 
apparatus smaller and lighter weight for recordings in the awake mouse.  Using 
our self-referencing MEAs that were selective for Glu measures, we reliably 
measured Glu for 7 days post-implantation in both the Str and PFC of the 
C57BL/6 mouse.  Through an attached guide cannula we locally applied a 
solution of 1 mM Glu and saw no loss in MEA sensitivity on days 3 through 7 
post-implantation.  However, we did observe changes in both uptake rate and 
time for 80 percent of the Glu signal decay (t80) over days.  Uptake rate became 
slower, while the t80’s became longer over days in both the Str and PFC.  With 
our self-referencing MEAs we were able to measure resting Glu levels in both 
brain areas and found that the Str had elevated resting Glu levels compared to 
the PFC.  Through the attached guide cannula we locally applied DL-threo-β-
hydroxyaspartate (THA), a non-selective Glu transport blocker and tetrodotoxin 
(TTX), a potent sodium-channel blocker to pharmacologically alter resting Glu 
levels.  We found that local application of THA increased resting Glu levels since 
the uptake was blocked, while TTX decreased resting Glu levels because 
neuronal depolarization and subsequent vesicular release of Glu was prevented.  
These two studies indicate that the source of resting Glu levels in the Str is at 
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least partially neuronally derived and not from reversal of the high-affinity 
transporters.  Finally, we measured Glu changes due to a stressor.  Introduction 
of a fox urine soaked cotton ball into the recording chamber resulted in an 
increase in Glu levels throughout the duration of the stressor.  Glu levels returned 
to baseline 15 minutes after the stressor was removed.  The ability to monitor Glu 
without anesthesia allowed us to study Glu dynamics for at least 7 days post-
implantation. When we couple this finding with our changes in Glu from a 
stressor such as fox urine we can design behavioral paradigms to better 
understand physiological release and uptake of Glu and apply this technique to 
better understand the role of Glu metabolizing enzymes on the neurotransmitter 
pool of Glu 
 
Copyright © Kevin Nicholas Hascup 
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Chapter Two: Materials and Methods 
 
Principles of In Vivo Electrochemistry 
In vivo electrochemistry utilizes microelectrodes that were implanted into 
the mammalian CNS providing a means to record chemical signaling of neurons.  
The microelectrode’s recording surface, or working electrode (normally an inert 
metal such as Pt or carbon, could oxidize or reduce compounds of interest.  A 
potential was applied versus a reference electrode, normally a Ag/AgCl reference 
electrode that was in ionic contact with the working microelectrode.  Low noise 
headstages, which include potentiostats, apply this potential and were computer-
controlled with multiple inputs to simultaneously record from several 
microelectrodes or several recording surfaces on a single MEA.  If the potential 
at the microelectrode surface was sufficient, molecules directly at the recording 
surface of the working electrode were either oxidized or reduced depending upon 
their intrinsic electrochemical properties.  Oxidized molecules donate one or 
more electrons to the recording surface while reduced molecules receive 
electrons from the recording surface.  The currents generated from those 
Faradaic reactions were linear with respect to concentration of the electroactive 
molecule(s) in the tissue surrounding the microelectrode.  This basic principle 
allows for in vitro calibration methods for in vivo studies.   
 One of the simplest electrochemical techniques was amperometry and 
involves the measurement of current at a constant fixed potential.  The current 
was continuously monitored, thus, events were measured as quickly as ≤ 1 ms.  
Since the voltage was applied continuously to the working electrode, the non-
Faradaic background current recorded from the microelectrode was low and 
allowed for sensitive measurements of electrochemically active molecules.   
Several neurochemicals reside in the extracellular space of the CNS that 
were electrochemically active on Pt recording surfaces at low or high oxidation 
potentials including ascorbic acid (AA), dopamine (DA), norepinephrine (NE), 
serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), homovanillic acid (HVA), 
nitric oxide (NO), uric acid, and 3,4-dihydroxyphenylacetic acid (DOPAC).  In 
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addition, enzymes were applied to the recording surface to produce an 
electrochemically active reporter molecule, such as hydrogen peroxide (H2O2), to 
allow measurements of molecules that were not inherently electrochemically 
active.  When a potential of +0.7 V versus a Ag/AgCl reference was applied to 
the Pt recording sites, the newly formed H2O2 oxidizes and the resulting change 
in current from the transfer of electrons to the Pt recording surface was detected.  
While O2 was required as a cofactor for oxidase enzymes, the oxidation of the 
reporter molecule, H2O2, generates a portion of the O2 for continued reactions.  
This did not, however, allow measures using oxidase enzymes in zero O2 
environments.  
An important and often forgotten aspect of microelectrodes was that 
analytes from only a small area (microns) of tissue surrounding the recording 
surface were detected.  This was useful for studying small or layered structures 
in the brain or the spinal cord.  Additionally, microelectrodes with multiple 
recordings surfaces could be geometrically arranged to measure analyte 
concentrations from two or more distinct brain regions.  Since microelectrodes 
coupled with amperometric techniques measured analytes of interest on rapid 
time scales (1-1000 ms), uptake and release kinetics of faster neurotransmitters, 
such as Glu, were easily studied.  
 
Microelectrode Array Fabrication 
Enzyme-based multisite MEAs were mass fabricated using 
photolithographic methods (Methods and Materials in Microelectronic 
Technology, 1984; Wire Bond, 1998; Photolithography, 2001).  For a detailed 
account regarding MEA design and use, refer to Hascup et al., 2006.  An 
advantage of photolithography allowed routine production of reproducible 
recording surfaces as small as 5-10 μm.  In addition multiple microelectrodes 
were patterned onto a single fabrication substrate (usually 2.5 cm x 2.5 cm) 
allowing for increased fabrication numbers at a decreased cost.  Finally, 
photolithographic methods were used to manufacture numerous MEA designs 
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with multiple recordings sites in well-defined, highly reproducible, geometrical 
configurations. 
Our multisite MEAs were constructed in conjunction with Thin Films 
Technology, Inc., (Buellton, California).  Initially, MEA photographic masks were 
designed on a computer aided design program where arrays of 4-16 recording 
sites were arranged on templates.  A 2.5 cm x 2.5 cm x 125 μm thick ceramic 
wafer (alumina, Al2O3, Coors Ceramic, Coors Superstrate 996) served as a 
common substrate for the MEAs.  Ceramic reduced the cross-talk from adjacent 
connecting lines.  Additionally, ceramic was strong and rigid, which aided in 
precise stereotaxic placement into tissues with minimal flexing or breaking.  The 
ceramic substrate was polished or lapped down to achieve MEAs as thin as 37.5 
microns.   
Following cleaning, photoresist was spun onto the ceramic wafer.  To 
transfer the MEA image onto the wafer, collimated light was passed through a 
photomask of the MEA design, thus exposing the design onto the photoresist.  
Spaces for the recording sites, connecting lines and bonding pads were not 
exposed to light.  Solvents were used to remove unexposed photoresist from the 
wafer.  Many 1 cm long MEAs (34-64) were patterned onto the wafer 
simultaneously to facilitate production and increase the number of MEAs that 
were made from the ceramic substrate (figure 2.1).  Patterning could also be 
performed on the reverse side of the ceramic wafer to increase recording site 
density for future generations of MEA designs. 
Next, an adhesion layer of Titanium (Ti) was used to allow Pt adhere to 
the ceramic substrate. Ti (500 Ǻ thick) was sputtered onto the developed 
photoresist-covered-ceramic wafer.  Following the adhesion layer, the active 
recording metal layer, Pt, for most of our work, was sputtered onto the substrate 
(~1.5 μm thick).  Solvents were used to remove the developed photoresist and 
unwanted metals left on the recording pads, connecting lines, and connecting 
pads.   
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Figure 2.1:  Ceramic Wafer  
  
Photograph of a ceramic wafer containing 34 microelectrodes with Pt bonding pads, connecting 
lines and recording sites (not visible) were patterned onto the 2.5 cm x 2.5 cm, 125 μm thick 
substrate. 
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 Once the Pt recording sites, connecting lines, and bonding pads were in 
place, the connecting lines were coated with an insulator using another 
photolithographic step.  The connecting lines act as wires to connect the bonding 
pads to the recording sites and must be insulated from aqueous environments. 
To accomplish this, the MEAs were again coated with photoresist.  A second 
photomask was used to define the areas where polyimide was placed.  Polyimide 
acts as an insulator to define the recording site active area and the bonding pads 
as well as reducing the cross talk between the connecting lines.  After the 
photoresist was developed, polyimide was spun onto the wafer (2-4 μm thick).  
Once the insulating layer was applied, only the recording sites and bonding pads 
were exposed.  The photoresist and excess polyimide were removed and the 
remaining polyimide was cured at 200oC. The complete fabrication process is 
depicted in figure 2.2.  
After the formation of the MEA on the ceramic wafer, a diamond saw was 
used to form or “cut out” the individual MEAs.  A major advantage of the diamond 
saw was that it produced highly polished edges for reduced tissue damage 
during implantation.  The ceramic wafer with Pt recording sites was attached to a 
printed circuit board (PCB) holder for easier handling and connection to recording 
equipment.  To connect the ceramic wafer to the PCB holder, each bonding pad 
was wire bonded to an individual Pt recording site on the ceramic wafer.  The tips 
were epoxied onto the paddle for stability and insulation of the wire bonds.  
Cutting and assembly was performed in conjunction with Hybrid Circuits, Inc., 
(Sunnyvale, CA).  The PCB holder and fully constructed multisite MEA for 
anesthetized measurements are shown in figures 2.3A and 2.3B, respectively.  
Figure 2.3C is a version of the MEA for awake animal recordings.   
Due to the flexibility of the fabrication process, our MEAs were 
manufactured with different recording site geometric configurations.  An S2 MEA 
was used for both anesthetized and freely moving experiments.  The ceramic tip 
of an S2 (figure 2.3D) has 4 Pt recording sites (333 µm X 15 µm) in a side-by-
side configuration.  This configuration allows for dual detection in a similar brain 
region.   
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Figure 2.2:  Microelectrode Array Fabrication Process 
 
Schematic of the fabrication sequence for the ceramic wafers with Pt recording sites.   
Ceramic Substrate 
Photo Resist 1 
Level 2 Pattern  
Platinum Film 
Titanium/Platinum 
Liftoff 
Photo Resist 2 
Level 1 Pattern 
Titanium Film 
 Spin or Sputter 
 Polyimide 
Polyimide Liftoff 
Cross Sectional 
View After Diamond 
Saw Cutting 
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Figure 2.3:  Microelectrode Array Photographs 
 
Photograph of the MEA PCB with and without the attached ceramic tip.  A.)  Close-up view of the 
PCB.  Numbers beneath the pin holes indicate the specific Pt recording site connection.  B.) Fully 
assembled MEA.  Black epoxy was used to insulate the wire bonding from the ceramic tip to the 
PCB as well as to provide stability.  Pins were soldered into place for MEA attachment into a dual 
inline pin (DIP) socket.  Pins placed in the upper left and right of the PCB provided added 
stability.  C.) Fully assembled MEA for recordings in freely moving animals.  D.)  Photomicrograph 
of an S2 ceramic tip containing 4 Pt recording sites in a side-by-side configuration.   
1 3 4 2
A 
B 
1 3 2 4 
C
D
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Potentiostat 
 Our headstage/potentiostat was referred to as the Fast Analytical Sensing 
Technology (FAST) 16 Mark II system (Quanteon L.L.C, Nicholasville, KY).  The 
purpose of the potentiostat was to create a constant potential difference between 
the Ag/AgCl reference electrode and the MEA to force a non-spontaneous redox 
reaction to occur.  The potentiostat held a constant potential at the reference 
electrode so that the applied potential at the working electrode was known.  In 
other words, the potential applied at the working electrode was measured against 
the standard potential of the reference electrode.  The FAST 16 Mark II system 
amplified and digitized the electrical current generated by oxidation or reduction 
reactions.  For our Glu experiments, the amplification resulted in a gain scaling 
factor of 200 pA/V.  Figure 2.4 shows an illustration of the flow of current through 
our FAST 16 Mark II recording system from a GluOx coated MEA.   
 Our Windows™ based FAST 16 Mark II system software created and 
recorded second-by-second (1 Hz), or faster data files.  The software was written 
for eight simultaneous channel recordings, which could increase as the number 
of Pt recording sites increases in future generations of MEAs. The FAST 16 Mark 
II software displayed amperometric or chronoamperometric recordings at display 
rates of up to 40 Hz (nominal 1-10 Hz).  Recorded files were exported to other 
Windows™ based applications, such as Excel™, for easier data processing; or 
processed directly through the data analysis software package on the FAST 16 
Mark II system software.  The low noise design and software oversampling 
allowed the FAST 16 Mark II recording system to be used for bench top 
experimentation without the need of a Faraday cage.  However, greater 
performance was achieved with the use of a Faraday cage or appropriate 
shielding for most applications. 
 
Microelectrode Array Cleaning Procedures 
MEAs received from Hybrid Circuits underwent a cleaning procedure to 
remove any particulate matter or residue from the Pt recording sites that were 
deposited  during  the manufacturing process.   New  MEAs  were  placed  into  a  
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Figure 2.4:  FAST 16 Mark II Potentiostat Diagram 
 
The above diagram outlines the flow of electrons through our FAST 16 Mark II recording system.  
The potentiostat held a constant potential of -0.7 V to our Ag/AgCl reference electrode which 
created an applied potential of +0.7 V at our working electrode.  In the case of an MEA coated 
with GluOx; when Glu came into contact with GluOx, it was metabolized into α-ketoglutarate and 
H2O2.  The H2O2 diffused through the exclusion layer that was used to repel interferents such as 
AA and DOPAC.  When the H2O2 came into contact with a Pt recording surface at an applied 
potential of +0.7 V, it was oxidized and the transfer of two electrons to the Pt recording sites were 
detected on the recording system.  To keep the reaction thermodynamically stable, the two 
electrons traveled to the Ag/AgCl reference electrode where two chloride ions were released.  
The half reactions are written beneath their respective reference and working electrodes.    
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stirred solution of Fisherbrand Citrisolv™ (Fisher Scientific, Catalog #22- 143-
975) for five minutes followed by a five minute rinse in ddH2O.  After the chemical 
cleaning procedure, a thin film can develop on the Pt recording sites, so a 
Kimwipe® (Kimberly-Clark Professional) was delicately swiped across the tip of 
the MEAs to remove this film and any excess ddH2O.  MEAs were then dried for 
fifteen minutes in an oven at 105 – 115 ºC prior to coating.   
 An advantage of these MEAs was the ability to reuse them for multiple 
experiments.  Any applied enzyme layers (described below) need to be removed 
from the Pt recording surfaces.  A slightly different cleaning procedure was 
employed for MEAs that were previously coated with an enzyme layer.  The MEA 
tip was placed into a stirred solution of ddH2O at 80°C to soften the protein matrix 
on the Pt recording sites.  Following 30 minutes of soaking, the MEAs were 
cleaned as described in the preceding paragraph and tested for response to 
H2O2 to ensure good sensitivity of the Pt recording surfaces. 
 
Exclusion Layers  
Exclusion layer coatings were applied after successful cleaning of the 
MEAs and were used to alter their recording properties.  Exclusion layers were 
applied to block or minimize undesirable electrochemically active compounds 
found in high concentrations in the CNS such as AA (250-500 μM) or DOPAC 
(25-40 µM).  By blocking these undesired electrochemically active molecules 
from the Pt recording sites, the MEA had better selectivity for the analyte of 
interest. The planar geometry of the multisite MEAs often affected how materials 
adhered to the recording surfaces.  Exclusion and enzyme layer coatings 
retarded compounds from diffusing to the MEA surface by creating a diffusion 
barrier, thus limiting the response time of the MEA.  For this reason, coating 
parametrics were performed to determine optimal coating procedures for both 
exclusion layer and enzyme layer coatings. 
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Nafion® Exclusion Layer 
Nafion®, an anionic Teflon® derivative, is one of the most widely used 
methods for improving the selectivity of voltammetric recordings in CNS tissue.  
Historically, Nafion® is used on the surface of carbon fiber microelectrodes for the 
detection of catecholamines (Gerhardt et al., 1984; Rice et al., 1985; Rose et al., 
1985; Kuhr and Wightman, 1986; Rose et al., 1986; Gerhardt and Hoffman, 
2001).  The negatively charged sulfonic acid groups substituted into the polymer 
matrix of Nafion® repeled anions from the Pt recording surfaces.  If these anions 
were not blocked, they caused high background signals that interfered with 
reliable recordings.  At the same time, the negatively charged sulfonic acid 
groups on Nafion® concentrated cationic species such as DA, NE and 5-HT.  
With the development of the multisite MEAs, Nafion® was a logical choice for an 
exclusion layer and was used reliably in our studies of Glu (Nickell, et al., 2004; 
Day et al., 2006; Nickell et al., 2006; Rutherford et al., 2007).  However, since 
Nafion® attracted catecholamines to the Pt recording surface, which were 
oxidizable on Pt, other exclusion layers were used in CNS regions with high 
catecholamine levels except in the freely moving mouse studies.  Only Nafion® 
coated MEAs were used for freely moving mouse studies due to its longevity in 
vivo compared to other exclusion layers. 
Nafion® (5%, Sigma-Aldrich, Catalog #27,470-4) was aliquoted into a 1 mL 
brown glass vial.  The MEA tip was then lowered half-way into the aliquot of 
Nafion® and then rotated in a circle five times lasting approximately one second 
per rotation.  The tip was pulled straight out of the Nafion® solution. Next, MEAs 
were placed into an oven at 165-175°C for four minutes to allow the Nafion® layer 
to cure on the tip.  In general, lower temperature curing produced thicker films 
compared to higher temperature curing (Gerhardt and Hoffman, 2001).  Also, 
longer drying times at higher temperatures produced MEAs with lower responses 
to both AA and to analytes such as Glu.  MEAs coated with excessive Nafion® 
showed little or no detectable response to electrochemically active molecules.  
MEAs not coated with enough Nafion® recorded high levels of background AA 
once inserted into the brain.  After MEAs cured, they were allowed to cool to 
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room temperature for 30 minutes before enzyme coating.  An important concept 
to remember was that once a prepared Nafion® coated MEA was placed into an 
aqueous solution (either a beaker or the brain) the tip must remain wet or at the 
very least, removed from solution for only a limited time.  When Nafion® dried 
after soaking, it cracked allowing areas where interferents passed through and 
were oxidized on the Pt recording surfaces.  If the Nafion® layer cracked, the 
MEA was no longer selective for the analyte being measured.  
 
1,3-phenylenediamine 
The organic molecule 1,3-phenylenediamine (mPD) was another chemical 
used to create an exclusion layer for Pt recording microelectrodes (Lowry et al., 
1998; McMahon and O’Neill, 2005; Kirwan et al., 2007).  A potential was applied 
to a solution of mPD causing mPD to electropolymerize on Pt recording surfaces.  
Historically, mPD or its derivate 1,2-phenylenediamine (oPD), was used on 
carbon fiber microelectrodes for selectivity and prevention of microelectrode 
fouling; a process where oxidizable molecules such as serotonin adhered to the 
carbon fiber surface thus preventing detection.  Electropolymerized mPD 
selectivity was achieved by forming a size exclusion layer approximately 30 nm 
in thickness (Murphy, 1998; Kirwan et al., 2007) that prevented larger molecules 
such as AA, DA, and DOPAC from reaching the recording surface.  Smaller 
molecules, such as nitric oxide and H2O2, were still able to pass through the 
matrix (Friedeman et al., 1996).  Since H2O2 was a reporter molecule for oxidase 
enzymes, this made mPD an ideal exclusion layer for our enzyme-based 
multisite MEAs (Lowry et al.,1998; Kirwan et al., 2007). 
The electropolymerizing procedure was completely different from Nafion® 
coating but had four distinct advantages.  1)  The matrix formed by mPD blocked 
catecholamines such as DA, NE, and 5-HT from reaching the Pt recording sites.  
This helped make the MEA more selective for measuring the analyte of interest, 
Glu.  2) The mPD was electropolymerized onto the MEA after the MEA was 
coated with an enzyme layer.  mPD electropolymerized through the enzyme layer 
and formed the matrix.  Since mPD was electropolymerized after enzyme 
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coating, additional coatings of mPD could be applied to the MEA surface without 
cleaning the MEA.  If the matrix degraded during an experiment, the MEA could 
be replated, recalibrated, and re-used to finish the experiment.  3)  Because a 
potential must be applied for mPD coating, individual Pt recording sites could 
also be selectively coated with mPD.  Removing the applied potential between a 
Pt recording site and the headstage prevented mPD from being 
electropolymerized onto that site.  4)  Once mPD was successfully 
electropolymerized onto the Pt recording sites, the solution did not have to 
remain wet.  Since mPD was hydrophilic (Murphy, 1998) our laboratory found 
that aqueous solutions slowly degraded the matrix over time, which made it 
unsuitable for chronic recordings in the freely moving mouse.  The 
electropolymerization procedure is outlined below. 
Our laboratory found that 1,3-phenylenediamine dihydrochloride, 99% 
(Sigma-Aldrich, Catalog# 235903-25g) worked best for electroplating and matrix 
formation on the Pt recording sites.  First, a solution of 5 mM mPD was prepared 
in a degassed solution of 0.05 M phosphate buffered saline (PBS).  Degassing 
was accomplished by bubbling nitrogen gas through the 0.05 M PBS solution for 
20 minutes to remove oxygen before dissolving mPD.  Once the 5 mM mPD was 
dissolved in the degassed 0.05 M PBS, the mPD solution was stored in a brown 
glass bottle to prevent oxidation from light.  If the solution turned yellow, it had 
oxidized and did not electropolymerize on the MEA recording surface.  Even with 
these storage methods, the 5 mM mPD solution oxidized after several hours so 
we recommended using the solution immediately.  When the mPD solution was 
prepared, the MEA was connected to the FAST 16 Mark II recording system and 
approximately 40 mL of the 5 mM mPD was poured into a 50 mL beaker. The 
MEA tip was lowered half-way into the solution along with a glass, Ag/AgCl 
reference electrode (Bioanalytical Systems, Inc. RE-5B, Catalog #MF-2079).  A 
fast-cyclic potential of +0.25 to +0.75 versus a Ag/AgCl reference electrode was 
applied for fifteen minutes to allow the mPD to electropolymerize onto the Pt 
recording sites.  At fifteen minutes, the MEA tip was removed from the 5 mM 
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mPD solution, rinsed with ddH2O, and stored at room temperature for 24 hours 
prior to calibration.    
 
Enzyme Layer Coatings 
Enzymes provided a means to convert a molecule that was not inherently 
electroactive, and thus not measurable, into a reporter molecule such as H2O2 
that was oxidized at the Pt recording surfaces of the MEAs.  The current 
measured from the oxidation of H2O2 generated during the enzymatic breakdown 
was directly proportional to the analyte concentration. Table 2.1 provides a list of 
available oxidase enzymes and their potential uses.    Oxidase enzymes that our 
laboratory has used to measure neurochemicals are shown in BOLD and include 
L-glutamate oxidase (GluOx) (Burmeister and Gerhardt, 2001; Burmeister et al., 
2002; Pomerleau et al., 2003; Nickell et al., 2005; Day et al., 2006; Rutherford et 
al., 2007), choline oxidase (Burmeister et al., 2004; Parikh et al., 2005) L-lactate 
oxidase (Burmeister et al., 2005) and L-glucose oxidase.   Furthermore, 
acetylcholine esterase was used to measure acetylcholine (in conjunction with 
choline oxidase) and catalase was used to prevent H2O2 detection.  
As previously mentioned, the O2 dependence of oxidase enzyme-coated 
MEAs is also a concern.  It is widely known that O2 is required by the enzymes to 
measure the analyte, but a portion is returned to the tissue by the oxidation of 
H2O2 to O2 and H+ at the MEA surfaces.  In our experience oxidase enzyme-
coated MEAs were relatively free from O2 dependence over a useful range in 
vivo (Burmeister et al., 2003), but certain applications, such as those during 
recordings of stroke episodes, require correction by use of an O2 sensing 
microelectrode.   
Immobilization of enzymes to the Pt recording surface helped stabilize the 
enzymes and made them active for longer periods of time.  Our laboratory has 
immobilized several of the oxidase enzymes onto the Pt recording surfaces. 
While the general procedure remains the same for crosslinking the enzymes to 
the Pt recording sites, relative ratios of the enzyme to protein mixtures varies.   
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Table 2.1:  Enzymes Capable of Producing a Reporter Molecule 
 
Enzyme Substrate Product Measure 
Acetylcholinesterase Acetylcholine Choline, Acetic Acid Choline with     Choline oxidase 
Alcohol oxidase Alcohol, O2 H2O2, Aldehyde Alcohols 
D-amino acid oxidase D-amino acids, O2 H2O2, NH4+, 2-oxo acid D-amino acids 
L-amino acid oxidase L-amino acids, O2 H2O2, NH4+, 2-oxo acid L-amino acids 
Ascorbate oxidase Ascorbate, O2 Dehydroascorbate 
Remove 
Ascorbate 
Aspartate oxidase Aspartate, O2 
H2O2, NH4+ 
Oxaloacetate Aspartate 
Catalase H2O2 O2 H2O2 
Cholesterol esterase 
Cholesteryl oleate, 
or other Cholesterol 
ester, Taurocholate 
Cholesterol, Oleic acid, 
or other corresponding 
ketone 
Cholesterol ester 
with Cholesterol 
oxidase 
Cholesterol Oxidase Cholesterol, O2 
H2O2                  
4-cholesten-3-one Cholesterol 
Choline Oxidase Choline, O2 H2O2, Betaine Choline 
Galactose oxidase D-galactose, O2 
H2O2                 
D-galacto-hexodialose Galactose 
Glucose oxidase Glucose, O2 H2O2,  Gluconic Acid Glucose 
L-glutamate oxidase L-glutamate, O2 H2O2,  α-ketoglutarate L-glutamate 
GABAase GABA             α-ketoglutarate 
NADPH, H+            
L-glutamate 
GABA with         
L-glutamate 
oxidase 
Glutaminase Glutamine NH4+, L-glutamate 
Glutamine with      
L-glutamate 
oxidase 
Glycerol kinase Glycerol, ATP Glycerol-3-phosphate, ADP 
Glycerol with      
Glycerol-3-
phosphate oxidase 
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Table 2.1:  (continued) 
 
Enzyme Substrate Product Measure 
Glycerol-3-phosphate 
oxidase 
Glycerol-3-
phosphate, O2 
H2O2  
Dihydroxyacetone 
phosphate 
Glycerol 
Hexokinase ATP, Glucose Glucose-6-phosphate, ADP 
ATP with           
L-glutamate 
oxidase 
Horseradish peroxidase H2O2 H2O,  O2 
Use as mediator 
for H2O2  detection 
Lactate oxidase Lactate, O2 H2O2, Pyruvate Lactate 
Lysine oxidase Lysine, O2 
H2O2, NH4+             
6-amino-2-oxohexanoic 
acid 
Lysine 
Pyruvate oxidase Pyruvate, O2, Phosphate 
H2O2, CO2,            
acetyl phosphate Pyruvate 
Sarcosine oxidase Sarcosine, O2 
H2O2, Glycine, 
Formaldehyde Sarcosine 
Xanthine oxidase Xanthine, O2 H2O2, Uric acid Xanthine 
 
This table shows oxidase enzymes that can be immobilized onto the Pt recording surface of our 
MEA.  The enzymes that were used to measure analytes of interest by our laboratory are in 
BOLD lettering. 
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Our laboratory focuses on GluOx for the detection of Glu dynamics in the 
mammalian CNS whose immobilization procedure is outlined in detail below. 
 
L-Glutamate Oxidase 
 GluOx was purified from a wheat bran culture of Streptomyces sp. X-119-
6 and metabolized Glu with co-substrates O2 and H2O to form α-ketoglutarate, 
H2O2, and ammonia (Kusakabe et al., 1984).  The enzyme had maximal 
specificity at physiological pH (7.4) and temperature (37°C) (Kusakabe et al., 
1983).  GluOx is specific for the L-enantiomer of Glu with a KM value of 0.21 mM 
and shows no activity for D-Glutamate nor did this enantiomer block enzyme 
activity (Kusakabe et al., 1983).  L-aspartate was also oxidized, but to a lesser 
extent (0.6%) and had a considerably higher KM value of 29 mM (Kusakabe et 
al., 1983).   Our laboratory has shown that local application of 200 µM L-
aspartate in vivo does not elicit a response on the MEA (Pomerleau et al., 2003).  
In addition, salt solutions such as potassium chloride, sodium chloride, nor 
calcium chloride do not have an effect on the relative activity of the enzyme 
(Kusakabe et al., 1983).  This was further verified when local application of 0.9% 
physiological saline, did not elicit a response on the MEA (Pomerleau et al., 
2003).   
 
L-Glutamate Oxidase Coating Procedure 
  A stock solution of GluOx (Associates of Cape Cod, Seikagaku America, 
Catalog #100645-1) was prepared by adding 50 μl of ddH2O to the lyophilized, 
purified enzyme in a vial to make a final concentration of 1 UI/μl.  All proteins and 
enzymes were brought to room temperature and 0.010 g of bovine serum 
albumin (BSA) Fraction V, 99% (Sigma-Aldrich, Catalog #A-3059) was dissolved 
in a 1.5 mL microcentrifuge tube containing 985 μl ddH2O by manual agitation.  
Once dissolved, 5 μl of glutaraldehyde (Glut) solution, Grade I, 25% (Sigma-
Aldrich Catalog #G-6257) was added to the BSA mixture and manually mixed by 
inversion five times.  The solution was then set aside for five minutes until it 
turned a faint yellow color.  Glut crosslinked proteins that adhered to the MEA 
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surface when cured.  The BSA served as a matrix to protect the oxidase enzyme 
activity during immobilization.  Next, 9 μl of the BSA/Glut mixture was removed 
and added to a 300 μl microcentrifuge tube and to this 1 μl of the GluOx stock 
solution (1 UI/μl) was added and mixed by pipette agitation.  This 10 μl solution 
had a final concentration of 1% BSA, 0.125% Glut, and approximately 1% GluOx.  
We have carried out an extensive series of parametric studies to determine this 
optimized stoichiometry for enzyme immobilization.   
All enzymes were applied to the Pt recording sites by hand.  Solutions 
were drawn up into a 10 μl Gastight® Hamilton microsyringe (Hamilton Co. 
Catalog #80065) and slowly dispensed to form a small droplet of solution at the 
tip of the microsyringe.  Using a dissecting microscope (and a steady set of 
hands), the droplet was briefly applied to the Pt recording sites.  The solution 
quickly dried, leaving behind a thin, translucent layer of enzyme that was visible 
underneath a dissecting microscope.  Two additional coats of enzyme were 
applied in the same manner with one minute dry times in between each coat.  
This procedure was complete once a visible film remained following coating.  The 
advantage of using multisite MEAs was that a pair of recording sites was coated 
with the enzyme mixture and the adjacent sites were coated with the inactive 
protein matrix (BSA and Glut) in the same manner as applying the enzyme 
mixture.  Our laboratory referred to this technique as “self-referencing” 
(Burmeister and Gerhardt, 2002) and this approach had many advantages which 
are discussed in more detail in the section entitled ‘Self-Referencing.” 
Once the enzyme and/or inactive protein matrix was applied, MEAs were 
stored at room temperature.  Enzyme-coated MEAs must cure at room 
temperature for 48-72 hours prior to calibration and experimentation.  Complete 
curing increased enzyme layer adhesion to the MEA surface. The 
enzyme/protein layers on “uncured MEAs” dissolved when placed in solution.  A 
48-72 hour curing time provided better sensitivity to Glu as well as increased the 
shelf-life of the MEAs.  Optimal curing times varied depending on temperature, 
humidity, and enzyme.  GluOx coated MEAs were optimal for at least three 
weeks..   
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Calibration 
 We often observed that the micro-fabricated MEAs have highly 
reproducible Pt recording surfaces.  However, manufacturing procedures only 
investigated the geometric surface area of the MEAs.  Since each Pt recording 
site on a MEA responded differently to H2O2 and therefore Glu, they must be 
calibrated in vitro prior to experimentation to determine standard curves.  Thus, 
calibrations were used to equate a change in current from the oxidation of H2O2 
to a proportional change in analyte concentration from the Glu generating the 
H2O2.  A known concentration of analyte was added to 40 mL of 0.05 M PBS 
solution at 37°C to generate a current in picoamperes (pA) that was measured by 
the FAST 16 Mark II system.  The FAST 16 Mark II system software recorded the 
current for each addition of analyte, created a calibration curve for each Pt 
recording site, and stored the slope (nA/µM) of this calibration.  Also, known 
interferents such as AA were added during the calibration to test the selectivity of 
the recording sites to the analyte of interest versus interferents.  When the 
experiment was performed, the calibration data was recalled and used to 
determine the concentration of analyte measured from the current during 
experiments in vivo.  
 
Calibration Preparation 
 Nafion® coated MEA tips were soaked in a solution of 0.05 M PBS at 37°C 
for at least one hour prior to calibration.  These MEAs can be placed in the PBS 
solution overnight for calibration the next morning.  The soaking time allowed for 
better diffusion of analytes through the Nafion® layer as well as activation of the 
enzyme layer.  The mPD coated MEAs, on the other hand, did not require long 
soaking times. The time period the MEA tip soaked in the calibration solution was 
sufficient for proper enzyme activation without additional soaking. 
 All stock solutions for Glu calibrations were prepared in ddH2O and listed 
below: 
1.) 20 mM AA (Ascorbic acid powder, Fisher Scientific,         
Catalog  #A62) 
  44
2.) 20 mM L-glutamic acid sodium salt hydrate, minimum 99% 
(Sigma-Aldrich, Catalog #G1626) 
3.) 2 mM DA (3-Hydroxytyramine hydrochloride, Sigma-Aldrich,   
Catalog #H-8502) 
4.) 8.8 mM H2O2 (Rite Aid, 3% H2O2 Topical Solution) 
Solutions were stored at 4°C.  AA and H2O2 were made fresh daily since they 
oxidize in solution.  Glu was made fresh on a weekly basis.  DA was kept for a 
month providing the stock solution contained 0.01 M perchloric acid.   
 
Calibration Procedure 
Forty milliliters of 0.05 M PBS was measured out with a graduated cylinder 
and added to a 50 mL beaker.  This beaker was placed in a recirculating water 
bath (Quanteon, L.L.C.) set at 37°C resting upon a battery operated, portable 
magnetic stir plate (Barnant Co., Model #700-0153).  The calibration temperature 
was maintained at 37°C to activate GluOx for physiologically relevant 
temperatures.  We used a battery operated stir plate to reduce potential AC (60 
Hz) current that affected the recordings.  A 10 x 3 mm stir bar was added to the 
0.05 M PBS and the solution was slowly stirred to facilitate diffusion without 
forming a vortex in the solution.  A glass Ag/AgCl reference electrode was placed 
in the buffer solution.  Finally, the MEA tip was lowered halfway into the buffer 
solution.   
After initial system settings were completed on the FAST 16 software, the 
FAST 16 Mark II recording system applied a potential of +0.7 V versus the 
Ag/AgCl reference to the MEA recording surfaces.  Once calibration started, the 
current was allowed to reach a stable baseline (approximately 10-15 minutes, but 
occasionally longer).  When a stable baseline was achieved, the baseline was 
marked. (When ‘marking’ a time point for an event, such as baseline, interferent, 
or analyte addition, was recorded by the FAST 16 Mark II software.  A series of 
data points before the ‘mark’ were averaged and used in the calibration analysis).  
Next, 500 μl of 20 mM AA (interferent) was added for a final beaker concentration 
of 250 μM.  When a new stable baseline was reached, the interferent was 
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marked.  Next, three, 40 μl additions of 20 mM Glu were added for final buffer 
concentrations of 20, 40, and 60 μM Glu.  Analyte marks were recorded after 
each addition to create the standard curve.  After 3 additions of analyte, 40 μl of 
2 mM DA (2 μM final beaker concentration) was added to the solution as a test 
substance and marked.  Finally, 40 μl of 8.8 mM H2O2 (8.8 μM final beaker 
concentration) was added to the solution to confirm MEA sensitivity and the 
addition was marked.  The test substances were used to check selectivity.  The 
additions of test substances did not factor into calculating the standard curve for 
the analyte of interest.  All chemicals used in vivo were tested in vitro to ensure 
that they were not electrochemically active on the Pt recording surface.  It was 
important to know whether a chemical was electrochemically active in vitro prior 
to its local application near the Pt recording sites during experimentation.  This 
guaranteed that in vitro or in vivo analyte concentration changes were from the 
analyte of interest rather than due to local application of drugs.  Upon completion 
of the calibration, the program was stopped, the data were saved, and the MEA 
tip was removed from the buffer solution and stored appropriately.  Nafion® 
coated MEAs were placed in 0.05 M PBS while mPD electroplated MEAs were 
kept dry.  Graphs of typical self-referencing Glu calibrations with either Nafion® or 
mPD applied as exclusion layers are shown in figures 2.5A and 2.5B, 
respectively.  
 
Microelectrode Array Calibration Criteria 
 During calibration, the FAST 16 Mark II recording software automatically 
calculated selectivity ratios for Glu over AA as well as the slope (MEA sensitivity 
for Glu), limit of detection (LOD), and linearity (R2).  What do all these numbers 
mean and how did one know if they have a satisfactory Glu MEA?  A poor R2 was 
rarely seen with good MEAs.  Since the MEA fabrication procedure was highly 
reproducible, we have found that Glu responses were extremely linear and often 
resulted in linear regression curve fits with R2 ≥ 0.99.   
Slope or sensitivity of the MEA referred to how well the MEA measured 
the change  in  Glu  concentration.   The  number was used to  equate  a  change   
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Figure 2.5:  Calibration Results From Nafion® and mPD Coated MEAs 
 
A) The calibration of a Nafion® coated Glu self-referencing MEA.  During calibration, solutions 
were added to determine each recording site’s sensitivity to Glu, selectivity for Glu over AA, 
lowest LOD, and responsiveness to other electroactive molecules (e.g. DA and H2O2). The 
enzyme-coated Glu recording site responded well to Glu and some electroactive molecules.  The 
enzyme-free sentinel site did not respond to Glu but showed similar responses to the same 
electroactive molecules. Final concentrations of each addition: 250 µM AA, 20, 40, and 60 µM 
Glu, 2 µM DA, and 8.8 µM H2O2. B.) Calibration of an mPD coated Glu self-referencing MEA.  All 
calibration concentrations were the same as previously described.  Note how mPD excluded the 
DA response on both the GluOx and sentinel recording sites.   
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in current to a change in Glu concentration. The slope was also used to calculate 
LODs, which were the most important criteria for determining if a MEA was 
satisfactory for use.  We use LODs to select MEAs because slopes were 
misleading.  LOD was defined as the analyte concentration that yielded an MEA 
response that was equivalent to 3 times the background noise of the recording 
system.  This was a conservative calculation of the lowest detectable change in 
analyte concentration that was not attributed to noise.  Our MEA LODs range 
from 0.2 to 1.0 μM, depending on the recording enzyme composition and stability 
of the sites.  Typically, for in vivo experiments MEAs with LODs ≤ 1 μM were 
used since this was smaller than the response expected.  
Selectivity referred to the ratio of the MEAs sensitivity to Glu over the 
sensitivity to interferents such as AA.  It was calculated by dividing the Glu slope 
by the AA slope.  A MEA with a selectivity of 100:1 meant that a 100 μM 
concentration increase of AA resulted in an apparent 1 μM concentration 
increase in Glu.  With a selectivity of 100:1, the MEA was 99% effective at 
blocking AA.  Selectivity ratios of 100:1 or greater were ideal, but selectivity ratios 
of 20:1 were used and effective at blocking interferents since this ratio was not a 
linear correlation.  In other words, a MEA with a selectivity of 50:1 was blocking 
approximately 98% of the AA while a MEA with a selectivity of 20:1 was still 
blocking approximately 95% of the AA signal. 
 
Glass Micropipettes  
After calibrations were completed, a glass micropipette was attached to 
the PCB holder so the tip of the glass micropipette rested among the 4 Pt 
recording sites.  Through this glass micropipette, drug solutions were locally 
applied for pharmacological manipulations of the CNS.  We used a vertical 
pipette puller (David Kopf Instruments, Model 700C, Catalog #730) to prepare 
single barrel (1 mm o.d., 0.58 mm i.d., A-M Systems, Inc., Catalog #601500) 
glass micropipettes.   Using an upright stereomicroscope, the tip of the 
micropipette was bumped against a glass stir rod to create an internal diameter 
of 12-15 μm.  Next, modeling clay was attached to the PCB holder.  The glass 
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micropipette was attached to the modeling clay (used to hold the glass 
micropipette steady while it was positioned among the recording sites).  Once the 
glass micropipette was properly positioned, it was held more firmly in place by 
applying melted Sticky Wax (Kerr Corporation, Catalog #00625) onto the PCB 
between the ceramic wafer and the modeling clay.  The drying of the Sticky Wax 
repositioned the glass micropipette relative to its placement amongst and above 
the Pt recording sites.  If necessary, the tip of a spatula was heated to help 
remodel the Sticky Wax and thus reposition the glass micropipette.  Figure 2.6A 
shows a glass micropipette attached to the PCB with modeling clay and Sticky 
Wax.   Figure 2.6B shows the tip of a glass micropipette positioned among the 
recording sites for an S2 MEA.  The tip of the glass micropipette did not touch the 
ceramic surface.  Rather it was positioned between 50-100 microns above the Pt 
recording sites (as shown in figure 2.6C).  This distance allowed an optimal 
amount of CNS tissue between the glass micropipette and MEA when it was 
lowered into the brain. If the MEA was too close to the Pt recording sites, 
pressure ejection of fluid caused a dilution artifact in vivo (an actual decrease in 
analyte concentration due to the introduction of exogenous fluid in the area of the 
Pt recording site).  If positioned too far, the rapid diffusion and uptake of Glu into 
glia limited its diffusion to the Pt recording sites on the MEA surface.  For proper 
positioning of the glass micropipette among the Pt recording sites, the MEA was 
viewed at two angles underneath a dissecting microscope.     
 The glass micropipette was filled with solution using a 30-gauge, four inch 
long hypodermic needle (Popper and Sons, Inc., Standard Female Luer Hub, 
Catalog #7400).  Glass micropipettes were always filled prior to implantation.  
First, drug solutions were drawn into a 1 mL tuberculin tip syringe (Beckton-
Dickinson, and Co., Catalog #309602), which was then attached to the intake 
end of a μStar 0.22 μm sterile filter (Costar Corp, Catalog #8110).  The other end 
of the filter attached to a 30-gauge, four inch long, hypodermic needle.  The 
solution was dispensed through the filter and ultimately through the hypodermic  
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Figure 2.6:  Positioning of the Glass Micropipette 
 
Photographs of a glass micropipette attached to a multisite MEA.  A.)  Photograph of the glass 
micropipette held in place with modeling clay and Sticky Wax.  B.)  Photomicrograph of a glass 
micropipette tip positioned among the four Pt recording sites on an S2 MEA.  C.) Side view 
photomicrograph of the glass micropipette tip held approximately 50 μm above the MEA tip.  
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needle.  The needle was inserted into the glass micropipette and filled from the 
pulled tip up to the open end without creating air bubbles within the glass 
micropipette.  Air bubbles prevented effective delivery of drugs by pressure 
ejection and made it difficult to determine the volume of fluid dispensed.  
Solutions were normally pressure ejected prior to MEA implantation into the brain 
to determine that there was a smooth fluid flow out of the glass micropipette.  
Solutions were removed from a glass micropipette by inserting the 30-gauge 
filling needle with an attached tuberculin syringe to draw up the solution. 
 
Ag/AgCl Reference Electrode 
While larger glass Ag/AgCl reference electrodes were suitable for mPD 
electropolymerization and MEA calibration, this reference electrode was too large 
for many biological applications.  For this reason, a smaller Ag/AgCl reference 
electrode was made at the start of every experiment.  Miniature Ag/AgCl 
reference electrodes were prepared by first stripping 0.25 inch of the Teflon® 
coating from each end of a silver wire (0.008 inch bare, 0.011 inch coated; A-M 
Systems, Inc., Catalog #786500). One of the stripped ends was soldered to a 
wire crimp pin (Mill-Max Mfg. Corp., Part #3603) for connection to the FAST 16 
Mark II headstage.  The other end was placed into a solution of 1 M HCl 
saturated with NaCl.  A Pt wire acted as the counter electrode and was also 
placed into the solution.   Our laboratory used a regulated power supply (Elenco 
Precision, Model XP-620) that outputs 9 V.  However, DC adapters ranging from 
1.5 V to 9 V were acceptable.    The negative lead was attached to the Pt counter 
electrode while the positive lead was connected to the Ag wire.  With both wires 
in solution, the applied potential attracts Cl- on the wire to form AgCl thus making 
the Ag/AgCl reference.  The plating potential was applied for approximately 10-
15 minutes.  When properly connected, bubbles formed around the Pt counter 
electrode.  These miniature Ag/AgCl references were soaked in 3M NaCl prior to 
use in vivo. 
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MEA Preparation for Awake, Freely Moving Mice 
Refer to Rutherford et al., 2007 for a complete description on preparing 
MEAs for chronic recordings.  For our awake, freely moving recordings, we used 
a smaller, lighter weight MEA, which is shown in figure 2.3C.  Microelectrode 
connecting wires were prepared by first stripping both ends of 30 American Wire 
Gauge (AWG) varnished copper wire (RadioShack).  One end of the copper 
connecting wire was soldered to a pin-hole on the row closest to the MEA tip.  
Four copper wires were soldered to the PCB, each corresponding to one of the 
Pt recording sites.  Once all wires were soldered, the MEA tip was coated with 
five minute epoxy, which protected the MEA connection from potential water or 
other liquid damage during the remaining portion of the procedure.  The MEA tip 
was coated with Nafion® (we found this exclusion layer worked longer for chronic 
implantations compared to mPD) and enzyme and inactive protein matrix 
solutions as previously described.  The enzyme and inactive protein matrix 
solutions were allowed to cure for 48-72 hours before the MEA modifications 
were completed. 
Once the enzyme cured, a gold-plated socket (Ginder Scientific Part #220-
S02) was attached to the other end of the copper wire (figure 2.7A).  Also, a 
miniature Ag/AgCl reference was prepared and attached to a gold socket. The 
gold sockets of the reference and MEA wires were inserted into a miniature, 
black connector (Ginder Scientific, 9-pin ABS Plug, Part #GS09PLG-220).  Pliers 
were used to push the gold sockets into the connector so that the gold sockets 
were flush with the miniature, black connector.  The copper wires were wrapped 
around the connector and the MEA tip was positioned parallel to the connector.  
Correct positioning of the MEA tip was essential for accurate stereotaxic 
placement into the brain.  Five minute epoxy was used to secure the MEA and 
wires, making sure that all wires were covered with epoxy.  The solder contacts 
on the gold sockets were also covered with epoxy to ensure that moisture did not 
penetrate the connector and disrupt the recording (figure 2.7B).   
Similar to anesthetized experiments, drugs were locally applied close to 
the Pt recording sites for pharmacological studies in freely moving mice.  Instead  
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Figure 2.7:  Awake, Freely Moving MEA Preparation 
 
Photographs of the assembly process for the awake, freely moving MEAs.  A.) Four copper wires 
were soldered to the MEA (one for each Pt recording site).  Gold sockets were soldered to the 
other end of each copper wire.  B.)  The gold sockets were inserted into a black connector along 
with a miniature Ag/AgCl reference wire.  The MEA was positioned parallel to the black connector 
and was held in place using five minute epoxy. C.)  A fully assembled MEA with attached guide 
cannula was held in place with Sticky Wax.  The guide cannula was held in place so an internal 
cannula was positioned among the four Pt recording sites.    
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of a glass micropipette, a 26-gauge stainless steel guide cannula (Plastics One 
Inc., C315G Cannula Guide 26GA 38172, PO: 052604AA, SO: 41123-1) was 
centered among the recording sites with sticky wax similar to the glass 
micropipette as previously described.  A 33 gauge stainless steel internal acute 
cannula (Plastics One Inc., C315IA Cannula Internal Acute, PO: 121409, SO: 
45203-1), slightly longer than the guide, was inserted into the guide cannula.  
The internal acute cannula tip was positioned among the four Pt recording sites 
of the MEA at a distance of approximately 70 μm above the MEA tip.  To prevent 
clogging of the guide cannula, a stainless steel dummy cannula (Plastics One 
Inc., C315DC Cannula dummy, PO: 121409, SO: 45203-3) remained in the guide 
cannula at all times, and was only removed when solutions were locally applied 
through the internal acute cannula.  An assembled MEA with attached guide 
cannula is shown in figure 2.7C.  
 
Freely Moving Recording Apparatus 
The recording headstage was slightly different from those used for in vitro 
and in vivo anesthetized animal recordings.  This headstage screwed directly 
onto the mouse MEA assembly connecting the chronically implanted MEA to the 
FAST 16 Mark II recording system.  The headstage consisted of a miniature 
connector with five connector pins (one connecting each of the four channels and 
one for the Ag/AgCl reference electrode).  The connector pins led to the four 
channel mini-amplifier, which was positioned as close as possible to the animal 
in order to minimize noise artifacts.  Shielded connecting wire, led to an electrical 
swivel (Airflyte Electronics Co., P/N 1001460-012) at the top of the recording 
chamber.  The headstage was connected at the top center of the recording 
apparatus to the electrical swivel (commutator) that contained twelve electrical 
contacts. The commutator allowed the animal to move freely to all areas of the 
behavior chamber.  Figure 2.8 diagrams the equipment used for freely moving 
recordings.   
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Figure 2.8:  Diagram of the Freely Moving Recording Chamber 
 
This diagram shows a mouse connected to the FAST 16 Mark II recording system for awake, 
freely moving recordings.  Briefly, once a mouse was introduced into the recording chamber it 
was connected to the primary amplifier, which attached to the electrical swivel allowing the mouse 
to move to all areas of the recording chamber.  The electrical swivel was connected to the FAST 
16 Mark II recording system where the signal was amplified and digitized on a PC workstation.  
The bottom right inset is a photograph of the electrical swivel mounted to the top of the recording 
chamber.    
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 Chronic Implantation Procedure 
For chronic implantation surgeries, mice were anesthetized with isoflurane 
and placed in a stereotaxic apparatus fitted with a mouse adapter (David Kopf 
Instruments, Model 926) and mouse anesthesia mask (David Kopf Instruments, 
Model 907).  A constant flow of isoflurane was maintained using a SurgiVet Tec 4 
Vaporizer.  Mouse body temperature was maintained with an isothermal heating 
pad at 37°C.  The mouse’s eyes were coated with artificial tears (www.medi-
vet.com, Catalog #11970) to help maintain fluid and prevent infection.  All 
surgeries were performed in a Vertical Laminar Flow Workstation, (Microzone 
Corp., VLF-2-4) with a High Efficiency Particulate Air (HEPA) filter.  Prior to 
incision, excess fur on the head was shaved and the skin directly on top of the 
mouse’s head (between the ears and from just behind the eyes to the neck) was 
wiped with a proviodine solution to keep the incision area clean and prevent 
infection.  The skin on top of the head was reflected, making as small an incision 
as necessary. The mouse underwent a craniotomy to remove a 2 mm x 2 mm 
portion of the skull for MEA implantation.  Additionally, three small holes (<0.5 
mm) were drilled in the skull with a Dremel® engraving cutting bit (#105) for 
placement of the reference electrode and two stainless steel skull screws (Small 
Parts Inc., Part #MPX-080-02-M) that helped hold the assembly in place.  Similar 
to the anesthetized studies, a Ag/AgCl reference electrode was implanted 
remotely from the recording site.  For our freely moving mouse experiments, 
MEAs were lowered into either the right PFC (AP: +1.5, ML: 0.3; DV: -2.4 vs 
bregma) or right Str (AP: +0.9, ML: 1.5, DV: -3.85 vs bregma) according to the 
atlas of Paxinos and Franklin (2004).  Figure 2.9 shows a diagram of the mouse 
skull with skull screws, Ag/AgCl reference wire, and MEA placement.  The 
assembly was secured with approximately four layers of Ortho-Jet Powder (Lang 
Dental Manufacturing Co., Inc. REF-1330) mixed with Jet Acrylic Liquid, (Lang 
Dental Manufacturing Co., Inc., REF-1406), which the skull screws help anchor in 
place.  The dental acrylic covered as much of the MEA PCB holder as possible, 
without adhering to the threads of the cannula or the MEA connector.  The dental  
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Figure 2.9:  MEA Implantation Surgery 
 
The above figure shows an overhead view of the mouse skull and the placement of the skull 
screws, Ag/AgCl reference wire, and MEA implantation site.   
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acrylic had a smooth texture to prevent the rodent from scratching the implanted 
MEA.  Following surgery, mice were placed on a heating pad to help maintain 
body temperature until they recovered from the anesthesia.  Three subcutaneous 
injections, totaling 1 mL of Ringer’s Solution, Mammal (Fisher Scientific, Catalog 
#S77939) were administered subcutaneously immediately following surgery.  
Mice were given three days to recover prior to the start of a recording session. 
 On experiment days, the mouse was allowed to explore the behavior 
chamber for 15-20 minutes before being connected to the FAST 16 Mark II 
recording system.  Usually, the first day of recordings involved local application of 
an isotonic solution of 1 mM Glu (pH ~ 7.4) to determine the MEA response 
before behavioral or pharmacological studies were conducted.  Ejected solutions 
were filtered and then delivered into the internal guide cannula with the aid of 28-
gauge tubing (Small Parts Inc.) fitted over a 10 μl Hamilton microsyringe.  The 
Hamilton syringe was inserted into a repeating dispenser (Hamilton, Co; PB600-
1) to provide accurate volume ejections of locally-applied chemicals.  The 
microsyringe with repeating dispenser was placed on top of the recording 
chamber while the tubing was lowered through the hole drilled out for the 
commutator into the recording chamber.  The dummy cannula was removed and 
the fluid cannula was inserted in its place.  The animals were not restrained to 
insert the cannula as restraining the mouse altered behavioral studies by 
stressing the rodent.    
 
Self-Referencing 
An advantage of photolithographic fabrication of MEA designs was the 
precise control of the layout of the MEAs allowing for multiple recording sites 
geometrically configured in a small area.  Multiple recording sites on a single 
MEA were used to remove chemical interferents that contributed to a portion of 
the analyte signal (Burmeister and Gerhardt, 2001).  Our laboratory referred to 
this principle as ‘self-referencing’ and it was commonly used in our data analysis. 
As mentioned in the coating section, the GluOx was applied to a pair of Pt 
recording sites while the chemically inactive protein matrix (BSA and Glut) was 
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applied to the adjacent pair of recording sites referred to as ‘sentinel sites’.  A 
schematic of the coating procedure with either Nafion® or mPD is shown in figure 
2.10.   
The GluOx coated Pt recording sites detected extracellular Glu 
concentrations (the analyte) in addition to molecules that the inactive protein 
matrix coated recording sites detected (interferents).  These additional molecules 
detected, included interferents such as AA and DOPAC as well as other 
neurotransmitters such as DA, NE, 5-HT.  (Refer to figures 2.5A and 2.5B that 
show a typical Glu self-referencing calibration where the GluOx coated sites 
responded to Glu while the inactive protein matrix coated sites did not.)   
The purpose of the inactive protein matrix on the self-referencing, or 
sentinel sites, was to make the response times of the sentinel sites similar to the 
GluOx recording sites.  As mentioned earlier, protein coats altered the diffusional 
properties of molecules to the Pt recording surfaces.  Without this inactive protein 
matrix layer, the sentinel sites would respond faster to interferents than the 
GluOx coated sites.  Protein layers on both pairs of Pt recordings sites were 
necessary to minimize differences between the temporal recording properties of 
the different MEA surfaces.  Ideally, the sentinel vs. analyte recording sites 
should be positioned side-by-side.  However, our current, manual enzyme 
coating procedures precluded this arrangement. 
Experimentally, self-referencing recordings were beneficial for providing 
qualitative as well as quantitative assessment of the analyte of interest.  During 
an experiment, the FAST 16 Mark II recording software allowed the user to 
simultaneously view changes in Glu concentration for all four recording sites.  If a 
peak was seen on the GluOx coated sites, but not the inactive protein matrix 
coated sites, this provided a good qualitative assessment that Glu was being 
measured.  Figure 2.11 shows a screen capture of a Glu self-referencing MEA 
during an in vivo experiment.   
 Quantitatively, the self-referencing method was even more powerful.  
Since some of the response on the GluOx coated sites was attributed to 
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Figure 2.10:  Nafion® and mPD Self-Referencing MEA Schematic 
 
Schematics and photomicrographs of an S2, Nafion® coated (A) and mPD coated (B), self-
referencing, Glu selective MEA.  The left side of each schematic shows the bottom pair of Pt 
recording sites coated with GluOx, BSA, and Glut. The Glu that came into contact with the GluOx 
was converted to α-ketoglutarate and H2O2.  The H2O2 readily diffused through the Nafion® or 
mPD layer that blocked anionic substances such as AA and DOPAC.  When the H2O2 came into 
contact with the Pt recording sites at a potential of +0.7 V versus a Ag/AgCl reference, the H2O2 
was oxidized and the resulting two electrons were transferred to the Pt recording site and the 
change in current was measured by the FAST 16 Mark II system.  The right side of each 
schematic shows the top pair of Pt recording sites coated with the inactive protein matrix of BSA 
and Glut, also referred to as the sentinel sites.  Since no GluOx was coated onto this pair of 
recording sites, Glu was not converted to a reporter molecule and thus was not measured on the 
Pt recording sites.  Once again, the Nafion® or mPD acts on these sites based on charge or size 
exclusion, respectively.  
 
 
 
 
 
  60
 
 
Figure 2.11:  Screen Capture of an In Vivo Glu Response on a Self-Referencing MEA 
 
Screen capture of the FAST-16 Mark II system with a self-referencing Glu MEA.  Stimulus-evoked 
(70 mM KCl) Glu release was measured in the motor cortex of a rhesus monkey.  Each colored 
line corresponds to a different Pt recording site (1=white, 2=red, 3=green, 4=blue).  Sites 1 and 2 
are coated with GluOx and show a rapid, robust increase in extracellular Glu compared to the two 
sentinel recording sites (Sites 3 and 4).   
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interferents, the sentinel sites were used to record the interferents contributing to 
the Glu response.  If the recording sites’ measure of Faradaic responses to DA 
and H2O2 are close (<10%) during calibration, the raw current data collected for a 
sentinel recording site was subtracted from the raw current obtained from the 
GluOx coated sites.  This new raw current, once divided by the slope of the 
corresponding GluOx recording site, provided the adjusted concentration of Glu 
that was free of interferents.  This unique feature of our MEAs allowed us to 
study resting Glu levels (Day et al., 2006; Rutherford et al., 2007), which is 
examined in more detail in chapter Five. 
 Besides removal of interferents that contributed to a portion of the analyte 
signal, self-referencing recordings removed periodic or random noise (Burmeister 
et al., 2002).  This was an obvious advantage because smaller changes in 
current (lower detection limits) were achieved.  Figure 2.12 illustrates removal of 
noise using self-referencing recordings.  The noisy upper trace was a response 
from a GluOx coated recording site, while the middle trace was the resulting 
sentinel site response.  When the sentinel site raw current is subtracted from the 
GluOx raw current and divided by the slope of the GluOx coated site, the signal-
to-noise ratio of the peaks was greatly improved as shown in the lower trace.  
This dual-channel noise subtraction approach is widely used in other 
methodologies such as electrophysiology and spectroscopy and is now used with 
the our MEAs. 
 
Signal Analysis 
A Picospritzer® III (Parker Hannifan, Corp, General Valve Operation) or 
related hardware was connected to the FAST 16 Mark II recording system, so 
when solutions were pressure ejected through the glass micropipette, or 
experimental events occurred, the software recorded these events.  The FAST 
16 Mark II recording system automatically saved amperometric data, time, and 
pressure ejection marks (external events) for all four channels for a specified 
time period.  All calculations were performed offline using a Microsoft Office 
ExcelTM macro created by Jason J. Burmeister. As the FAST 16 Mark II recording 
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Figure 2.12:  Example of Self-Referencing Subtraction 
 
Pressure ejection of 70 mM KCl (black arrowheads) caused a release of Glu in the Str of a 
C57BL/6 mouse.  Non-Faradaic current decreased the signal-to-noise ratio making it difficult to 
distinguish between current fluctuations and low Glu responses.  The noise occurred on both the 
GluOx coated sites (top, black trace) and the sentinel recordings sites (middle, red trace).  When 
the raw current from the sentinel recording site was subtracted from the raw current on the GluOx 
coated sites, the noise was removed creating a higher signal-to-noise ratio for Glu measurements 
(lower, blue trace).   
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software progressed, we analyzed individual peaks during the actual experiment.  
However, for the purposes of this dissertation, all data calculations were 
performed using the Microsoft Office ExcelTM macro.   
 Figure 2.13A shows a typical Glu current signal (blue) and the 
corresponding self-referencing current (red) at 10 Hz.  For Glu analysis, the 
absolute value of the self-referencing current was subtracted from the absolute 
value of the GluOx current and divided by the slope.  This yielded the Glu 
concentration trace free of interferents as shown in figure 2.13B. A 
stereomicroscope mounted on a universal boom stand fitted with a reticule 
monitored the amount of stimulus ejected from the glass micropipette (Friedmann 
and Gerhardt, 1992).  Pressure ejection of 70 mM KCl (70 mM KCl, 79 mM NaCl, 
2.5 mM CaCl2, pH 7.4) caused a depolarization event and released Glu into the 
extracellular space, causing a robust and reproducible rise in the Glu signal 
compared to baseline.  The maximum change in concentration compared to 
baseline was referred to as maximum amplitude or amplitude of the Glu signal.  
This value was normally recorded in μM units.  Next, the maximum amplitude of 
the signal was divided by the amount of stimulus (i.e. volume pressure ejected 
from the glass micropipette) necessary to elicit the Glu release.  Volume 
displacement was calibrated according to the pipette inner diameter.  (Note: the 
single barrel glass micropipettes had a solution volume of approximately 250 nl 
per mm of glass, but this varies with the inner diameter/total volume of the glass 
micropipette.  For this reason, we suggest using the type of glass micropipettes 
from A-M Systems, Inc., Catalog #601500 as discussed earlier.)  The volumes of 
stimulus ejected were recorded in nanoliters, so this calculation was referred to 
as amplitude per nanoliter with units μM/nl.  Finally, the time period for the signal 
to reach the maximum amplitude from baseline was recorded (in seconds) and 
referred to as rise time (tr).   
 Signal decay referred to the point of maximum amplitude of the 
signal to its return to baseline.  The clearance of Glu was a result of the rapid 
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Figure 2.13:  Analysis Parameters 
 
The top graph (A) shows the absolute value of the current from a GluOx coated site (blue) and a 
self-referencing site (red).    The bottom graph (B) is a Glu trace after the absolute value of the 
current from the self-referencing site was subtracted from the absolute value of the current from 
the GluOx coated site and divided by the slope of the GluOx coated site obtained during 
calibration.  Additionally, this trace shows examples of resting Glu levels, maximum amplitude 
(Max Amp), t80, and uptake rate.  The diamonds on both graphs indicate local application of 0.5 µl 
of 1 mM Glu. 
 
 
 
 
 
 
  65
uptake of Glu into glial and neuronal transporters (Danbolt, 2001).  Glu uptake 
followed apparent first order decay rate.  The decay of the Glu signal was fitted to 
the slope of the linear regression of the natural log transformation of the data 
over time and this was referred to as k-1 and had units of sec-1 (Parikh et al., 
2004).   When k-1 was multiplied by the maximum amplitude of the signal, the 
uptake rate, or micromolar of Glu removed from the extracellular space per 
second (μM/sec), was obtained.  Finally, the decay of the signal was examined at 
different percentages of decay.  These often include t50, t80, and t100, and follow 
the general format of tD (sec), where t refers to the time from maximum amplitude 
for the signal to decay by D percent.     
 
Development of Mouse Lines 
All transgenic and knockout (KO) mice were developed at the University of 
Kansas by Dr. Elias K. Michaelis’s laboratory.  All transgenes were inserted into 
the mouse genome under the control of the Neuronal specific enolase (NSE) 
promoter.  The NSE promoter has been shown to be expressed only in neurons 
of the brain and spinal cord (Choi et al., 1992; Peel et al., 1997).  Transgenic 
mice were generated by injecting mouse oocytes (C57BL/6J-SJL hybrid) with 
vectors containing cDNA of mouse GLUD1 or rat GPT placed under the control 
of the NSE promoter.  This promoter was excised from the pNSE-LacZ vector by 
first digesting the SV40 polyA tail of pNSE-LacZ vector and cloning it into pGEm-
7Z.  The NSE promoter was also excised and cloned into the modified pGEM-7Z.  
Finally, either a GLUD1 or GPT open reading frame was cloned into the pNSE-
GEM-7Z to create the pNSE-GLUD1 or pNSE-GPT vector, respectively.  This 
vector was digested, the DNA recovered, and microinjected into the nucleus of 
fertilized mouse ooctyes to generate either the GLUD1 or GPT transgenic mice.  
Oocytes were transferred to surrogate C57BL/6 or BALB/C mice.  Pups carrying 
the transgene were identified by PCR and Southern Blot Analysis. 
 
Copyright © Kevin Nicholas Hascup 
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Chapter Three: Glutamate Dynamics in Glutamate Dehydrogenase          
C57BL/6 and BALB/C Transgenic Mice 
 
Introduction 
 Glu is the predominant excitatory neurotransmitter in the mammalian CNS 
with an indirect excitotoxic role implicated in several neurodegenerative disorders 
including PD, AD, and ALS (Doble, 1999).  Evidence supports that mitochondrial 
damage leads to energy impairment and a decrease in intracellular ATP levels 
(Beal, 1992; Greene and Greenamyre, 1996; Doble, 1999).  As ATP levels 
decrease, the Na+/K+ ATPase, responsible for maintaining the resting membrane 
potential slows down causing membrane depolarization.  This can relieve the 
magnesium block on NMDA channels as well as open voltage-gated calcium 
channels.  With the magnesium block removed, the NMDA receptor is more 
susceptible to activation by ambient or even slightly elevated levels of 
extracellular Glu (Beal, 1992; Greene and Greenamyre, 1996; Doble, 1999). 
Over prolonged periods of time (years) this process becomes similar to what is 
seen in acute excitotoxicity.  For this reason, it has been postulated that slow, 
indirect excitotoxicity is partly responsible for the neuronal loss seen in several 
neurodegenerative disorders. Over-activation of the iGluRs are responsible for 
these excitotoxic effects (Gardoni and Di Luca, 2006) through the influx of 
calcium into the neuron (Doble, 1999).  NMDA receptor antagonists have 
beneficial effects on experimental models of PD (Nash et al., 2000; Loschmann 
et al., 2004) as well as blocking the development of L-DOPA-induced dyskinesias 
(Tahar et al., 2004; Wessell et al., 2004).  Clinical trials with memantine, an 
NMDA receptor antagonist, have shown functional improvement in AD patients 
with severe dementia (Parsons et al., 1999; Winblad and Poritis, 1999; Miguel-
Hidalgo et al., 2002).  Memantine does not accumulate in the channel during 
normal synaptic activity, which offers a novel approach for the treatment of AD. 
This drug blocks high levels of Glu at the NMDA receptor, while allowing 
activation by low levels of physiologically relevant neurotransmission.  (Hynd et 
al., 2004; Lipton, 2005).  Finally, ALS is characterized by the selective loss of 
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motor neurons that leads to the muscle weakening, paralysis, and eventual 
respiratory failure (Williams and Windebank, 1991; Doble, 1999; Rao and Weiss, 
2004).  While no specific NMDA antagonist drugs have been identified for the 
treatment of ALS, riluzole, a drug that inhibits neuronal release of Glu, increased 
the lifespan of ALS patients by 3 months (McGreer and McGreer, 2005).   
 Few studies have examined the cause for these excessive levels of Glu in 
neurodegenerative disorders such as ALS, which has the largest body of 
evidence supporting that excitotoxicity contributes to the progression of 
symptoms (Doble, 1999).  In ALS, several parameters involving dysfunction of 
glutamatergic neurotransmission have been identified including increased Glu 
levels in the CSF, decreased Glu uptake, and elevated amounts of Glu 
metabolizing enzymes (Heath and Shaw 2002).  Plaitakis and Caroscio (1987) 
showed increased fasting plasma levels of Glu in ALS patients, and others have 
shown increased levels of Glu in the CSF of ALS patients (Rothstein et al., 1990; 
Spreux-Varoquaux et al., 2002). Several studies have also reported contradictory 
findings indicating decreases in Glu levels in various regions of post-mortem 
CNS tissue in ALS patients compared to controls (Perry et al., 1987; Tsai et al., 
1990).  Deficiencies in Glu transporters are also implicated for the reason behind 
increased Glu levels in the CNS.  Rothstein and colleagues (1992) were the first 
to demonstrate decreased Glu transport using synaptosomes from affected brain 
areas of ALS patients.  Furthermore, it has been shown that the EAAT2 
transporter number is decreased in ALS patients compared to control (Rothstein 
et al., 1995; Fray et al., 1998; Sasaki et al., 2000). 
 However, a study conducted by Malessa and colleagues (1991) showed 
alterations in Glu metabolizing enzymes in ALS patients compared to control 
patients.  In particular, GLUD1 was upregulated in the ventral horn of the spinal 
cord of ALS patients compared to controls (Malessa et al., 1991).  This enzyme 
was also upregulated in the PFC of AD patients (Burbaeva et al., 2005), as well 
as schizophrenic patients (Burbaeva, 2003, 2007).  GLUD1 catalyzes a 
reversible reaction that favors Glu formation from ammonia and α-ketoglutarate 
(Yudkoff et al., 1991; Kanamori and Ross, 1995; Bak et al., 2006).  Unfortunately, 
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no specific modulators for this enzyme exist, which has prevented appropriate in 
vivo study of the role this enzyme plays on glutamatergic neurotransmission.  For 
this reason, a mouse model was created that overexpresses neuronal GLUD1 in 
both the C57BL/6 and BALB/C mouse strains to elucidate the role of GLUD1 on 
the neuronal contribution of Glu.   
 In the present study we examined the differences in stimulus-evoked Glu 
release and reuptake (using an isotonic solution of 70 mM KCl and 5 mM Glu; pH 
7.4) in the Str of C57BL/6 and BALB/C GLUD1 mice compared to wildtype (WT) 
littermates.  Stimulus-evoked Glu release provides an indication as to any 
differences upregulation of GLUD1 causes in the amount of Glu available for 
neuronal release.  Examining reuptake of stimulus-evoked Glu release as well as 
clearance of exogenously applied Glu provided information regarding Glu 
transporter availability or function in the transgenic mice compared to WT 
controls.   
 
Methods 
All transgenic mice were developed at the University of Kansas by Dr. 
Elias K. Michaelis’s laboratory.  The GLUD1 transgene was inserted into the 
mouse genome under the control of the Neuronal specific enolase (NSE) 
promoter.  The NSE promoter has been shown to be expressed only in neurons 
of the brain and spinal cord (Choi et al., 1992; Peel et al., 1997).  Transgenic 
mice were generated by injecting mouse oocytes (C57BL/6J-SJL hybrid) with 
vectors containing cDNA of mouse GLUD1 placed under the control of the NSE 
promoter.  This promoter was excised from the pNSE-LacZ vector by first 
digesting the SV40 polyA tail of pNSE-LacZ vector and cloning it into pGEm-7Z.  
The NSE promoter was also excised and cloned into the modified pGEM-7Z.  
Finally, a GLUD1 open reading frame was cloned into the pNSE-GEM-7Z to 
create the pNSE-GLUD1 vector.  This vector was digested, the DNA recovered, 
and microinjected into the nucleus of fertilized mouse ooctyes to generate the 
GLUD1 transgenic mice.  Oocytes were transferred to surrogate C57BL/6 or 
BALB/C mice.  Pups carrying the transgene were identified by PCR and 
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Southern Blot Analysis.  Progeny were eventually backcrossed into both a 
C57BL/6 or BALB/C mouse strains.  Our colleagues were interested in examining 
the in vivo effects of this enzyme in two different strains of mice, because of 
western blot studies that indicated exogenous expression of GLUD1 was 
increased in C57BL/6 mice compared to BALB/C mice (figure 3.1).  Gene copy 
number was assayed by Southern Blot analysis and determined to be 
upregulated three to four-fold in the transgenic mouse strains compared to WT 
littermates through the first four generations of breeding.   
 GLUD1 transgenic and WT C57BL/6 and BALB/C mice were transported 
to the University of Kentucky and housed as described in Chapter Two.  Male 
C57BL/6 and BALB/C mice between the ages of 8 and 12 months were used at 
the time of recordings.  Mice were given 3 i.p. injections of 12.5% urethane for a 
total dose of 1.25 g/kg.  All studies were conducted in the Str.  Glu recordings 
were conducted using enzyme-based MEAs with a sampling rate of 1 Hz. as 
previously described in Chapter Two.  At the time of our studies in the C57BL/6 
GLUD1 transgenic mice, self-referencing techniques were not being utilized.  As 
our MEA technology progressed, self-referencing was routinely utilized including 
the study with BALB/C GLUD1 transgenic mice.  A craniotomy was performed 
over both striatal hemispheres and MEAs were positioned using the coordinates 
from Paxinos and Franklin (2004) (AP: +0.9 mm; ML ± 1.5, ±1.7 mm; DV: -2.35, -
2.85, -3.35, -3.85 mm) in order to create a depth profile of the Str in transgenic 
and WT mice.  A glass micropipette with an internal diameter of 10-12 µm was 
attached to the PCB and positioned among the 4 Pt recording sites, resting 50-
100 µm above the recording surface.  Through this glass micropipette isotonic 
solutions of 70 mM KCl (70 mM KCl, 79 mM NaCl, 2.5 mM CaCl2; pH 7.4) or 5 
mM Glu (in 0.9% saline; pH 7.4) were locally applied to the surrounding brain 
tissue to study glutamatergic neurotransmission. Upon initial MEA implantation, a 
stable baseline recording was obtained for at least 30 minutes prior to local 
application of solutions.  When self-referencing MEAs were used, resting Glu 
levels were calculated at the end of this initial baseline time period.  After the 
initial baseline recording, solutions were locally applied at regular 30 second 
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Figure 3.1:   Western Blot Analysis of Exogenous GLUD1 
 
C57BL/6 mice showed increased endogenous expression for the enzyme GLUD1 compared to 
BALB/C mice.  BALB/C mice had approximately 55% the endogenous activity of GLUD1 
compared to C57BL/6 levels.  Data table and blots supplied by the University of Kansas. 
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intervals (for a total of 20 signals; 10 signals from each Pt recording site) to 
assess Glu dynamics at each dorsal ventral position. Due to the reproducibility 
of Glu signals in vivo (figure 3.2), all signals for a particular depth were averaged 
into a single data set for that depth.  Data analysis involved a two-tailed student’s 
t-test comparing GLUD1 transgenic to WT for each strain.  All data is reported as 
mean ± standard error of the mean and significance was defined as p < 0.05. 
 
Results 
 The fact that α-ketoglutarate was a product of GluOx activity and a 
substrate for GLUD1, we needed to determine the concentration of α-
ketoglutarate that would significantly decrease our MEA response to Glu.  To do 
this we calibrated the same GluOx MEA in 0.05M PBS with varying 
concentrations of α-ketoglutarate in the buffer.  We determined that 
approximately 5 mM α-ketoglutarate was required before a significant (p<0.05) 
drop in MEA sensitivity to Glu was observed (figure 3.3).  MEA current values 
after calibration in increasing buffer concentrations of α-ketoglutarate are shown 
in table 3.1.  Dicarboxylate transporters were found on both astrocytes and 
neurons indicating that α-ketoglutarate existed in the same location as our 
recordings, the extracellular space.  While no studies were found that determined 
the relative KM values for these transporters with α-ketoglutarate, KM values for 
similar TCA cycle substrates were found in the tens of micromolar range (Pajor, 
2006).  This was much less than the approximate 5 mM concentration needed to 
significantly reduce MEA sensitivity to Glu.   
 In the C57BL/6 GLUD1 transgenic and WT mice, local application of 70 
mM KCl resulted in robust, reproducible Glu signals compared to baseline.    We 
also observed that the GLUD1 transgenic mice released more Glu upon 
depolarization compared to WT littermates (Figure 3.4).  To quantitate this 
finding, we volume matched the amount of stimulus locally applied to both mouse 
groups.  Only Glu signals that were elicited by 100 to 200 nl of 70 mM KCl were 
used for this analysis, therefore, no significant difference in the amount of 
stimulus used was observed between the GLUD1 transgenic (134 ± 8 nl) and WT 
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Figure 3.2:  Reproducibility of Glu Signals From 70 mM KCl Depolarization 
 
The above trace demonstrated the reproducibility of Glu signals elicited due to stimulus-evoked 
release by 70 mM KCl.  Signals were from a GLUD1 transgenic BALB/C mouse and taken at 
approximately 30 second intervals.  The reproducibility of the Glu signals allowed us to average 
the individual signals for a given depth into a single data set.   
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Figure 3.3:  Effects of α-Ketoglutarate on MEA Sensitivity 
 
All four sites of a Glu selective MEA were coated with GluOx and its response to Glu was 
determined in 0.05 M PBS with increasing concentrations of α-ketoglutarate.  Concentrations of 5 
mM α-ketoglutarate and higher significantly (*p<0.05; #p<0.001) decreased the MEA sensitivity to 
Glu.  Data was from a single MEA over four trials.  A one-way analysis of variance (ANOVA) with 
Tukey’s post hoc was used to determine significance.   
  74
Table 3.1:  Amperometric Glu Current with Increasing Buffer Concentration of                    
α-Ketoglutarate 
 
[α-KG] 
(mM) 
0 1 3 5 7 10 
Current 
(pA) 
47.2 ± 3.2 44.1 ± 3.3 36.1 ± 3.5 32.9 ± 3.2 25.5 ± 2.7 23.3 ± 2.8 
 
Data is averaged from a single MEA over four trials and shown as mean ± standard error of the 
mean. 
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Figure 3.4:  70 mM KCl-Evoked Glu Release Traces in the C57BL/6 Mouse 
 
Series of amperometric Glu recordings showing differences in volume matched, stimulus-evoked 
Glu release in WT (red) and GLUD1 (blue) transgenic C57BL/6 mice.  Note the reproducibility of 
the signal and the significantly increased release of Glu in the GLUD1 transgenic mice compared 
to WT.   Arrows indicate time points for local application of an isotonic solution of 70 mM KCl (pH 
7.4). 
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(140 ± 6 nl) mice (figure 3.5A).  When the average maximal amplitude of Glu 
release is quantitated, C57BL/6 GLUD1 transgenic mice (9.9 ± 1.4 µM) released 
significantly more Glu (p < 0.05) compared to WT littermates (6.3 ± 0.7 µM) 
(figure 3.5B).  Using the same subset of signals, striatal, depth-related alterations 
in stimulus-evoked Glu release were also examined (figure 3.6).  The average 
Glu release was calculated at each depth (DV -2.25 to -3.75 mm) and compared 
amongst C57BL/6 GLUD1 transgenic and WT mice.  No significant differences 
were seen within groups of mice, however, a significant difference (p<0.05) in 
Glu release was observed at depth -2.25 and -3.25 mm between GLUD1 
transgenic (9.5 ± 1.4 µM and 12.7 ± 3.0 µM, respectively) and WT mice (5.4 ± 0.6 
µM and 5.7 ± 0.8 µM, respectively).   
 Since neurotransmitter uptake follows classical Michaelis-Mentin kinetics 
(Nicholson, 1995) and was affected by the amount of available substrate, Glu 
uptake was analyzed by selecting a subset of signals with maximum release 
values were in the range of 3-13 µM.  This range was chosen, because these 
peak Glu values were easily obtainable in both groups.  Within this subset of 
signals, no significant difference in average maximum release of Glu was 
observed in WT (6.3 ± 0.4 µM) and GLUD1 transgenic mice (7.8 ± 0.6 µM), nor 
was a significant difference in the uptake rate of stimulus-evoked Glu release 
observed between WT (1.8 ± 0.2 µM/sec) and GLUD1 transgenic mice (1.9 ± 0.3 
µM/sec) (figure 3.7).   
 Because Glu transporters were electrogenic (Takahashi et al., 1997, 
Doble, 1999) and the introduction of potassium ions and subsequent membrane 
depolarization changed their function, we wanted to determine transporter 
function without membrane depolarization.  To do this, we locally applied an 
isotonic solution of 5 mM Glu (pH 7.4) and used a subset of Glu signals that were 
in the same range as those used for our stimulus-evoked Glu uptake analysis, 3-
13 µM.  There was no significant difference in the maximal amplitude of 
exogenously applied 5 mM Glu in the C57BL/6 GLUD1 transgenic (7.7 ± 0.8 µM) 
and WT (9.5 ± 0.4 µM) mice (figure 3.8A).  Similar to the stimulus-evoked Glu 
data, there was no significant difference in the clearance rate for locally applied 
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Figure 3.5:  Stimulus-Evoked Glu Release in C57BL/6 GLUD1 Transgenic Mice 
 
A) Only Glu signals that were elicited by 70 mM KCl whose volumes ranged between 100 and 
200 nl were analyzed for the C57BL/6 GLUD1 transgenic (n=4) and WT (n=9) mice.  Since the 
volumes were matched, no significant difference in the amount of stimulus locally applied was 
observed between WT (140 ± 6 nl) and transgenic mice (134 ± 8 nl).  B) The average maximal 
amplitude of Glu released after local application of 70 mM KCl was significantly increased         
(*p < 0.05) in the GLUD1 transgenic (9.9 ± 1.4 µM) compared to WT littermates (6.3 ± 0.7 µM). 
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Figure 3.6:  Stimulus-Evoked  Glu  Release  Depth  Profile  in  the  C57BL/6  Mouse 
 
Average stimulus-evoked Glu release at different recording depths within the Str of C57BL/6 
GLUD1 transgenic (n=4) and WT (n=9) mice.  GLUD1 transgenic mice released significantly 
(*p<0.05) more Glu compared to WT littermates at depths -2.25 and -3.25 mm.  At recording 
depths -2.75 and -3.75 mm there was no significant difference in the amount of Glu released 
between the two mouse groups. (*p<0.05 based on a two-tailed t-test for comparing mouse 
groups at individual recording depths). 
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Figure 3.7:  Stimulus-Evoked Glu Uptake in the C57BL/6 Mouse Groups 
 
A)  To properly study uptake kinetics, a subset of Glu signals were examined whose average 
maximal amplitude fell in a range of 3-13 µM for both the C57BL/6 GLUD1 transgenic (n=4) and 
WT (n=9) mice.  No significant difference was observed between WT (6.3 ± 0.4 µM) and GLUD1 
transgenic (7.8 ± 0.6 µM) mice.  B)  There was no significant difference in the uptake rate of 
stimulus-evoked Glu between WT (1.8 ± 0.2 µM/sec) and GLUD1 transgenic mice (1.9 ± 0.3 
µM/sec).
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Figure 3.8:  Clearance of Exogenously Applied 5 mM Glu 
 
A)  A subset of Glu signals were examined whose average maximal amplitude fell in a range of 3-
13 µM for both the C57BL/6 GLUD1 transgenic (n=4) and WT (n=9) mice.  No significant 
difference was observed between WT (9.5 ± 0.4 µM) and GLUD1 transgenic (7.7 ± 0.8 µM) mice.  
B)  There was no significant difference in the rate of Glu clearance between WT (2.9 ± 0.2 
µM/sec) and GLUD1 transgenic mice (2.5 ± 0.5 µM/sec). 
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5 mM Glu in the WT (2.9 ± 0.2 µM/sec) and GLUD1 transgenic mice (2.5 ± 0.5 
µM/sec) (figure 3.8B). 
 In the BALB/C GLUD1 transgenic and WT mice, local application of 70 
mM KCl resulted in robust, reproducible Glu signals compared to baseline similar 
to what was observed in the C57BL/6 mouse groups.  From these traces we 
noticed that the BALB/C GLUD1 transgenic mice released more Glu upon 
depolarization compared to WT littermates (Figure 3.9).  To quantitate this 
finding, we volume matched the amount of stimulus locally applied to both mouse 
groups.  Only Glu signals that were elicited by 50 to 150 nl of 70 mM KCl were 
used for this analysis, therefore, no significant difference in the amount of 
stimulus used was observed between the BALB/C GLUD1 transgenic (106 ± 4 nl) 
and WT (98 ± 5 nl) mice (figure 3.10A).  When the average maximal amplitude of 
Glu release is quantitated, BALB/C GLUD1 transgenic mice (5.2 ± 0.4 µM) 
released significantly more Glu (p < 0.05) compared to WT littermates (3.9 ± 0.4 
µM) (figure 3.10B).  Using the same subset of signals, striatal, depth-related 
alterations in stimulus-evoked Glu release were also examined (figure 3.11).  The 
average Glu release was calculated at each depth (DV -2.25 to -3.75 mm) and 
compared amongst the BALB/C mouse groups. No significant differences were 
seen within groups of mice, however, a significant difference (p<0.01) in Glu 
release was observed at the ventral depth of -3.25 mm between GLUD1 
transgenic (6.1 ± 0.7 µM) and WT mice (2.7 ± 0.4 µM).   
 Since neurotransmitter uptake follows classical Michaelis-Mentin kinetics 
(Nicholson, 1995) and was affected by the amount of available substrate, Glu 
uptake was analyzed by selecting a subset of signals with maximum release 
values were in the range of 3-13 µM.  This range was chosen, because these 
peak Glu values were easily obtainable in both groups.  Within this subset of 
signals, no significant difference in average maximum release of Glu was 
observed in WT (5.2 ± 0.3 µM) and GLUD1 transgenic mice (5.4 ± 0.3 µM), nor 
was a significant difference in the uptake rate of stimulus-evoked Glu release 
seen between WT (1.3 ± 0.1 µM/sec) and GLUD1 transgenic mice (1.6 ± 0.2 
µM/sec) (figure 3.12). 
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Figure 3.9:  70 mM KCl-Evoked Glu Release Traces in the BALB/C Mouse 
 
Series of amperometric Glu recordings showed differences in volume matched stimulus-evoked 
Glu release in WT (red) and GLUD1 (blue) transgenic BALB/C mice.  Note the reproducibility of 
the signal and the significantly increased release of Glu in the GLUD1 transgenic mice compared 
to WT.   Arrows indicate time points for local application of an isotonic solution of 70 mM KCl (pH 
7.4). 
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Figure 3.10:  Stimulus-Evoked Glu Release in BALB/C GLUD1 Transgenic Mice 
 
A) Only Glu signals that were elicited by 70 mM KCl whose volumes ranged between 50 and 150 
nl were analyzed for the BALB/C GLUD1 transgenic (n=4) and WT (n=5) mice.  Since the 
volumes were matched, no significant difference in the amount of stimulus locally applied was 
observed between WT (98 ± 5 nl) and transgenic mice (106 ± 4 nl).  B) The average maximal 
amplitude of Glu released after local application of 70 mM KCl was significantly increased (*p < 
0.05) in the GLUD1 transgenic (5.2 ± 0.4 µM) mice compared to WT littermates (3.9 ± 0.4 µM).  
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Figure 3.11:  Stimulus-Evoked Glu Release Depth Profile in the BALB/C Transgenic Mice 
 
Average stimulus-evoked Glu release at different recording depths within the Str of BALB/C 
GLUD1 transgenic (n=4) and WT (n=5) mice.  GLUD1 transgenic mice (6.1 ± 0.7 µM) released 
significantly (**p<0.01) more Glu compared to WT littermates (2.7 ± 0.4 µM) at depth -3.25 mm.  
At the other three recording depths, there was no significant difference in the amount of Glu 
released between the two mouse groups.  (Significance based on a two-tailed t-test for 
comparing mouse groups at individual recording depths).   
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Figure 3.12:  Stimulus-Evoked Glu Uptake in the BALB/C Mouse Groups 
 
A)  A subset of Glu signals were examined whose average maximal amplitude fell in a range of 3-
13 µM for both the BALB/C GLUD1 transgenic (n=4) and WT (n=5) mice.  No significant 
difference was observed between WT (5.2 ± 0.3 µM) and GLUD1 transgenic (5.4 ± 0.3 µM) mice.  
B)  There was no significant difference in the rate of stimulus-evoked Glu clearance between WT 
(1.3 ± 0.1 µM/sec) and GLUD1 transgenic mice (1.6 ± 0.2 µM/sec). 
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 Due to the electrogenic nature of Glu transporters (Takahashi et al., 1997; 
Doble, 1999), we wanted to determine transporter function without membrane 
depolarization.  Do to this, we locally applied an isotonic solution of 5 mM Glu 
(pH 7.4) and used a subset of Glu signals that were in the same range as those 
used for our stimulus-evoked Glu uptake analysis (3-13 µM).  There was no 
significant difference in the maximal amplitude of exogenously applied 5 mM Glu 
in the BALB/C GLUD1 transgenic (7.8 ± 0.3 µM) and WT (8.3 ± 0.3 µM) mice 
(figure 3.13A).  Similar to the stimulus-evoked Glu data, there was no significant 
difference in the clearance rate for locally applied 5 mM Glu in the WT (2.5 ± 0.2 
µM/sec) and GLUD1 transgenic mice (2.4 ± 0.5 µM/sec) (figure 3.13B). 
 Since self-referencing MEAs were used to study the BALB/C GLUD1 
transgenic mice, we were able to determine resting Glu levels in the Str.  Thirty 
second baseline measures were taken prior to local application of 70 mM KCl at 
each recording depth.  Resting Glu levels were only measured when 70 mM KCl 
was in the barrel of the glass micropipette.  Possible diffusion of 5 mM Glu out of 
the barrel could cause unphysiologically elevated resting Glu levels.  Using our 
self-referencing recording techniques, resting Glu levels were determined and 
found to be similar in the Str of both WT (0.8 ± 0.1 µM) and GLUD1 transgenic 
mice (0.8 ± 0.2 µM; figure 3.14A).    Additionally, a depth analysis profile revealed 
resting Glu levels were similar at all recording depth within mouse groups and 
across groups of mice at individual depths (figure 3.14B). 
 Because the immunohistochemical data obtained from the University of 
Kansas revealed that endogenous expression of GLUD1 in the BALB/C mouse 
strain was approximately 55 percent the C57BL/6 strain (figure 3.15A), we 
wanted to compare maximal amplitude of stimulus-evoked Glu release in the WT 
and GLUD1 transgenic mouse strains.  When we compared the BALB/C WT 
mice to the C57BL/6 WT mice we saw that the BALB/C WT mice released 
significantly (p<0.01) less Glu upon stimulation compared to the C57BL/6 WT 
mice (figure 3.15B).  The average maximal values in the BALB/C WT mice were 
approximately 62 percent of the C57BL/6 WT mice. The BALB/C GLUD1 
transgenic  mice  released  significantly  (p<0.001)  less  Glu  upon  stimulation  
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Figure 3.13:  Clearance of Exogenously Applied 5 mM Glu in BALB/C Mice 
 
A)  A subset of Glu signals were examined whose average maximal amplitude fell in a range of 3-
13 µM for both the BALB/C GLUD1 transgenic (n=3) and WT (n=3) mice.  No significant 
difference was observed between WT (7.8 ± 0.3 µM) and GLUD1 transgenic (8.3 ± 0.3 µM) mice.  
B)  There was no significant difference in the rate of exogenously applied Glu clearance between 
WT (2.5 ± 0.2 µM/sec) and GLUD1 transgenic mice (2.4 ± 0.2 µM/sec). 
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Figure 3.14:  Resting Glu Levels in the BALB/C GLUD1 Transgenic Mice 
 
A) Averaged resting Glu levels were determined for the entire Str and no significant difference 
was found between WT (0.8 ± 0.1 µM) and GLUD1 transgenic mice (0.8 ± 0.2 µM).  B) Average 
resting Glu levels were determined for each depth within the Str.  No significant difference was 
observed within mouse groups neither at different depths nor across mouse groups at each 
recording depth.  
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Figure 3.15:  Endogenous GLUD1 Expression Correlates with Stimulus-Evoked Glu 
Release 
 
A) C57BL/6 mice showed increased endogenous expression for the enzyme GLUD1 compared to 
BALB/C mice.  BALB/C mice had approximately 55% endogenous activity of GLUD1 compared to 
C57BL/6 levels (*p<0.05).  Data table and blots supplied by the University of Kansas.  B) 
Comparison of stimulus-evoked Glu release between WT and GLUD1 transgenic mouse groups.  
BALB/C WT mice released approximately 62% of the amount of Glu as compared to C57BL/6 WT 
mice (**p<0.01) while BALB/C GLUD1 transgenic mice released approximately 53% of the 
amount of Glu compared to C57BL/6 GLUD1 transgenic mice (***p<0.001).   
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compared to the C57BL/6 GLUD1 transgenic mice.  The average maximal values 
of Glu release in the BALB/C GLUD1 transgenic mice were approximately 53 
percent of the C57BL/6 GLUD1 transgenic mice.  This further supports that an 
increase in gene copy number resulted in an increased stimulus-evoked Glu 
release. 
 A microarray study was conducted at the University of Kansas to 
determine any additional genes that were up or down regulated in the C57BL/6 
mice due to the insertion of the pNSE-lacZ vector with the GLUD1 cDNA insert.  
Several genes were upregulated two fold in the C57BL/6 GLUD1 transgenic mice 
compared to C57BL/6 WT mice (Table 3.2).  The ones related to glutamatergic 
neurotransmission involved a mGluR (mGluR7), two different subunits for the 
NMDA receptor (NMDA2A and NMDA2B), and a calcium binding protein 
(Calbindin-28K). 
 
Discussion 
 These were the first studies demonstrated by our laboratory that our 
MEAs could be used to reliably study Glu in a mouse model.  Local application of 
70 mM KCl as well as 5 mM Glu resulted in Glu signals that were robust    and 
reproducible in both the WT and GLUD1 transgenic mouse strains.  We observed 
important differences between these two groups of mice that were similar across 
strains.  First, local application of 70 mM KCl resulted in significantly (p<0.05) 
increased release of Glu compared to WT littermates in both the BALB/C and 
C57BL/6 mice.  When a depth profile of the Str was analyzed, there were 
regional differences in the amount of stimulus-evoked Glu release. Next, we 
determined that the rate of uptake for stimulus-evoked Glu release as well as 
local application of 5 mM Glu was similar in both the WT and GLUD1 transgenic 
mice for both mouse strains.  As our MEA methodology advanced, we were able 
to use self-referencing techniques to determine resting Glu levels in the BALB/C 
mouse.  There was no significant difference in resting Glu levels in the BALB/C 
WT and GLUD1 transgenic mice.  A DNA microarray study revealed that some 
genes were upregulated 2 fold in the C57BL/6 GLUD1 transgenic mice compared 
to the WT mice.                          
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Table 3.2:  Microarray  Comparison  of  Transgenic  to  WT  GLUD1  C57BL/6  Mice 
 
Gene Protein Transgenic/WT Gene Ratio 
Grm7 mGluR7 2.092 
Grin2a NMDA2A 2.058 
Grin2b NMDA2B 2.058 
Calb1 Calbindin-28K 2.056 
 
A microarray study revealed that additional genes were upregulated two-fold in the GLUD1 
transgenic C57BL/6 mouse group compared to WT littermates.   
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 GLUD1 catalyzes a reversible reaction that favors Glu formation from 
ammonia and α-ketoglutarate (Yudkoff et al., 1991; Kanamori and Ross, 1995; 
Bak et al., 2006).  Unfortunately, no specific modulators for this enzyme exist, 
which has prevented appropriate in vivo study of the role this enzyme plays on 
glutamatergic neurotransmission.   For this reason, a mouse model was created 
that overexpresses neuronal GLUD1 in both the C57BL/6 and BALB/C mouse 
strains to elucidate the role of GLUD1 on the neuronal contribution of Glu.  Local 
application of 70 mM KCl resulted in significantly increased Glu release in the 
GLUD1 transgenic mice compared to WT mice for both C57BL/6 and BALB/C 
mouse strains.  In addition, when a depth profile of the Str was conducted, there 
were specific depths where Glu release was significantly increased in the GLUD1 
transgenic mice compared to the WT mice.  In the C57BL/6 GLUD1 transgenic 
mice, depths -2.25 and -3.25 mm showed significantly increased Glu release 
compared to the WT mice.  Only depth -3.25 mm in the BALB/C GLUD1 
transgenic mice had significantly increased stimulus-evoked Glu release 
compared to WT mice.  Depth -2.25 mm was elevated in the BALB/C GLUD1 
transgenic mice compared to WT mice, however, it was not significant.  This 
demonstrated the advantage of our recording capability to measure discrete 
regions within a large brain structure.  Other in vivo recording techniques, such 
as microdialysis, are too large to perform this type of analysis.  Because of this 
advantage, we have shown that the Str is not a homogenous structure for Glu 
release and regional differences exist.  More importantly, this was the first study 
that shows upregulation of a Glu metabolizing enzyme was responsible for 
increased neuronal release of Glu.  
 The uptake rate for stimulus-evoked Glu release as well as the clearance 
of exogenously applied Glu was determined for both mouse strains.  There was 
no significant difference in the stimulus-evoked Glu uptake rate or clearance of 
exogenously applied Glu observed between GLUD1 transgenic and WT mice in 
both strains.  However, we did observe that the uptake rate of exogenously 
applied Glu was increased in both strains of the GLUD1 transgenic and WT mice 
when compared to the uptake of stimulus-evoked Glu.  Since Glu uptake was 
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driven by electrochemical gradients across the cell membrane to produce a 
negative membrane potential (Takahashi et al., 1997; Doble, 1999), 
depolarization of glial membranes by the local application of 70 mM KCl may be 
responsible for the decreased stimulus-evoked Glu uptake compared to the 
clearance rate of exogenously applied Glu.  Despite this, both chemicals showed 
the same trends, which indicated that Glu uptake was similar between the 
GLUD1 transgenic and WT mice.  Even though the GLUD1 transgenic mice 
released significantly more Glu compared to WT mice during chemical 
stimulation, they removed this Glu from the extracellular space at the same rate 
as WT mice.  This meant that extracellular concentrations of Glu in the GLUD1 
transgenic mice were elevated for longer periods of time upon stimulation 
compared to WT mice.  Over a prolonged period of time, these elevated levels 
may lead to slow-indirect excitotoxicity.   
 Using our self-referencing recording techniques, we were able to record 
resting Glu levels in the Str of BALB/C WT and GLUD1 transgenic mice.  Resting 
Glu levels were similar in the WT and GLUD1 transgenic BALB/C mice.  This 
indicated that ambient levels of Glu were not elevated in the GLUD1 transgenic 
mice despite the fact that more Glu was released upon stimulation.  One possible 
explanation for this finding was that resting Glu levels were analyzed in 
anesthetized mice. Anesthetics such as urethane, which was used in these 
experiments, exert their effects by enhancing inhibitory synaptic 
neurotransmission as well as inhibiting excitatory neurotransmission (Hara and 
Harris, 2002).  Our lab has also demonstrated that urethane significantly 
decreased resting Glu levels by 58 percent (Rutherford et al., 2007).  Because of 
these two factors, anesthetized animal models may not provide accurate 
measures of resting Glu and future experiments in awake, freely moving GLUD1 
transgenic mice are needed to better determine unstimulated levels of Glu.   
 To determine additional genes that may have been up or down regulated 
due to the introduction of the GLUD1 vector, a DNA microarray study was 
conducted on the C57BL/6 mouse strain at the University of Kansas.  This study 
revealed that gene expression encoding several receptors for Glu signaling were 
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increased two fold (table 3.2).  The mGluR7 gene was increased.  This is a G-
protein coupled inhibitory autoreceptor found on both pre- and post-synaptic 
neurons.  In addition, two subunits of the NMDA receptor, the NMDA2A and 
NMDA2B were increased.  The NMDA2A receptor is the subunit for which Glu 
binds to open the calcium pore (Furukawa et al., 2005).  Finally, the gene for an 
intracellular calcium binding protein, Calbindin-28K, was also upregulated.  
Calbindin-28K buffers high levels of intracellular calcium, but Calbindin-28K is 
found in low levels in motor neurons and is non-existent in spinal motor neurons 
(Van Den Bosch et al., 2006).  While the microarray study did not correlate gene 
copy number to actual protein levels, it seemed evident that the GLUD1 
transgenic mice were attempting to compensate for the increased amount of 
stimulus-evoked Glu release and the possibility of slow, indirect excitotoxicity. 
 Upon completion of the study with the GLUD1 transgenic C57BL/6 mouse, 
it was decided to let a small group of the transgenic mice age to determine if any 
phenotypic traits developed.  At 16 months of age, we noticed that the mice 
developed lower limb abnormalities that affected their movement, gait, and 
righting behavior.  As of yet, BALB/C mice have not displayed such 
characteristics.  Upon further histological examination conducted at the 
University of Kansas, it was determined that the GLUD1 transgenic mice had 
severe atrophy of Betz cells in layer IV of the motor cortex (figure 3.16) as well as 
atrophy of the lower motor neuron in the ventral horn of the spinal cord (figure 
3.17).  These two areas were associated with motoric movement and helped to 
explain the motor deficits seen in the GLUD1 transgenic mice at 16 months of 
age.   
 The histology from the University of Kansas was not easily explained by 
itself, however, taken as a whole with our in vivo amperometric data we have 
proposed a working hypothesis as outlined in figure 3.18.  Upregulation of 
GLUD1 genes leads to production of more GLUD1 protein.  This in turn lead to 
the synthesis of Glu from α-ketoglutarate and subsequent increased vesicle 
packaging of Glu in glutamatergic neurons.  With increased amounts of Glu in  
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Figure 3.16:  C57BL/6 GLUD1 Transgenic Mouse Motor Cortex Histology 
 
The motor cortex of WT (left) and GLUD1 transgenic (right) C57BL/6 mice were stained for 
neurons.  GLUD1 transgenic mice showed severe atrophy of the large pyramidal neurons in 
Layer IV of the motor cortex associated with motor movement.  Staining and figures courtesy of 
the University of Kansas, Dr. Elias K. Michaelis’ laboratory. 
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Figure 3.17:  C57BL/6 GLUD1 Transgenic Mouse Spinal Cord Histopathology 
 
The ventral horn of the spinal cord in WT (left) and GLUD1 transgenic (right) C57BL/6 mice were 
stained for neurons.  GLUD1 transgenic mice showed severe atrophy of the large lower motor 
neurons in the ventral horn of the spinal cord associated with motor movement.  Staining and 
figures courtesy of the University of Kansas, Dr. Elias K. Michaelis’ laboratory. 
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vesicles, the GLUD1 transgenic mice release more Glu into the extracellular 
space upon stimulus-evoked Glu release as compared to WT mice as shown 
with our amperometry data.  Recent data have shown that pre-synaptic 
cytoplasmic Glu availability affects the mean quantal amplitude, which implies 
increased vesicular filling of Glu and more Glu released upon depolarization. 
(Ishikawa et al., 2002; Wilson et al., 2005; Wu et al., 2007).    Our amperometry 
data also showed that Glu uptake was the same rate in the GLUD1 transgenic 
mice compared to WT mice.  This means that more Glu is available in the 
synaptic cleft to activate iGluRs and mGluRs; in particular the NMDA receptor, 
whose Glu binding domain has been shown by DNA microarray data to be 
upregulated in GLUD1 transgenic mice.  Since motor neurons have little to no 
calcium sequestering proteins (Van Den Bosch et al., 2005) mitochondria are 
forced to buffer the intracellular calcium.  Over time, if the mitochondria become 
damaged by excessive intracellular calcium, proteases, oxygenases, and 
reactive oxygen species (ROS) form, which are key mediators of excitotoxic cell 
death (Nicholls and Budd, 2001).  This may explain the severe motor 
impairments and histological motor neuron atrophy staining seen in GLUD1 
transgenic mice at 16 months of age.   
 Using in vivo amperometry with our Glu selective MEAs, we demonstrated 
that upregulation of GLUD1 led to a significant increase in stimulus-evoked Glu 
release in both the C57BL/6 and BALB/C mouse strains.  Stimulus-evoked Glu 
release was also significantly higher in the C57BL/6 mouse strain compared to 
the BALB/C strain possibly due to the higher endogenous activity of GLUD1 in 
C57BL/6 mice.  We hypothesize that this increased stimulus-evoked Glu release 
caused excitotoxicity over time (16 months) that selectively damaged motor 
neurons in both the motor cortex and spinal cord leading to severe motoric 
deficits in the GLUD1 transgenic mice.  Despite the fact that stimulus-evoked Glu 
release was elevated in the BALB/C mice, it was not sufficient to cause 
excitotoxicity since the same phenotypic traits were not observed in this strain of 
mouse.  To our knowledge, the GLUD1 transgenic C57BL/6 mouse model was 
the first animal model that showed spontaneous motor neurodegeneration. 
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Figure 3.18:  Proposed Excitotoxic Mechanism for GLUD1 C57BL/6 Mice 
 
Our proposed hypothesis of the excitotoxic mechanism underlying the motor deficits seen in 
GLUD1 C57BL/6 trangenic mice.  The above figure depicted two synapses, one from a healthy, 
WT mouse (left) and the other synapse from GLUD1 transgenic C57BL/6 mice (right).  
Upregulation of GLUD1 genes led to production of more GLUD1 protein.  This in turn led to the 
synthesis of Glu from α-ketoglutarate and subsequent increased vesicle packaging of Glu in 
glutamatergic neurons.  With increased amounts of Glu in vesicles, the GLUD1 transgenic mice 
released more Glu into the extracellular space after stimulus compared to WT.   Glu uptake was 
similar between GLUD1 transgenic mice and WT mice.  More Glu was available in the synaptic 
cleft of GLUD1 trangsenic mice to activate iGluRs and mGluRs; in particular the NMDA receptor, 
whose gene for the Glu binding domain was upregulated in GLUD1 transgenic mice.  Since motor 
neurons had little to no calcium sequestering proteins, mitochondria were forced to buffer the 
intracellular calcium.  Over time, if the mitochondria became damaged by excessive intracellular 
calcium, proteases, oxygenases, and reactive oxygen species (ROS) formed, which were key 
mediators of excitotoxic cell death.  
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Chapter Four: Glutamate Dynamics in Glutamate Pyruvate              
Transaminase Transgenic and Knockout C57BL/6 Mice 
 
Introduction  
 The glutamate-glutamine cycle is a well understood mechanism that is 
essential for glutamatergic neurotransmission.  Upon depolarization and 
vesicular release of Glu, the neurotransmitter is taken up into astrocytes by high 
affinity transporters (Danbolt, 2001).  Once in the astrocytes, Glu is degraded into 
glutamine by glutamine synthetase that is localized only in astrocytes.  Glutamine 
is not neurotoxic and therefore it can be safely transported out of the astrocytes 
through System N located on astroglial cells. In the extracellular space, 
glutamine is transported into neurons through System A (Bak et al., 2006).  
When returned to the neuron, glutamine is converted back into Glu by PAG, 
which is located on the inner mitochondrial membrane (Kvamme et al., 2000).  
This Glu formed is returned to the cytosol and subsequently packaged into 
vesicles for future neurotransmitter signaling.   
 Since neurons are incapable of net synthesis of Glu from glucose 
(Waagepetersen et al., 2005), the Glutamate-glutamine cycle was previously 
thought to provide neurons with all the Glu necessary for neurotransmitter 
signaling.  Because of this theory, the glutamate-glutamine cycle was originally 
thought to operate in a stoichiometric one-to-one ratio.  For every Glu released, 
one glutamine was transported into neurons to replenish the neurotransmitter 
pool of Glu. However, recent evidence suggests this theory is simplistic (Broman 
et al., 2000; Fonnum, 1993; Peng et al., 1993; Danbolt, 2001; Waagepetersen et 
al., 2000; Hertz, 2004; Waagepetersen et al., 2005) due to recent 13C NMR data 
that suggests one-third of the Glu in the Glutamate-glutamine cycle is newly 
synthesized from glucose (Gruetter et al., 2001; Hertz, 2004).  This indicates that 
other enzymes must be responsible for synthesis and degradation of Glu for the 
neurotransmitter pool.  Glu is closely related metabolically to the TCA cycle 
(Hertz, 2004; Waagepetersen et al., 2005).  For example, when Glu is 
transported into astrocytes, it can be metabolized into glutamine by glutamine 
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synthetase or transaminated into α-ketoglutarate.          Alpha-ketoglutarate can 
then enter the TCA cycle where it eventually metabolizes into malate, which 
decarboxylates into pyruvate and reduces to lactate.  Lactate can be transported 
out of astrocytes and into neurons by monocarboxylate transporters (Gladden, 
2004).  Once in the neurons, lactate can oxidize to pyruvate and either re-enter 
the TCA cycle or transaminates back into Glu for neurotransmitter packaging and 
signaling (Refer to figure 1.2).  This example demonstrates one of the many 
possible fates of Glu and is used to show the complicated competition for Glu 
between cellular energy demands and neurotransmitter signaling.  Furthermore, 
Hassel and Bråthe (2000) demonstrate that it is possible to obtain Glu formation 
independent of glutamine.  This implies that enzymes other than PAG and 
glutamine synthetase are responsible for de novo synthesis or degradation of 
Glu.  Two such Glu metabolizing enzymes found in neurons are GPT and 
GLUD1.  Chapter Three highlighted the effects of upregulation of GLUD1 on 
increasing Glu for neurotransmitter release.  We wanted to characterize how 
upregulation or knockout of the GPT gene affects the neurotransmitter pool of 
Glu in the mouse Str. 
 GPT exists as a dimmer with a molecular mass of approximately 100 kDa 
in most species (Saier and Jenkins, 1967).  The enzyme catalyzes a reversible 
transaminase reaction using pyruvate as a co-substrate to form alanine and α-
ketoglutarate (Figure 1.3A).  Biochemical studies show GPT activity in both the 
cytosol and mitochondria of astrocytes and neurons (Balazs and Haslam, 1965; 
Erecińska et al., 1994), but the greatest activity is found in astrocytes of the 
cerebral cortex (Westergaard et al., 1993).  It is debated throughout the literature 
whether GPT favors Glu degradation (Saier Jr. and Jenkins, 1967; Ruščák et al., 
1982; Erecińska et al., 1994) or synthesis (Peng et al., 1991, 1993; Schousboe et 
al., 2003).  This process most likely depends on the amount of 
substrates/products available.  However, Matthews and colleagues (2000, 2003) 
demonstrated that GPT is an active Glu degrading enzyme that acts as an 
effective neuroprotectant in cell culture models of exogenous and endogenous 
Glu excitotoxicity.  Unfortunately, GPT does not exist in the extracellular space 
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and, due to its large size, is unable to cross the blood-brain barrier.  This makes 
it an unsuitable candidate for excitotoxicity thereapeutics; nevertheless these 
studies demonstrate the propensity for GPT to metabolize Glu.   
 Due to the broad spectrum of transaminase molecules found in the brain, 
there are no specific modulators for this enzyme.  To determine the role GPT 
plays on the neurotransmitter pool of Glu, two different mouse models were 
created.  The first model has upregulated activity of GPT, while the second 
model has removed this gene altogether.  In the present study we examined the 
differences in stimulus-evoked Glu release and reuptake (using an isotonic 
solution of 70 mM KCl and 5 mM Glu; pH 7.4) in the Str of GPT transgenic as 
well as knockout (KO) C57BL/6 mice. Stimulus-evoked Glu release provides an 
indication as to any differences upregulation or KO of GPT causes in the amount 
of Glu available for neuronal release.  Examining reuptake of stimulus-evoked 
Glu release and clearance of exogenously applied Glu provides information 
regarding Glu transporter availability or function in the transgenic and KO mice 
compared to WT controls.   
Methods 
 All transgenic mice were developed at the University of Kansas by Dr. 
Elias K. Michaelis’s laboratory.  A rat GPT transgene was inserted into the 
mouse genome under the control of the Neuronal specific enolase (NSE) 
promoter.  The NSE promoter has been shown to be expressed only in neurons 
of the brain and spinal cord (Choi et al., 1992; Peel et al., 1997).  Transgenic 
mice were generated by injecting mouse oocytes (C57BL/6J-SJL hybrid) with 
vectors containing cDNA of rat GPT placed under the control of the NSE 
promoter.  This promoter was excised from the pNSE-LacZ vector by first 
digesting the SV40 polyA tail of pNSE-LacZ vector and cloning it into pGEm-7Z.  
The NSE promoter was also excised and cloned into the modified pGEM-7Z.  
Finally, a GPT open reading frame was cloned into the pNSE-GEM-7Z to create 
the pNSE-GPT vector for the GPT transgenic mice.  To create the GPT KO line, 
a nonfunctional rat GPT open reading frame was cloned into the pNSE-GEM-7Z 
vector.  The vector was digested, the DNA recovered, and microinjected into the 
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nucleus of fertilized mouse ooctyes to generate either the GPT transgenic or KO 
mice.  Oocytes were transferred to surrogate C57BL/6 mice.  Pups carrying the 
transgene were identified by PCR and Southern Blot Analysis.  Progeny were 
eventually backcrossed into a C57BL/6 mouse strain.  Gene copy number was 
assayed by Southern Blot analysis and determined to be upregulated three to 
four-fold in the transgenic mouse strains compared to WT littermates through the 
first four generations of breeding.   
 GPT transgenic and KO C57BL/6 mice were transported to the University 
of Kentucky and housed as described in Chapter Two.  For the GPT C57BL/6 
mice, males between the ages of 8 and 12 months were used at the time of 
recordings.  For the GPT KO study, both male and female mice were studied.  
Only the results from the female analysis were included in this chapter.  Breeding 
prevented sufficient numbers of male homozygous mice for complete analysis.  
All data regarding male GPT KO mice are found in Appendix A.  Mice were given 
3 i.p. injections of 12.5% urethane for a total dose of 1.25 g/kg.  All studies were 
conducted in the Str.  Glu recordings were conducted using enzyme-based 
MEAs with a sampling rate of 1 Hz as previously described in Chapter Two.  At 
the time of our studies in the C57BL/6 GPT transgenic mice, self-referencing 
techniques were not utilized.  As our MEA technology progressed, self-
referencing was routinely utilized including the study with GPT KO mice.  A 
craniotomy was performed over both striatal hemispheres and MEAs were 
stereotaxically placed using the coordinates from Paxinos and Franklin (2004) 
(AP: +0.9 mm; ML ± 1.5, ±1.7 mm; DV: -2.25, -2.75, -3.25, -3.75 mm vs bregma) 
in order to create a depth profile of the Str.  A glass micropipette with an internal 
diameter of 10-12 µm was attached to the PCB and positioned among the four Pt 
recording sites, resting 50-100 µm above the recording surface.  Through this 
glass micropipette isotonic solutions of 70 mM KCl (70 mM KCl, 79 mM NaCl, 2.5 
mM CaCl2; pH 7.4) and 5 mM Glu (in 0.9% saline; pH 7.4) were locally applied to 
the surrounding brain tissue to study glutamatergic neurotransmission.  Upon 
initial MEA placement, a stable baseline recording was obtained for at least 30 
minutes prior to local application of solutions.  When self-referencing MEAs were 
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used, resting Glu levels were calculated during this initial baseline time period.  
After the initial baseline recording, solutions were locally applied at regular 30 
second intervals (for a total of 20 signals; 10 signals from each Pt recording site) 
to assess Glu dynamics at each dorsal ventral position. Due to the reproducibility 
of Glu signals in vivo (figure 4.1), all signals for a particular depth were averaged 
into a single data set for that depth.  Data analysis involved a two-tailed student’s 
t-test comparing GPT transgenic to WT mice.  An ANOVA with a Tukey’s post 
hoc test was used to analyze the GPT KO data to compare heterozygous and 
homozygous to control.  All data was reported as mean ± standard error of the 
mean and significance was defined as p < 0.05. 
 
Results 
 In the C57BL/6 GPT transgenic and WT mice, local application of 70 mM 
KCl resulted in robust, reproducible Glu signals compared to baseline (figure 
4.2).    We did not observe any significant difference in the amount of Glu 
released between transgenic and WT mice.  To quantitate this finding, we 
volume matched the amount of stimulus locally applied to both mouse groups.  
Only Glu signals that were elicited by 100 to 200 nl of 70 mM KCl were used for 
this analysis, therefore, no significant difference in the amount of stimulus applied 
was observed between the GPT transgenic (131 ± 7 nl) and WT (140 ± 6 nl) mice 
(figure 4.3A).  When the average maximal amplitude of Glu release was 
quantitated, there was no significant difference in the amount of Glu released 
between WT (6.3 ± 0.7 µM) and GPT transgenic (6.1 ± 0.9 µM) mice (figure 
4.3B).  Using the same subset of signals, any striatal, depth-related alterations in 
stimulus-evoked Glu release were also examined (figure 4.4).  The average Glu 
release was calculated at each depth (DV -2.25 to -3.75 mm) and compared 
amongst groups. No significant differences were seen within groups of mice 
across the different depths.  On average, GPT transgenic mice released slightly 
more Glu compared to WT mice at depth -2.25, 3.25, and 3.75 mm; however, it 
was not a significant difference.   
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Figure 4.1:  Reproducibility of Glu Signals from 70 mM KCl Depolarization 
 
The above trace demonstrated the reproducibility of Glu signals elicited due to stimulus-evoked 
release by 70 mM KCl.  Signals were from a GPT KO homozygous C57BL/6 mouse and taken at 
approximately 30 second intervals.  The reproducibility of the Glu signals allowed us to average 
the individual signals for a given depth into a single data set.  Arrows indicated time point of local 
application of an isotonic solution of 70 mM KCl.  
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Figure 4.2:  70 mM KCl-Evoked Glu Release Traces in the GPT Transgenic Mice 
 
Series of amperometric Glu recordings showing differences in volume matched stimulus-evoked 
Glu release in WT (red) and GPT (blue) transgenic mice.  Note the reproducibility of the signal in 
both WT and GPT transgenic mice.  Arrows indicate time points for local application of an isotonic 
solution of 70 mM KCl (pH 7.4). 
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Figure 4.3:  Stimulus-Evoked Glu Release in GPT Transgenic Mice 
 
A) Only Glu signals that were elicited by 70 mM KCl whose volumes ranged between 100 and 
200 nl were analyzed for the GPT transgenic (n=4) and WT (n=9) mice.  Since the volumes were 
matched, no significant difference in the amount of stimulus locally applied was observed 
between WT (140 ± 6 nl) and transgenic mice (131 ± 7 nl).  B) The average maximal amplitude of 
Glu released upon local application of 70 mM KCl was not significantly different in the GPT 
transgenic (6.1 ± 0.9 µM) compared to WT littermates (6.3 ± 0.7 µM). 
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Figure 4.4:  Stimulus-Evoked Glu Release Depth Profile in the GPT Transgenic Mouse 
 
Average stimulus-evoked Glu release at different recording depths within the Str of GPT 
transgenic (n=4) and WT (n=9) mice.  No significant differences were observed within groups of 
mice across the different depths.  On average, GPT transgenic mice released slightly more Glu 
compared to WT mice at depths -2.25, 3.25, and 3.75 mm; however, it was not a significant 
difference.  A two-tailed t-test was conducted at each depth for statistical analysis. 
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 Since neurotransmitter uptake follows classical Michaelis-Mentin kinetics 
(Nicholson, 1995) and was affected by the amount of available substrate, Glu 
uptake was analyzed by selecting a subset of signals with maximum release 
values were in the range of 3-13 µM.  This range was chosen, because these 
peak Glu values were easily obtainable in both groups.  Within this subset of 
signals, no significant difference in average maximum release of Glu was 
observed in WT (6.3 ± 0.4 µM) and GPT transgenic (6.3 ± 0.6 µM) mice (figure 
4.5A).  We did observe a significant decrease in the uptake rate of stimulus-
evoked Glu seen between WT (1.8 ± 0.2 µM/sec) and GPT transgenic (0.7 ± 0.1 
µM/sec) mice (figure 4.5B).  Using the same subset of signals, we wanted to 
examine if there was any depth related alterations in the uptake rate of stimulus-
evoked Glu release (figure 4.6).  No significant differences were seen within 
groups of mice across the different depths.  On average, GPT transgenic mice 
had slower uptake of Glu compared to WT mice over all depths.  This decrease 
was only significant (**p<0.01) at DV -3.25 mm between WT (2.0 ± 0.3 µM/sec) 
and GPT transgenic (0.6 ± 0.2 µM/sec) mice.   
 Because Glu transporters are electrogenic (Takahashi et al., 1997; Doble, 
1997) and the introduction of potassium ions and subsequent membrane 
depolarization changed their function, we wanted to determine transporter 
function without membrane depolarization.  To do this, we locally applied an 
isotonic solution of 5 mM Glu (pH 7.4) and used a subset of Glu signals that were 
in the range of 3-13 µM, which was the same range used to analyze the uptake 
of stimulus-evoked Glu.  Since we amplitude matched, there was no significant 
difference in the maximal amplitude of exogenously applied 5 mM Glu in the GPT 
transgenic (8.3 ± 0.6 µM) and WT (9.5 ± 0.4 µM) mice (figure 4.7A).  Similar to 
the stimulus-evoked Glu uptake data, there was a significant decrease (**p<0.01) 
in the clearance rate for locally applied 5 mM Glu for the GPT transgenic (1.7 ± 
0.2 µM/sec) mice compared to WT (2.9 ± 0.2 µM/sec) mice  (figure 4.7B).  Using 
the same subset of signals, we wanted to examine if there was any depth related 
alterations in the clearance of exogenously applied Glu (figure 4.8).  No 
significant  differences  were  seen  within  groups  of  mice  across  the  different  
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Figure 4.5:  Stimulus-Evoked Glu Uptake in the GPT Transgenic Mouse Groups 
 
A)  A subset of Glu signals were examined whose average maximal amplitude fell in a range of 3-
13 µM for both the GPT transgenic (n=4) and WT (n=9) mice.  No significant difference was 
observed between WT (6.3 ± 0.4 µM) and GPT transgenic (6.3 ± 0.6 µM) mice.  B)  When the 
uptake rate of stimulus-evoked Glu was examined, GPT transgenic (0.7 ± 0.2 µM/sec) mice 
cleared Glu significantly (***p <0.001) slower compared to WT (1.8 ± 0.2 µM/sec) mice. 
  111
 
 
Figure 4.6:  Stimulus-Evoked Glu Uptake Depth Profile in the GPT Transgenic Mouse 
 
Average stimulus-evoked Glu release at different recording depths within the Str of GPT 
transgenic (n=4) and WT (n=9) mice.  No significant differences were observed within groups of 
mice across the different depths.  On average, GPT transgenic mice had slower uptake of Glu 
compared to WT mice across all depths.  This decrease was only significant (**p<0.01) at DV       
-3.25 mm between WT (2.0 ± 0.3 µM/sec) and GPT transgenic (0.6 ± 0.2 µM/sec) mice. A two-
tailed t-test was conducted at each depth for statistical analysis. 
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Figure 4.7:  5 mM Glu Clearance in the GPT Transgenic Mouse Groups 
 
A)  A subset of Glu signals were examined whose average maximal amplitude fell in a range of 3-
13 µM for both the GPT transgenic (n=4) and WT (n=9) mice.  No significant difference was 
observed between WT (9.5 ± 0.4 µM) and GPT transgenic (8.3 ± 0.6 µM) mice.  B)  When the 
clearance of exogenously applied Glu was examined, GPT transgenic (1.7 ± 0.2 µM/sec) mice 
cleared Glu significantly (**p <0.01) slower than WT (2.9 ± 0.2 µM/sec) mice. 
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Figure 4.8:  Exogenously Applied 5 mM Glu Clearance Depth Analysis 
 
Average uptake rate of exogenously applied 5 mM Glu at different recording depths within the Str 
of GPT transgenic (n=4) and WT (n=9) mice.  No significant differences were observed within 
groups of mice across the different depths.  GPT transgenic mice had significantly (*p<0.05) 
slower uptake than WT mice at depths -2.75 mm (1.5 ± 0.4 µM/sec and 2.8 ± 0.4 µM/sec, 
respectively)  and -3.25 mm (1.8 ± 0.5 µM/sec and 3.4 ± 0.4 µM/sec, respectively). A two-tailed t-
test was conducted at each depth for statistical analysis. 
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depths.  We observed that GPT transgenic mice had a significantly (p<0.05) 
slower uptake rate of exogenously applied 5mM Glu compared to WT mice at 
depths -2.75 mm (1.5 ± 0.4 µM/sec and 2.8 ± 0.4 µM/sec, respectively) and -3.25 
mm (1.8 ± 0.5 µM/sec and 3.4 ± 0.4 µM/sec, respectively).    
 Next, we wanted to perform the same series of recordings in the GPT KO 
mouse groups.  Local application of 70 mM KCl resulted in robust, reproducible 
Glu signals compared to baseline similar to what was observed in the GPT 
transgenic mouse groups.  From these traces we noticed that the GPT 
heterozygous and WT mice released similar amounts of Glu upon depolarization, 
however, the homozygous mice released significantly more Glu than either group 
(figure 4.9).  To quantitate this finding, we volume matched the amount of 
stimulus locally applied to both mouse groups.  Only Glu signals that were 
elicited by 50 to 150 nl of 70 mM KCl were used for this analysis, therefore, no 
significant difference in the amount of stimulus used was observed between the 
GPT WT (101 ± 4 nl), heterozygous (93 ± 8 nl) and homozygous (107 ± 5 nl) 
mice (figure 4.10A).  When the average maximal amplitude of Glu release was 
quantitated, GPT homozygous mice (5.9 ± 0.8 µM) released significantly more 
Glu (p < 0.05) compared to WT (4.1 ± 0.3 µM) and heterozygous (4.0 ± 0.7 µM) 
littermates (figure 4.10B).  Using the same subset of signals, striatal, depth-
related alterations in stimulus-evoked Glu release were also examined (figure 
4.11).  The average Glu release was calculated at each depth (DV -2.25 to -3.75 
mm) and compared amongst the GPT KO mouse groups. No significant 
differences were seen within groups of mice across all depths.  On average, the 
GPT homozygous mice released more Glu compared to WT and heterozygous 
mice at each recording depth, however, it was not a significant difference at any 
recording depth.   
 Since neurotransmitter uptake follows classical Michaelis-Mentin kinetics 
(Nicholson, 1995) and was affected by the amount of available substrate, Glu 
uptake was analyzed by selecting a subset of signals with maximum release 
values were in the range of 3-13 µM.  This range was chosen, because these 
peak Glu values were easily obtainable in both groups.  Within this subset of 
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Figure 4.9:  70 mM KCl-Evoked Glu Release Traces in the Female GPT KO Mice 
 
Series of amperometric Glu recordings showed differences in volume matched stimulus-evoked 
Glu release in WT (+/+; red), heterozygous (+/-; blue) and homozygous (-/-; yellow) mice.  Note 
the reproducibility of the signal in all three groups.  The heterozygous mice had similar amounts 
of stimulus-evoked Glu release compared to WT mice, while the homozygous mice had increased 
release compared to either group.  Arrows indicated time points for local application of an isotonic 
solution of 70 mM KCl (pH 7.4). 
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Figure 4.10:  Stimulus-Evoked Glu Release in the Female GPT KO Mice 
 
A) Only Glu signals that were elicited by 70 mM KCl whose volumes ranged between 50 and 150 
nl were analyzed for the GPT WT (n=5; +/+; red), heterozygous (n=4; +/-; blue) and homozygous 
(n=4; -/-; yellow) mice.  Since the volumes were matched, no significant difference in the amount 
of stimulus locally applied was observed between WT (101 ± 4 nl), heterozygous (93 ± 8 nl), 
homozygous (107 ± 5 nl) mice.  B) The average maximal amplitude of Glu released upon local 
application of 70 mM KCl was significantly increased (*p < 0.05) in the GPT homozygous mice 
(5.9 ± 0.8 µM) compared to WT (4.1 ± 0.3 µM) and heterozygous (4.0 ± 0.7 µM) littermates. 
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Figure 4.11:  Stimulus-Evoked Glu Release Depth Profile in the Female GPT KO Mice 
 
Average stimulus-evoked Glu release at different recording depths within the Str of GPT WT 
(n=5; +/+; red), heterozygous (n=4; +/-; blue), and homozygous (n=4; -/-; yellow) mice.  No 
significant differences were observed within groups of mice across the different depths.  On 
average, GPT homozygous mice released slightly more Glu compared to WT and heterozygous 
mice at all recording depths; however, it was not a significant difference.  A one-way ANOVA  
with Tukey’s post hoc was conducted at each depth for statistical analysis. 
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signals, no significant difference in average maximum release of Glu was 
observed in WT (4.8 ± 0.3 µM), heterozygous (6.0 ± 0.5 µM) and homozygous 
(6.1 ± 0.4 µM) mice, nor was a significant difference in the uptake rate of 
stimulus-evoked Glu release observed between WT (1.5 ± 0.1 µM/sec), 
heterozygous (1.8 ± 0.2 µM/sec), and homozygous (1.6 ± 0.2 µM/sec) mice 
(figure 4.12).   
 Due to the electrogenic nature of Glu transporters (Takahashi et al., 1997; 
Doble, 1997), we wanted to determine transporter function without membrane 
depolarization.  To do this, we locally applied an isotonic solution of 5 mM Glu 
(pH 7.4) and examined a subset of Glu signals that were in the range of 3-13 µM, 
which was the same range as those used for our stimulus-evoked Glu uptake 
analysis.  There was no significant difference in the maximal amplitude of 
exogenously applied 5 mM Glu in the GPT WT (8.6 ± 0.3 µM), heterozygous (8.4 
± 0.4 µM), and homozygous (7.8 ± 0.3 µM) mice (figure 4.13A).  Unlike the 
stimulus-evoked Glu uptake, we observed slower clearance in the heterozygous 
(2.5 ± 0.3 µM/sec) mice compared to the WT (3.1 ± 0.2 µM/sec) mice.  The 
homozygous mice (2.3 ± 0.2 µM/sec) had a significantly (p<0.05) slower 
clearance of exogenously applied Glu compared to WT mice (figure 4.13B).  
Using the same subset of signals, striatal depth-related alterations in 
exogenously applied 5 mM Glu clearance was examined (figure 4.14).  The 
average clearance rate was calculated at each recording depth (DV -2.25 to -
3.75 mm) and compared amongst the GPT KO mouse groups.  No significant 
differences were seen within groups of mice across all depths.  On average, the 
GPT homozygous mice had slower clearance of exogenously applied 5 mM Glu 
compared to WT mice at each recording depth, however, it was not a significant 
difference at any recording depth.   
 Since self-referencing MEAs were used to study the GPT KO mice, we 
were able to determine resting Glu levels in the Str.  Thirty second baseline 
measures were taken prior to local application of 70 mM KCl.  Resting Glu levels 
were only measured when 70 mM KCl was in the barrel of the glass micropipette.  
Possible  diffusion  of  5   mM  Glu   out  of  the  barrel  caused  unphysiologically  
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Figure 4.12:  Stimulus-Evoked Glu Uptake in the Female GPT KO Mice 
 
A) Subset of Glu signals were examined whose average maximal amplitude fell in a range of 3-13 
µM for both the GPT WT (n=5; +/+; red), heterozgyous (n=4; +/-; blue), and homozygous (n=4;     
-/-; yellow) mice.  No significant difference was observed between WT (4.8 ± 0.3 µM), 
heterozygous (6.0 ± 0.5 µM) and homozygous (6.1 ± 0.4 µM) mice.  B)  When the uptake rate of 
stimulus-evoked Glu was examined, no significant differences were seen between WT (1.5 ± 0.1 
µM/sec), heterozygous (1.8 ± 0.2 µM/sec), and homozygous (1.6 ± 0.2 µM/sec) mice. 
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Figure 4.13:  5 mM Glu Clearance in the Female GPT KO Mice 
 
A)  A subset of Glu signals were examined whose average maximal amplitude fell in a range of 3-
13 µM for the GPT  WT (n=5; +/+; red), heterozygous (n=4; +/-; blue), and homozygous (n=4;       
-/-; yellow) mice.  There was no significant difference in the maximal amplitude of exogenously 
applied 5 mM Glu in the GPT WT (8.6 ± 0.3 µM), heterozygous (8.4 ± 0.4 µM), homozygous (7.8 
± 0.3 µM) mice.  B) We observed slower clearance in the heterozygous (2.5 ± 0.3 µM/sec) mice 
compared to the WT (3.1 ± 0.2 µM/sec) mice.  The homozygous mice (2.3 ± 0.2 µM/sec) had a 
significantly (*p<0.05) slower clearance rate of exogenously applied Glu compared to WT mice. 
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Figure 4.14:  5 mM Glu Clearance Depth Profile in the Female GPT KO Mice 
 
Average stimulus-evoked Glu release at different recording depths within the Str of GPT WT 
(n=5; +/+; red), heterozygous (n=4; +/-; blue), and homozygous (n=4; -/-; yellow) mice.  No 
significant differences were observed within groups of mice across the different depths.  On 
average, GPT homozygous mice had slower clearance of exogenously applied 5 mM Glu 
compared to WT mice at all recording depths; however, it was not a significant difference.  A one-
way ANOVA with a Tukey’s post hoc was conducted at each depth for statistical analysis. 
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elevated levels of resting Glu.  Using our self-referencing recording techniques, 
resting Glu levels were similar in the Str of WT (0.9 ± 0.1 µM), heterozygous   
(1.4 ± 0.4 µM) and homozygous (1.0 ± 0.1 µM) mice (figure 4.15A).  Additionally, 
a depth analysis profile revealed resting Glu levels were similar at all recording 
depth within mouse groups.  On average, GPT heterozygous mice had elevated 
resting Glu levels at all recording depths, but this was not significant (figure 
4.15B). 
   
 Discussion 
 GPT catalyzes a reversible transaminase reaction using pyruvate as a co-
substrate to form alanine and α-ketoglutarate.  It is debated throughout the 
literature  whether  GPT  favors  Glu  degradation  (Saier  Jr.  and  Jenkins, 1967;  
Ruščák et al., 1982; Erecińska et al., 1994) or synthesis (Peng et al., 1991, 1993; 
Schousboe et al., 2003).  This process most likely depends on the amount of 
substrates/products available.  Matthews and colleagues (2000, 2003) 
demonstrated that GPT was an active Glu degrading enzyme that acted as an 
effective neuroprotectant in cell culture models of exogenous and endogenous 
Glu excitotoxicity.  The broad spectrum of transaminase molecules in the brain 
made it difficult to develop specific modulators for this enzyme.  To determine the 
role GPT played in glutamatergic neurotransmission, two different mouse models 
were created.  The first model had upregulated activity of GPT while the second 
model had removed this gene altogether.   
 Local application of 70 mM KCl resulted in robust, reproducible Glu 
signals in both the GPT transgenic and GPT KO mouse groups.  When the 
average maximal amplitude of Glu release was quantitated we saw no significant 
differences between the GPT transgenic and WT littermates nor any significant 
depth related differences in stimulus-evoked Glu release between the two 
groups.  We observed that the GPT transgenic mice had significantly slower 
uptake rates of stimulus-evoked Glu as well as clearance of exogenously applied 
5 mM Glu.  A depth profile revealed GPT transgenic mice, on average, had a 
slower rate of Glu uptake compared to WT mice, which became significant at 
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Figure 4.15:  Resting Glu Levels in the Female GPT KO Mice 
 
A) Resting Glu levels were averaged through the entire Str and no significant (p=0.16) differences 
were found between WT (0.9 ± 0.1 µM), heterozygous (1.4 ± 0.4 µM) and homozygous (1.0 ± 0.1 
µM) mice.  B) Average resting Glu levels were determined for each depth within the Str of WT 
(+/+; red), heterozygous (+/-; blue), and homozygous (-/-; yellow).  No significant difference was 
observed within mouse groups over the different recording depths.  On average, GPT 
heterozygous mice had elevated resting Glu levels at all recording depths, but this was not 
significant.  A one-way ANOVA with a Tukey’s post hoc was conducted at each depth for 
statistical analysis. 
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recording depths -2.75 mm and -3.25 mm.  In the GPT KO, homozygous mice 
had a significantly increased release of Glu compared to WT after local 
application of 70 mM KCl.  A depth profile revealed that GPT homozygous KO 
mice, on average, released more Glu at all recording depths compared to WT 
mice.  These values were not significant at any recording depth.  We observed 
no significant difference in the uptake rate of stimulus-evoked Glu release, but 
found that the clearance rate after local application of 5 mM Glu in the 
homozygous mice was significantly slower compared to WT.  A depth profile 
showed no significant difference at any of the recording depths.   Since self-
referencing MEAs were used for the GPT KO study, we were able to record 
resting Glu levels in these mice.  We saw no significant difference in Glu resting 
levels among the mouse groups, but GPT heterozygous mice, on average, had 
nonsignificantly (p=0.16) higher Glu resting levels compared to WT and 
homozygous mice.  This was also observed at all recording depths.   
  We observed no significant difference in stimulus-evoked Glu release in 
the GPT transgenic mouse groups.  The same experiment in the GPT KO mice 
revealed that homozygous mice released significantly more Glu compared to WT 
littermates.  Depth profiles of the Str showed no significant differences among the 
GPT transgenic as well as the GPT KO mice.  The GPT homozygous mice 
showed a trend of higher stimulus-evoked Glu release.  Our depth profile 
analysis demonstrated the advantage of our recording capability to measure 
discrete regions within a large brain structure.  Other in vivo recording 
techniques, such as microdialysis, were too large to perform this type of analysis.  
Because of this advantage we showed that the Str was not a homogenous 
structure for Glu release and regional differences exist.  More importantly, we 
demonstrated that knockout of a Glu metabolizing enzyme is responsible for 
increased neuronal release of Glu.  Since cell culture studies have demonstrated 
the propensity for GPT to metabolize Glu (Matthews et al., 2000, 2003) it was 
reasonable to hypothesize that dysfunction of this gene led to an increase in Glu 
availability for vesicular release from neurons.  What was more difficult to explain 
was the fact that upregulation of the same gene showed no decrease in stimulus-
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evoked Glu release.  Increasing the gene copy number did not necessarily 
correlate to an increase in enzyme production.  Also, since Glu is the 
predominant excitatory pathway throughout the mammalian CNS, a minimum 
amount of Glu must be made available for neurotransmission to maintain normal 
brain function (Wojcik et al., 2004; Takamori, 2006). Other Glu metabolizing 
enzymes (such as GLUD1, PAG and/or aspartate aminotransferase) may 
compensate for the increased activity of GPT and return Glu to those levels seen 
for normal neurotransmission as in WT mice.  A quantitative western blot 
analysis of Glu metabolizing enzymes must be run to test this hypothesis.      
 The uptake rate for stimulus-evoked Glu release as well as clearance of 
exogenously applied Glu was determined for both GPT transgenic and KO 
groups.  We determined that Glu uptake of stimulus-evoked Glu as well as 
clearance of exogenously applied Glu was significantly decreased in the GPT 
transgenic mice.  In the GPT KO mice we saw now significant change in uptake 
of stimulus-evoked Glu, but did see a significant decrease in the clearance rate 
of exogenously applied 5 mM in the homozygous mouse group.  Since Glu 
uptake was driven by electrochemical gradients across the cell membrane to 
produce a negative membrane potential (Takahashi et al., 1997; Doble, 1999), 
depolarization of glial membranes by the local application of 70 mM KCl may be 
responsible for the differences in the uptake rates when compared to clearance 
rates of exogenously applied 5 mM Glu in the GPT KO mice.  This may also 
explain why the uptake rate in both the GPT transgenic and GPT KO was faster 
for exogenously applied 5 mM Glu compared to stimulus-evoked Glu uptake.  
What was more difficult to explain was how a Glu metabolizing enzyme affected 
Glu transporter function.  Investigation of the mouse genome revealed that the 
mouse GPT and EAAT1 gene are both located on chromosome 15.  We 
hypothesize that insertion or disruption of the GPT gene had downstream affects 
on the EAAT1 gene.  If production of the EAAT1 protein was compromised, this 
may explain the significantly decreased uptake rate compared to WT littermates.  
Further studies on transporter number or function need to be completed to 
address these issues. 
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 Using our self-referencing recording techniques, we were able to record 
resting Glu levels in the Str of GPT KO mice.  Resting Glu levels were similar in 
the WT, heterozygous, and homozygous mouse groups, despite the differences 
seen in stimulus-evoked Glu release as well as decreases in the clearance rate 
of exogenously applied Glu in the homozygous mice.  These two factors led one 
to hypothesize that resting Glu levels were elevated in the homozygous mice 
compared to WT littermates.  One possible explanation for this finding was that 
resting Glu levels were analyzed in anesthetized mice.  Anesthetics such as 
urethane exert their effects by enhancing inhibitory synaptic neurotransmission 
as well as inhibiting excitatory neurotransmission (Hara and Harris, 2002).  Our 
laboratory has also demonstrated that urethane significantly decreased resting 
Glu levels by 58 percent (Rutherford et al., 2007).  Because of these two factors, 
anesthetized mouse models may not provide accurate measures of resting Glu.   
 Using in vivo amperometry with our Glu selective MEAs, we demonstrated 
that upregulation of GPT did not change stimulus-evoked Glu release, but 
significantly decreased the rate at which Glu was cleared from the extracellular 
space.  Stimulus-evoked Glu release was significantly higher in the homozygous 
GPT KO mice.  The GPT homozygous mice also showed a significantly slower 
ability to clear exogenously applied 5 mM Glu from the extracellular space.  
Despite these alterations on glutamatergic neurotransmission, we have not 
observed any phenotypic changes in either the GPT transgenic or the GPT KO 
mice. The significantly decreased uptake rate seen in GPT transgenic as well as 
the GPT homozygous mice was an interesting finding.  Studies have found that 
EAAT expression or uptake of Glu was decreased in several neurological 
disorders including ALS, Huntington’s disease (HD), and AD (Beart and O’Shea 
2007).  One would hypothesize to observe similar characteristics as the 
aforementioned neurological disorders in these transgenic and KO mice due to 
decreased Glu uptake.   
 
Copyright © Kevin Nicholas Hascup 
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Chapter Five:  Understanding L-Glutamate Dynamics in the                        
Awake, Freely Moving C57BL/6 Mouse 
 
Introduction 
 Previous sections have focused on Glu neurotransmission in ethyl 
carbamate (urethane) anesthetized transgenic mouse models.  Urethane is an 
injectible anesthetic widely used in animal research (Hara and Harris, 2002; 
Sabeti et al., 2003) that modulates ligand-gated ion channels to mediate 
anesthesia-induced CNS depression (Yamakura et al., 2001).  It has already 
been shown that urethane has minimal affects on dopamine clearance (Sabeti et 
al., 2003), which is the reasoning for using this anesthetic by our laboratory for 
non-survival surgeries.  However, data indicates that urethane inhibits responses 
of NMDA and AMPA receptors (Hara and Harris, 2002).  Rutherford and 
colleagues (2007) have also demonstrated that urethane can lower resting Glu 
levels by 58 percent.  In addition, general anesthetics such as isoflurane, can 
inhibit NMDA and AMPA receptors (Yamakura et al., 2001; Mellon et al., 2007) 
as well as inhibiting potassium-evoked release (Larsen and Langmoen, 1998; 
Liachenko et al., 1999) and re-uptake (Liachenko et al., 1999) of Glu. These are 
just two examples of commonly used anesthetics in animal laboratories.  Many 
other general anesthetics affect iGluRs (Perouansky et al., 1998; Yamakura et 
al., 2001; Mellon et al., 2007). These studies indicate that most anesthetics exert 
some action or affect on the glutamatergic system.  In an attempt to better 
understand Glu neurotransmission without the effects of anesthesia, our 
laboratory has begun to use the MEA technology in awake, freely moving 
animals.     
 Currently, in vivo microdialysis is the most commonly used technique to 
study extracellular Glu in freely moving mice (Olive et al., 2000; Uezono et al., 
2001; Wang et al., 2005; Holmer et al., 2005; Zuo et al., 2006; Hao et al., 2007; 
Win-Shwe et al., 2007). Microdialysis utilizes semipermeable membranes to 
restrict the diffusion of extracellular molecules or neurotransmitters along their 
concentration gradients (Ungerstedt, 1984; Di Chiara et al., 1996). With 
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microdialysis, several analytes can be measured simultaneously allowing for 
studies of multiple neurotransmitter systems.  However, the temporal and spatial 
resolution of this technique may be inadequate to properly measure the fast 
dynamics of Glu neurotransmission.  Strides are being made to increase the 
temporal resolution into several second intervals by coupling microdialysis with 
capillary electrophoresis (Tucci et al., 1997; Kennedy et al., 2002; Rossell et al., 
2003).  Even with these recent improvements, it is unlikely that microdialysis can 
achieve the sub-second response time necessary for studying in vivo Glu 
dynamics due to diffusion processes required for molecules to cross the dialysis 
membrane.  While collection and analyzing of microdialysis samples 
corresponding to one second intervals is possible (Rossell et al., 2003), work by 
Kennedy’s group shows that band broadening of the sample within the tubing 
prevents this technique from achieving response times faster than ten seconds 
(Lada et al., 1997).  Since Glu neurotransmission occurs on a sub-second to 
second time scale (Kinney et al., 1997), faster recording techniques are 
necessary to understand its release and uptake dynamics.  Furthermore, several 
microdialysis studies report that the Glu overflow measured with microdialysis is 
not TTX – dependent (Timmerman and Westerink, 1997; Baker et al., 2002; 
Melendez et al., 2005). This suggests that Glu signals measured from 
microdialysis are not neuronally derived, which does not fulfill the classical 
criteria for exocytotic release and questions the source of resting Glu levels  
 To make matters worse, the large size of the microdialysis probe causes 
substantial short- and long-term trauma, which is evidenced by histological, 
physiological, and biochemical changes in nearby CNS tissue (Bungay et al., 
2003).  During the first hours after implantation the blood-brain barrier is 
disrupted, blood flow to the tissue surrounding the probe is decreased and 
release of neurotransmitters is altered (Westerink, 1995).  Positron emission 
tomography (PET) imaging has revealed that glucose metabolism is drastically 
and irreversibly altered by chronic implantation of a microdialysis cannula/probe 
(Schiffer et al., 2006).  Three days after implantation a glial barrier is observed 
and may account for probe blockage (Benveniste and Diemer, 1987).  This glial 
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barrier is markedly increased if nonfunctional microdialysis probes are removed 
and functional probes are reinserted in an attempt to continue freely moving 
studies within the same animal (Georgieva et al., 1992). Clapp-Lilly and 
colleagues (1999) demonstrate that ultrastructural damage occurs up to 1.4 mm 
away from a microdialysis probe implant site.  In addition, normal dialysate 
perfusion and removal of material by the probe may produce concentration 
gradients that damage tissue up to several millimeters away from the implant site 
(Bungay et al., 1990).  The implantation damage caused by microdialysis probes 
has drastic effects on local neurotransmitter dynamics. Carbon fiber 
microelectrodes coupled with voltammetric techniques were used to show that 
stimulus-evoked dopamine release is attenuated up to 220-250 µm from the 
probe implant site (Yang et al., 1998; Borland et al., 2005).  If this probe-induced 
trauma along with glial barrier formation is not taken into account for 
microdialysis analysis, the estimation of extracellular concentrations and 
clearance of neurotransmitters such as DA and Glu can be underestimated (Lu et 
al., 1998; Yang et al., 1998; Bungay et al., 2003).  Furthermore, Frumberg and 
colleagues (2007) demonstrated that rats implanted with microdialysis probes in 
the right Str performed significantly worse in object recognition tasks despite no 
change in locomotor activity.  These studies demonstrate the excessive damage 
caused by a dialysis probe as well as question the physiological validity of 
dialysis samples. 
 Within the past decade, several groups have developed Glu selective 
microelectrodes to address the above inconsistencies with microdialysis studies 
on glutamatergic physiology (Hu et al., 1994; Rahman et al., 2005) and some 
studies utilizing these microelectrodes show that Glu is TTX-dependent (Kulagina 
et al., 1999; Day et al., 2006; Oldenziel et al., 2006).  Our laboratory has 
developed an enzyme-based MEA that is capable of detecting low levels of Glu 
on a sub-second time scale (500-800 msec) that is free from CNS interferents 
such as DOPAC and AA (Burmeister and Gerhardt, 2001; Burmeister et al., 
2002).  These MEAs have been successfully used by our laboratory to measure 
Glu dynamics in aged Fischer 344 rats (Nickell et al., 2004; Nickell et al., 2007) 
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as well as resting Glu levels in Fischer 344 rats (Day et al., 2006).  Even more 
recently, our laboratory has successfully modified these MEAs for chronic 
recordings in awake, freely moving rats (Rutherford et al., 2007).  The present 
study concerns the adaptation and validation of these MEAs for selective Glu 
recordings in the awake, freely moving mouse model.  First, we have adapted 
our methodology for chronic recordings of resting and phasic (rapid) changes in 
Glu in awake mice.  Next, we investigated the reproducibility of such methods for 
measures in the C57BL/6 PFC and Str.  Finally, we studied the pharmacological 
effects TTX and THA have on resting Glu levels in the mouse Str.   
 
Methods 
 All materials and methods for freely moving recording were thoroughly 
outlined in Chapter Two.  Male C57BL/6 between the ages of 5 and 6 months 
were used at the time of recordings.  Glu recordings were conducted using self-
referencing, enzyme-based MEAs with a sampling rate of 1 Hz. A craniotomy 
was performed over the Str (AP: +0.9 mm; ML: -1.5 mm; DV: -3.85 mm vs. 
bregma) or PFC (AP: +1.54 mm, ML: 0.3 mm, DV: -2.45 mm vs. bregma) and 
MEAs were implanted using the coordinates from Paxinos and Franklin (2004).  
A stainless steel guide cannula was attached to the PCB and positioned so an 
internal, acute stainless steel cannula was positioned among the 4 Pt recording 
sites, resting 50-100 µm above the recording surface.  Through this internal 
cannula isotonic solutions of 1 mM Glu (in 0.9% saline; pH 7.4); 0.9% 
physiological saline, citrate, 100 µM THA, and 1 µM TTX (all pH 7.4) were locally 
applied to the surrounding brain tissue to study glutamatergic neurotransmission.  
Prior to connecting the mouse pedestal with the FAST 16 Mark II recording 
system, mice were allowed to freely roam around the recording chamber for at 
least 30 minutes to acclimate to their environment.  Once connected to the FAST 
16 Mark II recording system, the mice underwent a minimum 60 minute 
acclimation period to establish a stable baseline recording.  Following this 
acclimation period, the dummy cannula was removed and the internal, acute 
cannula (connected to a 10 µl Hamilton Syringe) was inserted into the guide 
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cannula on recording sessions when chemicals were locally applied.  After the 
internal cannula was inserted, another acclimation period of 30 minutes was 
allowed to reestablish baseline.  Following this period, resting Glu, the effects of 
locally applied Glu, TTX or THA were studied for up to three additional hours.  
The volumes of locally applied Glu were kept constant at 0.5 µl while the volumes 
for locally applied TTX, THA, and appropriate controls, saline (THA) and citrate 
(TTX), were kept at 1.0 µl. 
 Following completion of all recording sessions (after multiple days of 
recording), mice were anesthetized with isoflurane and transcardially perfused 
with 0.9% saline followed by 4% paraformaldehyde.  The brain was removed and 
stored in 4% paraformaldehyde for three days followed by storage in 0.1 M 
phosphate buffer (10% sucrose) for sectioning and staining to confirm MEA 
placement. 
 Data analysis involved a one-way ANOVA with Tukey’s post hoc to 
examine any differences in resting Glu levels, maximal amplitude, t80 and uptake 
rate of Glu over multiple days post-implantation.  A two-tailed student’s t-test was 
used to compare different brain regions on similar days as well as differences in 
resting Glu after local application of THA or TTX compared to appropriate 
controls (0.9% saline and citrate, respectively). All data were reported as mean ± 
standard error of the mean and significance was defined as p < 0.05. 
 
Results 
 The FAST 16 Mark II recording system along with our modified MEA 
allowed for reliable second-by-second recordings of Glu in the Str and PFC of 
awake, freely moving mice.  We consistently implanted the pedestal assemblies 
and recorded Glu for as long as 2 weeks in awake mice.  Local application of an 
isotonic solution of Glu (1 mM; 0.5 µl; pH 7.4) through the internal cannula was 
used to verify Glu recordings in vivo.  Figure 5.1 shows representative Glu 
signals in the Str (A) and PFC (B) of awake, freely moving mice.   Glu measures 
were robust and reproducible within brain regions, and over multiple days (figure 
5.2).  
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Figure 5.1:  Representative Glu Traces After Local Application of 1 mM Glu 
 
Representative traces of locally applied Glu (1 mM; 0.5 µl) in the Str (A) and PFC (B) of male 
C57BL/6 mice.  Glu was locally applied at the time points indicated by the arrows.  A rapid, 
reproducible spike was recorded in both brain regions using self-referencing MEAs. Maximal 
peak height suggests in vivo Glu signal from local application of Glu (arrows), while baseline 
measures suggest resting Glu levels.  
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Figure 5.2:  Local Application of Glu in the PFC and Str 
 
Locally applied Glu data for days 3, 5, and 7 post-implantation in the Str (A, n=8) and PFC (B, 
n=6) of C57BL/6 mice.  Glu (0.5 µl, 1 mM) was locally applied in both brain regions over multiple 
days and recorded using a self-referencing MEA.  Substantial and stable Glu recordings were 
observed over all days measured indicating reliable, in vivo Glu measurements for at least 7 days 
post-implantation.  Average maximum amplitude over days within brain regions as well as 
between the PFC (30.5 ± 7.8) and the Str (35.6 ± 9.9) was not significantly different. 
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 An isotonic solution of Glu (1 mM; 0.5 µl; pH 7.4) was locally applied in the 
PFC and Str of male, C57BL/6 mice on days 3, 5, and 7 post-implantation.  As 
shown in figure 5.2, Glu signals were reproducible over multiple days within the 
Str (figure 5.2A) and PFC (figure 5.2B) as well as similar between the two brain 
regions.  Table 5.1 provides a list of the average maximum amplitude values on 
days 3, 5 and 7 post-implantation for both brain regions.   
 No significant difference in maximal Glu response was observed between 
brain regions after local application of 1 mM Glu.  We observed differences in the 
clearance of locally applied Glu as shown by the traces in figure 5.3.  When we 
examined the uptake rate of locally applied 1 mM Glu (figure 5.4) we found that 
both the Str (figure 5.4A) and PFC (figure 5.4B) cleared exogenously applied Glu 
slower over days, however, this was not significant.  We also observed that the 
Str (13.4 ± 4.2 µM/sec), on average, had a faster clearance of Glu compared to 
the PFC (5.8 ± 1.9 µM/sec), but this was not significant (p=0.17) between brain 
regions on either day 3, 5, or 7 post implantation (figure 5.4C).  Table 5.2 
provides a list of the average uptake rate values on days 3, 5 and 7 post-
implantation.  Due to the long duration of decay signals coupled with the fact that 
our uptake rate analysis only factors the first 5 seconds of signal decay, we 
wanted to examine the time period it takes to clear 80% of the Glu signal (t80) 
(figure 5.5).  We did not observe any significant difference in the t80 of locally 
applied Glu over days in the Str (figure 5.5A) and PFC (figure 5.5B) of C57BL/6 
mice.  We noticed a nonsignificant increase in t80 over days in both brain regions.  
Also, the average t80 was increased in the PFC compared to the Str, which 
became significant (p<0.05) on day 7 post-implantation (17.2 ± 2.9 sec and 10.0 
± 1.6 sec, respectively). Table 5.2 provides a list of the average t80 values for 
days 3, 5 and 7 post-implantation for both brain regions. 
 Resting Glu measures in the awake mice were measured in the PFC and 
Str of male, C57BL/6 mice on days 3 through 7 post-implantation using the self-
referencing technique described in Chapter Two.  Briefly, the self-referencing site 
current was subtracted from the Glu recording site current, and divided by the 
Glu  recording  site  slope  obtained  from  in vitro  calibration.   We  observed  no  
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Table 5.1:  Local Application and Resting Glu Measures on Days 3 through 7 Post-
Implantation  
 
  Days Post-Implantation  
 Brain 
Region   3  4  5  6  7  Average  
 
PFC 
(n=6) 
 
 
31.4 ± 7.2 
 
n/a 
 
31.7 ± 7.7 
 
n/a 
 
28.4 ± 8.6 
 
30.5 ± 7.8 
Lo
ca
lly
 A
pp
lie
d 
G
lu
 (μ
M
) 
 
Str  
(n=8) 
 
 
35.6 ± 11.3 
 
n/a 
 
36.4 ± 8.7 
 
n/a 
 
34.7 ± 9.7 
 
35.6 ± 9.9 
 
PFC 
(n=8) 
 
 
3.3 ± 1.3 
 
3.2 ± 1.1 
 
4.0 ± 0.9 
 
3.0 ± 0.9 
 
3.0 ± 1.0 
 
3.3 ± 1.0 
R
es
tin
g 
G
lu
 (μ
M
) 
 
Str 
(n=10) 
 
 
5.5 ± 1.3 
 
 
5.0 ± 1.0 
 
 
5.1 ± 1.1 
 
 
4.4 ± 1.1 
 
 
4.9 ± 1.2 
 
5.0 ± 1.2 
 
The extracellular Glu concentrations in the PFC and Str from local application of 1 mM Glu (0.5 
µl) and resting Glu levels on days 3 through 7 post-implantation.   
  136
 
 
Figure 5.3:  Representative Traces of Glu Clearance in the Str and PFC 
 
Local application of 1 mM Glu (0.5 µl; pH 7.4) resulted in similar maximal amplitude between 
MEAs implanted in the Str and PFC of C57BL/6 mice.  We observed that clearance kinetics were 
different between the two brain regions.  Traces were from day 3 post-implantation for both brain 
regions. 
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Figure 5.4:  Clearance Rate of Locally Applied 1 mM Glu 
 
Clearance rate of locally applied 1 mM Glu in the Str (A, n=8) and PFC (B, n=6) of C57BL/6 mice 
on days 3, 5, and 7 post-implantation.  There was non significant decrease in the clearance of 
Glu over days within a brain region (p=0.17, Str; p=0.37, PFC). C)  Comparison of clearance rate 
between brain regions over days.  When a two-tailed t-test was used to compare brain regions 
over days there was no significant difference in the clearance of exogenously applied 1 mM Glu 
on either day 3 (p=0.16), 5 (p=0.28), or 7 (p=0.12).   
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Figure 5.5:  t80 of Locally Applied 1 mM Glu  
 
The time period for 80 percent of the Glu signal to decay (t80) in the Str (A, n=8) and PFC (B, n=6) 
of C57BL/6 mice.  There was a nonsignificant trend towards increasing t80 over increasing days 
post-implantation (p=0.35, Str; p=0.32, PFC).  The PFC of C57BL/6 mice cleared exogenously 
applied 1 mM Glu slower compared to the Str of C57BL/6 mice, which was significant (*p<0.05) 
on day 7 post-implantation, but not on days 3 (p=0.08) or 5 (p=0.22) post implantation (two-tailed 
t-test between Str and PFC on day 7 post-implantation). 
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Table 5.2:  Clearance Kinetics of Exogenously Applied 1 mM Glu 
 
Days Post-Implantation 
 Brain 
Region   3   5   7  Average 
 
PFC (n=6) 
 
 
7.5 ± 2.1 
 
6.1 ± 2.2 
 
3.7 ± 1.3 
 
5.8 ± 1.9 
 
Uptake  
Rate 
(µM/sec)  
Str (n=8) 
 
 
20.7 ± 7.0 
 
10.7 ± 3.2 
 
8.8 ± 2.3 
 
13.4 ± 4.2 
 
PFC (n=6) 
 
 
7.5 ± 2.1 
 
13.2 ± 2.8 
 
17.2 ± 2.9 
 
12.6 ± 2.6 
 
 
t80 
(sec)  
Str (n=8) 
 
 
6.9 ± 1.3 
 
 
8.7 ± 1.5 
 
 
10.0 ± 1.6 
 
8.5 ± 1.5 
 
The clearance of extracellular Glu concentrations after local application of 1 mM Glu (0.5 µl) in 
the PFC and Str on days 3 through 7 post-implantation.   
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significant difference in resting Glu over days in the Str (figure 5.6A) and the PFC  
(figure 5.6B).  However, the average resting Glu levels were decreased in the 
PFC compared to the Str although not significantly (p=0.31).  Table 5.1 provides 
a list of the average resting Glu levels for days 3 through 7 post-implantation for 
both brain regions.  
 We wanted to determine how blocking the high-affinity transporters 
located on glial cells (Danbolt, 2001) affected resting Glu levels in the Str. To test 
this we locally applied 100 µM of THA, a transportable, competitive inhibitor for 
all excitatory amino acid transporters (EAAT) (Anderson et al., 2001; Chatton et 
al., 2001; Gaillet et al., 2001), in the Str of C57BL/6 mice.  Figure 5.7A shows Glu 
tracings after local application of 100 µM THA (1.0 µl) in 0.9% saline (pH 7.4) and 
0.9% saline control (1.0 µl, pH 7.4).  Local application of 100 µM THA in saline 
caused a significant increase (p < 0.05) in resting Glu levels (2.9 ± 1.2 µM; n=7) 
compared to saline control (0.3 ± 0.1 µM; n=7) (figure 5.7B).  This was 
approximately a 60% increase in resting Glu levels in the Str when compared to 
our study in table 5.1. 
 We further investigated the source of resting Glu by determining the extent 
of exocytotic release from neurons.  To test this, we locally applied TTX, a 
sodium channel blocker that prevented depolarization and subsequently 
terminated the action potential-dependent vesicular release of Glu.  Local 
application of 1 µM TTX (1.0 µl, pH 7.4), in an isotonic solution of citrate, in the 
Str of C57BL/6 mice caused a significant decrease (*p < 0.05) in resting Glu 
levels (-1.0 ± 0.2 µM; n=6) compared to an isotonic solution of citrate control (1.0 
µl, pH 7.4) (-0.3 ± 0.1 µM; n=6) (figure 5.8).  This was approximately a 20% 
decrease in resting Glu in the Str when compared to our study in table 5.1.   
 Finally, we wanted to study the affects of a stressor on resting Glu levels.  
To do this, we applied fox urine on a cotton ball and introduced it into the 
recording chamber for 5 minutes.  The Glu trace in figure 5.9 shows that the fox 
urine stressor caused a robust increase (~7 µM) in Glu levels in the Str of 
C57BL/6 mice throughout the duration of the stressor (black line).  Glu levels 
returned to baseline approximately 15 minutes after the stressor was removed.   
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Figure 5.6:  Resting Glu Levels in the Str and PFC 
 
Resting Glu levels were assessed on days 3 through 7 post-implantation in the Str (A, n=10) and 
PFC (B, n=8) of C57BL/6 mice.  Self-referencing MEAs were used to determine resting Glu 
levels.  The self-referencing site current was subtracted from the GluOx coated site current, and 
divided by the GluOx slope, to yield resting Glu levels.  Average resting Glu over days between 
the PFC (3.3 ± 1.0) and the Str (5.0 ± 1.2) of male C57BL/6 mice was not significantly (p=0.31) 
different.   
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Figure 5.7:  Local Application of 100 µM THA 
 
Effects of local application of THA.  A) Representative tracings of local application of THA (1.0 µl; 
100 µM) and 0.9% saline control (1.0 µl) in the Str of C57BL/6 mice.  Local application of THA 
resulted in a robust, sustained increase in extracellular Glu compared to saline control.  B)  
Change in resting Glu levels were significantly increased with local application of THA (2.9 ± 1.2 
µM; n=7) compared to saline control (0.3 ± 0.1 µM; n=7) (*p < 0.05).   
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Figure 5.8:  Local Application of 1 µM TTX 
 
Effects of local application of TTX.  A) Representative tracings of local application of TTX (1.0 µl; 
1 µM) and citrate control (1.0 µl) in the Str of C57BL/6 mice.  Local application of TTX resulted in 
a robust, sustained decrease in extracellular Glu compared to citrate control.  B)  Change in 
resting Glu levels were significantly decreased with local application of TTX (-1.0 ± 0.2 µM; n=6) 
compared to citrate control (-0.3 ± 0.1 µM; n=6) (*p <0.05). 
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Figure 5.9:  Fox Urine Affects Resting Glu Levels 
 
A fox urine soaked cotton ball was introduced into the recording chamber for 5 minutes (black 
line).  During this time period Glu levels rose to approximately 7 µM above baseline until the fox 
urine soaked cotton ball was removed.  Glu levels returned to baseline approximately 15 minutes 
after removal of the cotton ball. 
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Discussion 
 The objective of this study was to adapt our current method for enzyme-
based second-by-second Glu detection used in anesthetized animals or isolated 
preparations, to a system that can be used in awake, freely moving mice over 
multiple days.  The small size and lightweight design of the pedestal allowed for 
chronic recordings with limited effects on the mouse’s behavior and ability to 
perform everyday activities.  We also wanted to develop a technology that was 
able to record second-by-second measures of Glu over multiple days, unlike 
microdialysis studies in freely moving mice, or other animals, that are normally 
performed in a single day over minute time scales (Olive et al., 2000; Uezono et 
al., 2001; Wang et al., 2005; Holmer et al., 2005 a,b; Zuo et al., 2006; Hao et al., 
2007; Win-Shwe et al., 2007).  Similar to the work conducted by Rutherford and 
colleagues (2007) this study demonstrated the ability of our enzyme-based MEAs 
to reliably measure Glu for at least 7 days post-implantation.  In addition, the 
small size of the ceramic tip of our MEA produced less damage than a 
chronically implanted microdialysis probe (Clapp-Lilly et al., 1999; Borland et al., 
2005; Rutherford et al., 2007), which allowed us to sample physiologically 
relevant Glu (Drew et al., 2004).  The small size of our MEAs, in conjunction with 
our self-referencing capability (Burmeister and Gerhardt, 2001), allowed us to 
measure resting levels of Glu and determine that a portion was TTX-dependent 
and not from reversal of the high-affinity transporters for Glu as demonstrated 
using THA to block the EAATs. 
 When using in vivo amperometry, the ability to selectively identify the 
molecule of interest was questioned; however, our laboratory overcame these 
issues.  First, the enzyme-based MEAs differentially recorded a specific 
molecule, in this case Glu, due to the high selectivity of GluOx for its substrate 
(Glu) (Kusakabe et al., 1983).  Varying the applied potential to the Pt recording 
surface is another way we identify the molecule of interest.  The reporter 
molecule, H2O2 that was produced from the metabolism of Glu by GluOx was 
predominantly oxidizable at +0.7 V vs. a Ag/AgCl reference electrode.  When the 
applied potential is dropped to +0.2 V vs. a Ag/AgCl reference electrode, much of 
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the H2O2 was no longer oxidized at the Pt recording surface resulting in a 
decrease in signal (Day et al., 2006; Rutherford et al., 2007).  Finally, the ability 
to perform self-referencing and subtract off interferents from the Glu signal 
enhanced the selectivity of our MEA.  Since the sentinel sites were not coated 
with GluOx, they did not respond to changes in extracellular concentrations of 
Glu, thereby allowing us to qualitatively visualize responses that were solely from 
a Glu source.  Furthermore, the offline subtraction method allowed us to remove 
any possible interferents or noise artifacts that quantitatively added to the 
extracellular Glu concentration.  Self-referencing methods were employed 
throughout this study to ensure that resting and peak responses (maximum 
amplitude) were due primarily to changes in extracellular Glu levels.   
 We locally applied an isotonic solution of Glu (0.5 µl, 1mM) in the PFC and 
Str of the C57BL/6 mouse on days 3, 5 and 7 post-implantation to determine the 
longevity of the enzyme-based MEA in vivo.  We saw no significant change in 
MEA sensitivity for Glu in either brain region on days 3 - 7 post-implantation.  
Both brain regions had similar responses to local application (0.5 µl) of 1 mM Glu 
with the Str (35.6 ± 9.9 µM) having slightly higher responses (p=0.71), on 
average, compared to the PFC (30.5 ± 7.8 µM) as shown in table 5.1.  Rutherford 
and colleagues (2007) observed similar in vivo MEA longevity to Glu in the PFC 
and Str of Fischer 344 and Long Evans rat strains.  Since there was no decline in 
MEA response for Glu we concluded that the enzyme activity of GluOx, when 
adhered to our Pt recordings sites of our MEA, was viable for at least 7 days in 
vivo.  This had important implications as we progress this technology to study 
behavior related changes in extracellular Glu over days in the awake, freely 
moving mouse.   
 To better understand the clearance of exogenously applied 1 mM Glu we 
examined the uptake rate and time for 80% decay (t80) of the Glu signals on days 
3, 5 and 7 post-implantation.  We found that in both the PFC and Str there was a 
nonsignificant decrease in uptake rate over days.  We also noticed that the 
average Glu uptake rate in the Str (13.4 ± 4.2 µM/sec) was increased compared 
to the PFC (5.8 ± 1.9 µM/sec), but not significantly (p=0.17).  Due to the long 
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duration of Glu uptake after local application of 1 mM Glu in the freely moving 
mice we also decided to look at the time period for 80 percent of the signal to 
decay (t80).  Both the Str (p=0.35) and PFC (p=0.32) had a nonsignificant 
increase in t80 over days, which was to be expected since the uptake rate 
decreased over days.  On average, the PFC (12.6 ± 2.6 sec) had a longer t80 
compared to the Str (8.5 ± 1.5 sec), which was significant (p<0.05) on day 7 post-
implantation.  Since we saw a slower uptake rate in the PFC compared to the Str, 
it was expected that the duration of clearance was longer in the PFC.  These 
differences indicate several possibilities.  Clearance differences between brain 
regions could indicate that there was a variation in Glu transporter number 
between the two brain regions, with the Str having a higher density of 
transporters resulting in faster clearance.  Addressing changes in Glu clearance 
over days within a brain region was more difficult to explain.  Differences in 
cellular density and number of synapses between brain regions (and even within 
the neocortex) could affect diffusion of neurotransmitters as well as transporter 
numbers (DeFelipe et al., 2002).  We know that our MEAs caused only limited 
damage to the surrounding brain tissue (Rutherford, et al., 2007); however, we 
were uncertain on the extent of damage caused by the guide cannula; especially, 
when factoring in removal/insertion of the dummy and internal cannula over 
multiple days.  If we were damaging the surrounding glia, it would go to reason 
there would be less transporters available thus slowing Glu uptake over days in 
both brain regions (Yi and Hazell, 2006; Beschorner et al., 2007).  We were also 
unsure of what local application of 1 mM Glu does to the surrounding CNS 
tissue.  This could induce transporter trafficking to and from the plasma 
membrane thus affecting clearance kinetics over days (Fournier, et al., 2004). 
 Our MEA self-referencing recording techniques were also used to 
effectively and reliably measure resting Glu levels (Day et al., 2006; Rutherford et 
al., 2007).  As shown in table 5.1 our data indicated that there was no significant 
(p=0.31) change in resting Glu levels over days within the PFC and the Str nor 
averaged across brain regions (3.3 ± 1.0 µM; 5.0 ± 1.2 µM, respectively).  The 
limited number of publications using microdialysis in freely moving C57BL/6 mice 
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to study resting Glu levels made it difficult to compare the techniques.  We were 
unaware of any studies using microdialysis in the PFC of freely moving C57BL/6 
mice, but Meshul’s group had three separate studies with probe placement in the 
Str (Holmer et al., 2005 a,b; Shakil et al., 2005).  In table 5.3, our resting Glu 
values utilizing our enzyme-based MEA technology coupled with in vivo 
amperometry in the Str of freely moving C57BL/6 mice were higher (at least 
double in two studies) compared to what Meshul’s group observed using 
microdialysis.  These discrepancies may be explained by the difference in 
sampling time and method as well as the origin of the Glu pool being sampled.  
The small size of our MEA tips caused less damage compared to a microdialysis 
probe (Clapp-Lilly et al., 1999; Peters et al., 2004; Borland et al., 2005; 
Rutherford et al., 2007) which helped to improve the spatial resolution of the 
sampling method (Drew et al., 2004).  Furthermore, our considerably faster 
sampling rate allowed us to measure Glu closer to the synapse and subsequently 
the neuronal pool of Glu (Drew et al., 2004). 
 Our laboratory was also interested in determining how resting Glu levels in 
the Str were affected by blocking all EAATs using the transportable competitive 
inhibitor, THA (Figure 7).  Local application of an isotonic solution of 100 µM THA 
(1.0 µl, pH 7.4) caused a significant (p<0.05) increase (2.9 ± 1.2 µM) in resting 
Glu levels when compared to 0.9% saline control (0.3 ± 0.1 µM).  This was an 
approximate 60% increase in resting Glu levels in the Str when compared to 
averaged resting Glu Str values from table 5.1.  Furthermore, local application of 
THA resulted in sustained Glu elevation when compared to our data from local 
application of exogenous Glu.  This was expected since resting Glu was now 
competing for uptake with THA whereas exogenously applied Glu induced an 
immediate effect without competition for uptake present.  When blocking the high 
affinity transporters, resting Glu levels were from diffusion from the synapse and 
essentially neuronal sources.  Unfortunately, heteroexchange of Glu from 
astrocytes cannot be ruled out with transportable inhibitors, however, even non-
transportable  inhibitors  such  as  D,L-threo-β-benzyloxyaspartate  (TBOA)  were  
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Table 5.3:  Comparison of Resting Glu Levels in the Str of C57BL/6 Mice 
 
Author Technique Sampling Interval Location Resting Glu (µM) 
 
Hascup, K.N. et al. 
 
amperometry 1 sec Striatum 5.0 ± 1.2  
 
Holmer, H.K. et al. 
 
microdialysis 15 min Striatum 3.5 ± 0.1 to 4.2 ± 0.1  
 
Holmer, H.K. et al. 
 
microdialysis 15 min Striatum ~ 2.75 
 
Shakil, S.S. et al. 
 
microdialysis 15 min Striatum 1.2 ± 0.1 to 1.8 ± 0.1 
 
 
Resting Glu levels in the Str of C57BL/6 mice when measured using MEAs compared to studies 
using microdialysis probes.   
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shown to induce heteroexchange at similar concentrations (Anderson et al., 
2001). 
 To determine the neuronal contribution to resting Glu levels in the Str, the 
sodium channel blocker, TTX, was locally applied adjacent to the MEA.  Local 
application of an isotonic solution of 1 µM TTX (1.0 µl; pH 7.4) (-1.0 ± 0.2 µM) 
caused a significant decrease (p < 0.05) in resting Glu levels compared to citrate 
control (1.0 µl; pH 7.4) (-0.3 ± 0.1 µM).   This was an approximate 20% decrease 
in resting Glu levels in the Str when compared to averaged resting Glu levels 
from table 5.1.  This observation was in contrast with several microdialysis 
studies examining TTX-dependency in rats (Timmerman and Westerink, 1997) 
and further supported findings conducted by our laboratory in rats (Day et al., 
2006) and others using microelectrodes (Kulagina et al., 1999; Oldenziel et al., 
2006).  Unlike other TTX studies using Glu selective microelectrodes in 
anesthetized rats, our freely moving mouse studies did not completely attenuate 
resting Glu levels for two possible reasons.  First, our laboratory demonstrated 
that the use of anesthetic significantly decreased resting Glu levels (Rutherford, 
et al., 2007) in rats.  Anesthetics such as chloral hydrate and urethane exert their 
effects by enhancing inhibitory synaptic neurotransmission as well as inhibiting 
excitatory neurotransmission (Hara and Harris, 2002); possibly making the 
glutamatergic system more susceptible to blockade of sodium channels by TTX.  
Second, our concentration of TTX (1 μM) used was 100 fold lower compared to 
those used in the anesthetized rat studies (Kulagina et al., 1999; Day et al., 
2006; Oldenziel et al., 2006).  It should be noted that TTX concentrations of 5 µM 
and higher were locally applied and resulted in severe lower limb paralysis 
forcing us to immediately euthanize these mice according to our approved 
protocols.   
 Finally, we wanted to study the effects of a stressor on resting Glu levels.  
To do this, we applied fox urine on a cotton ball and introduced it into the 
recording chamber for 5 minutes, which resulted in a ~7 µM increase in Glu 
levels.  Glu levels rose throughout the 5 minute stressor and took approximately 
15 minutes to return to baseline after removal.  Since this was an odor stressor, it 
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took time for the smell to diffuse out of the recording chamber once the cotton 
ball was removed, which may explain the prolonged time period for levels to 
return to baseline.  This experiment demonstrated our ability to record changes in 
Glu due to behaviorally related stimuli.   
 In summary, the present studies using MEAs configured for second-by-
second Glu measurements were viable for at least 7 days post-implantation in 
the awake, freely moving mouse.  This increased recording time span has helped 
us to better understand resting Glu levels.  We observed a nonsignificant 
difference in resting Glu levels between the PFC and Str of awake C57BL/6 
mice.  We also observed that local application of pharmacological agents such 
THA and TTX altered resting Glu levels.  We saw a significant increase in resting 
Glu levels with the addition of THA and a significant decrease in resting Glu 
levels with the addition of TTX, which indicated that resting Glu levels were 
neuronally derived. These findings provided evidence that the high spatial and 
low temporal resolution provided by our MEA technology was necessary to better 
understand resting Glu levels.  Furthermore the ability to monitor Glu without 
anesthesia allowed us to study Glu dynamics for at least 7 days post-
implantation. When we couple this finding with our changes in Glu from a 
stressor such as fox urine we can design behavioral paradigms to better 
understand physiological release and uptake of Glu. 
 
Copyright © Kevin Nicholas Hascup 
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Chapter Six: Conclusion 
 
Introduction 
 The most important findings from our GLUD1 transgenic mouse studies is 
their increased stimulus-evoked Glu release as well as their spontaneous motor 
neuron degeneration.  It is well known that excessive Glu release and activation 
of post-synaptic receptors can kill neurons (Olney, 1978).  This has undoubtedly 
led us to the model excitotoxicity proposed in Chapter III.  Upregulation of 
GLUD1 gene leads to production of more GLUD1 protein.  This in turn leads to 
the synthesis of Glu from α-ketoglutarate and subsequent increased vesicle 
packaging of Glu in glutamatergic neurons.  With increased amounts of Glu in 
vesicles, the GLUD1 transgenic mice released more Glu into the extracellular 
space after stimulus compared to WT.   Since there is not a compensatory 
increase in Glu uptake in the GLUD1 transgenic mice, more Glu is available in 
the synaptic cleft of GLUD1 trangsenic mice to activate iGluRs and mGluRs.  In 
particular the NMDA receptor, whose gene for the Glu binding domain was 
upregulated in GLUD1 transgenic mice.  Since motor neurons have little to no 
calcium sequestering proteins (Van Den Bosch et al., 2005), mitochondria are 
forced to buffer the intracellular calcium.  Over time, if the mitochondria become 
damaged by excessive intracellular calcium, proteases, oxygenases, and 
reactive oxygen species (ROS) form, which are key mediators of excitotoxic cell 
death.  Despite this model, it doesn’t explain what neurological disease state 
these mice most closely represent.  Unfortunately, there is not a simple 
relationship between high extracellular levels of glutamate and neuronal death 
(Obrenovitch and Urenjak, 1997), which makes narrowing this transgenic mouse 
down to a specific disease state a daunting task. 
 
Alzheimer’s Disease 
 AD is a chronic degenerative neurological disorder characterized by 
progressive loss of memory and cognition (Katzman and Saitoh, 1991).  
Pathologically, AD is characterized by three major hallmarks: senile plaques 
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consisting of amyloid β-peptide (Aβ), neurofibrillary tangles consisting of 
hyperphosphorylated tau protein, and loss of synapses (Katzman and Saitoh, 
1991).  Since Glu is involved in cognition, it goes to reason that this 
neurotransmitter plays a key role in the progression of AD.  Recent studies 
suggest that glutamate-induced NMDA receptor activation stimulates amyloid 
precursor protein to produce Aβ (Gordon-Krajcer et al., 2002).  Burbaeva and 
colleagues (2005) determined that GLUD1 was increased in brain tissue 
homogenate from the prefrontal cortex (PFC) of Alzheimer’s disease (AD) 
patients compared to control patients. This group concludes that alterations in 
Glu metabolizing enzymes may be responsible for changes in the extracellular 
concentration of Glu.  If an increase in GLUD1 is causing an increase in 
extracellular concentrations of Glu, this may lead to over stimulation of NMDA 
receptors and excess Aβ production with consequent oxidative stress-induced 
neuroexcitotoxicity.  Studies have also shown that the EAAT2 activity is 
significantly reduced in the brains of AD patients (Masliah, et al., 1996).  Other 
studies have found a correlation between loss of glutamine synthetase and 
cognitive and functional status of AD patients (Antuono et al., 2001).  Inhibition of 
Glu transport, coupled with decreased activity of glutamine synthetase or 
increased activity of GLUD1, may lead to increased extracellular levels of Glu. 
These increased levels of extracellular Glu can cause excessive stimulation of 
NMDA receptors and excitotoxic processes involving excess intraneuronal 
Calcium accumulation and eventual neuronal death.   
   The information provided above presents some potential similarities 
between the GLUD1 transgenic mice as a model of AD.  Our studies have not 
directly examined the GLUD1 transgenic mouse brains for formation of senile 
plaques or tauopathies.  Staining at the University of Kansas has shown 
ubiquitinated protein aggregates in the hippocampus of 16-20 month old GLUD1 
mice.  These results suggested the appearance of aggresome-like structures in 
vulnerable neurons of GLUD1 transgenic mice, indicating neuronal stress.  AD 
patients show that CA1 neurons are selectively damaged at an early stage of the 
disease and the same neurons show accumulations of ubiquitinated-proteins.  
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We cannot make definitive conclusions regarding the levels of EAAT2 
transporters in the GLUD1 transgenic mice because the appropriate experiments 
to examine this have not been conducted.  However, no difference in Glu uptake 
was observed with our MEA studies.  In addition, no studies were conducted to 
determine activity of glutamine synthetase.  The oxidative stress due to Aβ may 
explain EAAT2 and glutamine synthetase dysfunction, but this has not been 
elucidated in the GLUD1 motor deficient mice.  The biggest drawback to 
elucidating this mouse as a model of AD is the fact that the mice show no 
cognitive impairment in behavioral memory studies, a hallmark of AD in humans.  
More studies are needed to examine these factors to provide additional 
information to better characterize these mice as a model of AD.   
 
Amyotrophic Lateral Sclerosis 
 ALS is a chronic progressive disorder characterized by the selective 
degeneration of motor neurons in the cerebral cortex, brainstem, and spinal cord 
(Danbolt, 2001).  Symptoms normally are muscular weakness and atrophy which 
leads to extensive paralysis and death due to respiratory failure generally within 
2-5 years from diagnosis (McGeer and McGeer, 2005).  There is a growing body 
of evidence implicating excitotoxicity as a contributing factor to motor neuron 
injury either as a primary or secondary mechanisms (Heath and Shaw, 2002).  A 
study conducted by Malessa and colleagues (1991) have shown that GLUD1 is 
upregulated in the ventral horn of the spinal cord of ALS patients.  It is well 
documented that Glu levels are increased in the CSF of ALS patients (Rothstein 
et. al, 1990; Doble, 1999; Heath and Shaw, 2002; Spreux-Varoquaux et al., 
2002).  Since the GLUD1 reaction favors Glu formation, this finding by Malessa 
and colleagues, suggests a causative relation for the increased levels of Glu.  
These CSF Glu levels may be high enough to cause excitotoxicity and damage 
motor neurons—a hallmark of ALS.  Other studies have shown that EAAT2 levels 
are lower resulting in reduced uptake of extracellular Glu (Rothstein et al., 1992).  
Currently, it is not clear if the reduced EAAT2 expression is the primary event 
leading to motor neuron death and ALS or if the reduced expression is secondary 
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to the neuron loss; however, available data suggests it to be the later (Danbolt, 
2001).   
 The information presented above provides a strong case for categorizing 
the GLUD1 transgenic mice as a model of ALS.  We know from our 
electrochemical studies that increased gene copy number leads to an increase of 
stimulus-evoked Glu release.  At 16 months of age, these mice have obvious 
movement and righting impairments.  Histological data provided by the University 
of Kansas clearly show upper and lower motor neuron atrophy and necrosis in 
the GLUD1 transgenic mice.  The only piece of evidence not supporting a model 
of ALS is a decrease in the EAAT2 levels.  We cannot make definitive 
conclusions regarding the levels of EAAT2 transporters in the GLUD1 transgenic 
mice because the appropriate experiments to examine this have not been 
conducted.  However, no difference in Glu uptake was observed with our MEA 
studies.  If transporter levels are decreased as a secondary mechanism, it might 
go to reason that we should not have seen differences in Glu clearance since all 
our electrochemical studies were conducted in GLUD1 mice that were 8-12 
months of age.  Similar studies in the 16 month motor deficient GLUD1 
transgenic mice might help elucidate this question as well as provide us with 
more information to better characterize these mice as a model of ALS.    
 
Epilepsy 
 Epilepsy is a chronic neurological disorder characterized by recurring 
seizures.  As the principal excitatory neurotransmitter, Glu inevitably plays a role 
in the initation and spreading of seizure activity (Danbolt, 2001).  Studies have 
shown that Glu levels are elevated in patients with various epilepsies and it has 
been shown that Glu is elevated patients just prior to the onset of seizures 
(Danbolt, 2001).  It is not known if defective uptake plays a role in epilepsy in 
humans, but reduced expression of transporters has been shown to cause or be 
associated with seizures in animal models (Danbolt, 2001).  For example, mice 
lacking EAAT2 develop spontaneous seizures.  
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 The motor deficient GLUD1 mice would not be categorized well as a 
model of epilepsy.  Despite the fact that force plate actometer studies conducted 
at the Unversity of Kansas have noted seizure like activity during behavioral 
studies in some of the GLUD1 motor deficient mice.  However, this does not 
explain the motor deficits observed in these mice.  Also, we cannot make 
definitive conclusions regarding the levels of EAAT2 transporters in the GLUD1 
transgenic mice because the appropriate experiments to examine this have not 
been conducted.  However, no difference in Glu uptake was observed with our 
MEA studies.  Based on these findings the GLUD1 motor deficient mice are not a 
good model of epilepsy. 
   
Huntington’s Disease 
 Huntington’s disease (HD) is a neurodegenerative disorder characterized 
by adult onset with choreic movements combined with mental impairments.  The 
gene responsible for HD is localised on chromosome 4 that encodes the protein 
huntingtin.  The disease is caused by the presence of strings of CAG repeats in 
the DNA that introduce polyglutamine sequences into the protein that endows the 
protein with neurotoxic properties (Doble, 1999).  Initial observations showed that 
the NMDA agonist, quinolinic acid, reproduce the lesions seen in HD. Additional 
studies suggest that selective neurodegeneration can be produced by energy 
impairment, which sensitizes striatal neurons to the excitotoxic effects of Glu, 
which is a classic case of slow excitotoxicity.   
 The motor deficient GLUD1 mice would not be categorized well as a 
potential model of HD.  The main similarities are centered on the movement 
disorders.  Histological studies show that the large upper and lower motor 
neurons are deteriorating in the GLUD1 mice.  This is unlike HD where the larger 
neurons are spared and the medium sized neurons atrophy.  Also, there is no 
indication that the huntingtin protein is altered in these mice, but a direct 
examination of this protein in the GLUD1 mice is needed before anything 
definitive can claimed.  But based on these early observations, the GLUD1 motor 
deficient mice is not a good model of HD. 
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Parkinsons Disease 
 PD is a progressive degenerative neurological disorder pathologically 
characterized by motor symptoms that include rigidity, hypokinesia and tremor, 
which is a result of massive and selective loss of dopaminergic neurons in the 
nigrostriatal pathway (Doble, 1999).  This causes imbalance in the motor circuits 
in the basal ganglia, which leads to a net increase in inhibitory output from the 
basal ganglia to the thalamus (Doble, 1999).  This results in profound 
modifications of glutamatergic firing throughout the basal ganglia.  Some 
experimental evidence suggests that neurodegeneration of dopaminergic 
neurons in substantia nigra involves a toxic action exerted by Glu on the NMDA 
receptor.   
 The motor deficient GLUD1 mice would not be categorized well as a 
potential model of HD.  The main similarities are centered around the movement 
disorders.  The main difference is the fact that there appears to be no loss of 
dopaminergic neurons in the GLUD1 motor deficient mice.  Preliminary studies 
conducted in Dr. Don Gash’s laboratory showed no loss of dopaminergic neurons 
as well as tyrosine hydroxylase staining for catecholamines.  Since loss of 
dopaminergic neurons is a hallmark sign of PD in humans, based on these 
preliminary studies, it would be impossible to use the GLUD1 motor deficient 
mice as a model of PD.      
 
Final Notes 
 Based on the data presented for the predominant neurological disorders 
described in this chapter, the most likely candidate that the GLUD1 motor 
deficient mice would model is ALS.  The GLUD1 mice show spontaneous 
motorneuron degeneration around 16 months of age, which is slightly past the 
half-way time point of a mouse’s lifespan.  This is similar age of onset for people 
who develop ALS.  The histopathology is similar between ALS and the GLUD1 
mice.  In both, the spontaneous degeneration is limited to the large upper and 
lower pyramidal neurons.  More studies are needed to provide a stronger case.  
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For example, we have not studied the role of Calcium ions, which is speculated 
to lead to formation of reactive oxygen species, which is implicated in models of 
excitotoxicity.  A long term goal of this project is to provide evidence that shows 
the increased levels stimulus-evoked Glu release due to upregulation of the 
GLUD1 gene leads to overstimulation of the NMDA receptor and subsequent 
Calcium influx and eventual reactive oxygen species formation leading to motor 
neuron degeneration.  But these early studies indicate something not normally 
studied when it comes to neurological disorders.  Dysregulation of Glu 
metabolizing enzymes may be the initial event that leads to a cascade of 
problems that overtime causes the severe memory or motor impairments.  More 
studies throughout the scientific community need to be conducted in animal 
models of neurological diseases to address this issue. 
 
Copyright © Kevin Nicholas Hascup 
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Appendix A:  L-Glutamate Dynamics in Male Glutamate Pyruvate     
Transaminase Knock Out Mice 
 
Introduction 
 The development of the GPT KO mouse line was one of several 
transgenic mouse lines bred in Dr. Elias Michaelis’s research laboratory at the 
University of Kansas.  Unfortunately, their laboratory was not equipped or funded 
to maintain a large breeding colony for each transgenic model being studied.  For 
this reason, litters were kept small, which forced our early studies to examine 
both male and female GPT KO mice.  Our preliminary studies indicated several 
gender differences in Glu regulation when examining this first set of GPT KO 
mice.  This was expected since the limited data examining hormonal regulation 
on Glu neurotransmission indicates that female hormones act as antagonists on 
iGluRs (Bergeron et al., 1996).  Because of its antagonistic effects on iGluRs, 
progesterone has been shown to be a successful post-injury treatment for stroke 
and traumatic brain injury in both males and females (Stein, 2001).  In addition, 
recent work suggests that the estrogen receptor alpha (ERα) is found at 
extranuclear sites on neurons where they directly modulate excitation or 
inhibition (Stein, 2001 and Toran-Allerand, 1996).  Since females, not males 
maintain circulating blood plasma levels of progesterone and occasionally 
estrogen, we hypothesized that male and female GPT KO mice would differ in 
Glu neurotransmission. 
 These differences we observed in our preliminary studies warranted 
further examination with a larger number of animals for both male and female 
GPT KO mice.  However, due to the age range used in these studies, the small 
litters, and the fact that the University of Kansas was performing behavioral and 
histological studies on these mice, few male GPT homozygous mice were 
available for study.  This made it difficult to statistically compare the male and 
female GPT KO groups.  All data regarding the male GPT KO mice are given 
below and general comparisons between genders are discussed.   
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Methods 
 All transgenic mice were developed at the University of Kansas by Dr. 
Elias K. Michaelis’s laboratory.  A nonfunctional rat GPT transgene was inserted 
into the mouse genome under the control of the Neuronal specific enolase (NSE) 
promoter.  The NSE promoter has been shown to be expressed only in neurons 
of the brain and spinal cord (Choi et al., 1992; Peel et al., 1997).  Transgenic 
mice were generated by injecting mouse oocytes (C57BL/6J-SJL hybrid) with 
vectors containing cDNA of nonfunctional rat GPT placed under the control of the 
NSE promoter.  This promoter was excised from the pNSE-LacZ vector by first 
digesting the SV40 polyA tail of pNSE-LacZ vector and cloning it into pGEm-7Z.  
The NSE promoter was also excised and cloned into the modified pGEM-7Z.  
Finally, a nonfunctional GPT open reading frame was cloned into the pNSE-
GEM-7Z to create the pNSE-GPT vector for the GPT transgenic mice.  The 
vector was digested, the DNA recovered, and microinjected into the nucleus of 
fertilized mouse ooctyes to generate the GPT KO mice.  Oocytes were 
transferred to surrogate C57BL/6 mice.  Pups carrying the transgene were 
identified by PCR and Southern Blot Analysis.  Progeny were eventually 
backcrossed into a C57BL/6 mouse strain.   
 GPT KO C57BL/6 mice were transported to the University of Kentucky 
and housed as described in Chapter Two.  For the GPT KO study, both male and 
female mice were studied.  Only the results from the male analysis are included 
in this Appendix; the female analysis is found in Chapter Four.  Breeding limited 
sufficient numbers of male homozygous mice (n=2) for complete analysis and 
comparison between genders  
 Mice were given 3 i.p. injections of 12.5% urethane for a total dose of 1.25 
g/kg.  All studies were conducted in the Str.  Glu recordings were conducted 
using enzyme-based MEAs with a sampling rate of 1 Hz as previously described 
in Chapter Two.  A craniotomy was performed over both striatal hemispheres and 
MEAs were stereotaxically placed using the coordinates from Paxinos and 
Franklin (2004) (AP: +0.9 mm; ML: ± 1.5, ±1.7 mm; DV: -2.25, -2.75, -3.25, -3.75 
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mm vs bregma) in order to create a depth profile of the Str in transgenic and WT 
mice.  A glass micropipette with an internal diameter of 10-12 µm was attached 
to the PCB and positioned among the four Pt recording sites, resting 50-100 µm 
above the recording surface.  Through this glass micropipette isotonic solutions 
of 70 mM KCl (70 mM KCl, 79 mM NaCl, 2.5 mM CaCl2; pH 7.4) and 5 mM Glu 
(in 0.9% saline; pH 7.4) were locally applied to the surrounding brain tissue to 
study glutamatergic neurotransmission.  Upon initial MEA placement, a stable 
baseline recording was obtained for at least 30 minutes prior to local application 
of solutions.  Since self-referencing MEAs were used, resting Glu levels were 
calculated during this initial baseline time period.  After the initial baseline 
recording, solutions were locally applied at regular 30 second intervals (for a total 
of 20 signals; 10 signals from each Pt recording site) to assess Glu dynamics at 
each recording depth.  Due to the reproducibility of Glu signals in vivo, all signals 
for a particular depth were averaged into a single data set for that depth.  Data 
analysis involved an ANOVA with a Tukey’s post hoc test to compare GPT KO 
groups.  All data was reported as mean ± standard error of the mean and 
significance was defined as p < 0.05. 
 
Results  
 Local application of 70 mM KCl resulted in robust, reproducible Glu 
signals compared to baseline. To quantitate the amount of Glu released, we 
volume matched the amount of stimulus locally applied to all three mouse 
groups.  Only Glu signals that were elicited by 50 to 150 nl of 70 mM KCl were 
used for this analysis, therefore, no significant difference in the amount of 
stimulus used was observed between the GPT WT (107 ± 4 nl), heterozygous 
(97 ± 4 nl) and homozygous (109 ± 9 nl) mice (figure A.1A).  When the average 
maximal amplitude of Glu release was quantitated, GPT heterozygous mice (10.9 
± 1.3 µM) released significantly more Glu (p < 0.001) compared to WT (2.9 ± 0.5 
µM) and (p < 0.05) homozygous (3.9 ± 1.2 µM) littermates (figure A.1B).  Using 
the same subset of signals, striatal, depth-related alterations in stimulus-evoked 
Glu  release  were  also  examined  (figure A.2).  The  average  Glu  release  was  
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Figure A.1:  Stimulus-Evoked Glu Release in the Male GPT KO Mice 
 
A) Only Glu signals that were elicited by 70 mM KCl whose volumes ranged between 50 and 150 
nl were analyzed for the GPT WT (n=4; +/+; red), heterozygous (n=7; +/-; blue) and homozygous 
(n=2; -/-; yellow) mice.  Since the volumes were matched, no significant difference in the amount 
of stimulus locally applied was observed between WT (107 ± 4 nl), heterozygous (97 ± 4 nl), 
homozygous (109 ± 9 nl) mice.  B) The average maximal amplitude of Glu released upon local 
application of 70 mM KCl was significantly increased (***p < 0.001) in the GPT heterozygous 
mice (10.9 ± 1.3 µM; blue) compared to WT (2.9 ± 0.5 µM; red) and homozygous (3.9 ± 1.2 µM; 
yellow) littermates.  Male GPT heterozygous mice also released significantly (# p < 0.05) more 
Glu compared to homozygous mice.  
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Figure A.2:  Stimulus-Evoked Glu Release Depth Profile in the Male GPT KO Mice 
 
Average stimulus-evoked Glu release at different recording depths within the Str of GPT WT 
(n=4; red; +/+), heterozygous (n=7; blue; +/-), and homozygous (n=2; yellow; -/-) mice.  GPT 
heterozygous (15.1 ± 3.6 µM) mice released significantly (p < 0.05) more Glu compared to WT 
(2.9 ± 0.9 µM) and homozygous (4.7 ± 2.4 µM) mice at recording depth -2.25 mm.   A trend was 
also observed for increased Glu release at recording depth -2.75 and -3.75 mm.  A one-way 
ANOVA with Tukey’s post hoc was conducted at each depth for statistical analysis. 
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calculated at each depth (DV -2.25 to -3.75 mm) and compared amongst the 
GPT KO mouse groups.  GPT KO heterozygous mice released significantly (p < 
0.05) more Glu at depth -2.25 mm compared to WT and homozygous mice.  
Also, at recording depths -2.75 mm and -3.75 mm the average maximal Glu 
released for GPT KO heterozygous mice approached significance (p = 0.07 and 
p = 0.06, respectively).   
 Since neurotransmitter uptake follows classical Michaelis-Mentin kinetics 
(Nicholson, 1995) and was affected by the amount of available substrate, Glu 
uptake was analyzed by selecting a subset of signals with maximum release 
values were in the range of 3-13 µM.  This range was chosen, because these 
peak Glu values were easily obtainable in both groups.  Within this subset of  
signals, no significant difference in average maximum release of Glu was 
observed in WT (4.8 ± 0.4 µM), heterozygous (5.9 ± 0.3 µM) and homozygous 
(6.0 ± 0.4 µM) mice (figure A.3A).  We did observe significantly faster Glu uptake 
in the GPT KO heterozygous (p < 0.05; 1.8 ± 0.2 µM/sec) and homozygous (p < 
0.001; 2.8 ± 0.4 µM/sec) mice compared to WT (1.2 ± 0.1 µM/sec).  We also 
observed that the GPT homozygous mice had significantly (p < 0.05) faster Glu 
uptake compared to heterozygous mice (figure A.3B).  Examining the same 
subset of signals, a striatal depth analysis was performed for Glu uptake (figure 
A.4).  At recording depth -3.75 mm, GPT homozygous mice had a significantly (p 
< 0.05) faster Glu uptake rate (2.6 ± 0.4 µM/sec) compared to WT (1.0 ± 0.2 
µM/sec) mice.  Stimulus-evoked Glu uptake in the GPT heterozygous (3.3 ± 1.2 
µM/sec) mice approached significance (p = 0.0513) compared to WT (1.0 ± 0.1 
µM/sec) mice at the recording depth -3.25 mm.   
 Due to the electrogenic nature of Glu transporters (Takahashi et al., 1997; 
Doble, 1999), we wanted to determine transporter function without membrane 
depolarization.  We locally applied an isotonic solution of 5 mM Glu (pH 7.4) and 
examined a subset of Glu signals.  Unfortunately, the low number of animals 
studied for the GPT homozygous group limited the number of signals.  For this 
reason, we had to analyze signals that were in the range of 8-13 µM, which was 
a higher range as those used for our stimulus-evoked Glu uptake analysis.  
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Figure A.3:  Stimulus-Evoked  Glu  Uptake  in  the  Male  GPT  KO  Mouse  Groups 
 
A) Subset of Glu signals were examined whose average maximal amplitude fell in a range of 3-13 
µM for both the GPT WT (n=4; +/+; red), heterozgyous (n=7; +/-; blue), and homozygous (n=2;     
-/-; yellow) mice.  No significant difference was observed between WT (4.8 ± 0.3 µM), 
heterozygous (6.0 ± 0.5 µM) and homozygous (6.1 ± 0.4 µM) mice.  B)  When the uptake rate of 
stimulus-evoked Glu was examined, both heterozygous (1.8 ± 0.2 µM/sec; blue), and 
homozygous (2.8 ± 0.4 µM/sec; yellow) mice had significantly faster Glu uptake (*p < 0.05, ***p < 
0.001; respectively) compared to WT (1.2 ± 0.1 µM/sec; red) mice.  Also, GPT homozygous mice 
had a significantly (#p < 0.05) faster Glu uptake compared to heterozygous mice. 
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Figure A.4:  Stimulus-evoked Glu Uptake Depth Profile in the Male GPT KO Mice 
 
Average stimulus-evoked Glu release at different recording depths within the Str of GPT KO WT 
(n=4; +/+; red), heterozygous (n=7; +/-; blue), and homozygous (n=2; -/-; yellow) mice.  On 
average, GPT homozygous mice had faster uptake of stimulus-evoked Glu compared to WT and 
heterozygous mice at all recording depths.  This became significant (*p < 0.05) at recording depth 
-3.75 mm and approached significance at depth -3.25 mm when compared to WT mice.  A one-
way ANOVA with a Tukey’s post hoc was conducted at each depth for statistical analysis. 
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When examining this range of signals, there was no significant difference in the 
maximal amplitude of exogenously applied 5 mM Glu in the GPT WT (9.4 ± 0.4 
µM), heterozygous (9.9 ± 0.4 µM), and homozygous (10.5 ± 0.4 µM) mice (figure 
A.5A).  Similar to the stimulus-evoked Glu uptake study, we observed 
significantly (p < 0.001) faster uptake in the homozygous (6.1 ± 0.3 µM/sec) mice 
compared to the WT (3.0 ± 0.4 µM/sec) and heterozygous (3.6 ± 0.3 µM/sec) 
mice  (figure A.5B).  Using the same subset of signals, striatal depth-related 
alterations in clearance of exogenously applied 5 mM Glu was examined (figure 
A.6).  The average clearance rate was calculated at each recording depth (DV     
-2.25 to -3.75 mm) and compared amongst the GPT KO mouse groups.  The 
clearance of exogenously applied 5 mM Glu was significantly (p < 0.05) faster in 
the GPT homozygous mice compared to controls at recording depths -2.75 mm 
(6.0 ± 0.5 µM/sec and 2.9 ± 0.8 µM/sec, respectively) and -3.75 mm (6.2 ± 0.7 
µM/sec and 2.3 ± 0.4 µM/sec, respectively).  At recording depth -3.25 mm, we 
observed a nonsignificant increase (p = 0.1) in the clearance of exogenously 
applied 5 mM Glu compared to WT littermates.  The limited range of amplitudes 
chosen for this study made it difficult to obtain enough values to perform 
statistical analysis at recording depth -2.25 mm.   
 Since self-referencing MEAs were used to study the GPT KO mice, we 
were able to determine resting Glu levels in the Str.  Thirty second baseline 
measures were taken prior to local application of 70 mM KCl.  Resting Glu levels 
were only measured when 70 mM KCl was in the barrel of the glass micropipette.  
Possible diffusion of 5 mM Glu out of the barrel caused unphysiologically 
elevated levels of resting Glu.  Using our self-referencing recording techniques, 
resting Glu levels showed a nonsignificant (p=0.09) decreasing trend in 
heterozygous (0.9 ± 0.1 µM) and homozygous (0.4 ± 0.1 µM) mice when 
compared to control (1.1 ± 0.3 µM) mice (figure A.7A).  Additionally, a depth 
analysis profile revealed a similar trend at all recording depths to what was 
observed when the recording depths were averaged.  GPT control mice had 
elevated resting Glu levels at all recording depths, but this was not significant 
(figure A.7B). 
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Figure A.5:  5 mM Glu Clearance in the Male GPT KO Mouse Groups 
 
A)  A subset of Glu signals were examined whose average maximal amplitude fell in a range of 8-
13 µM for the GPT  WT (n=3; +/+; red), heterozygous (n=5; +/-; blue), and homozygous (n=2; -/-; 
yellow) mice.  There was no significant difference in the maximal amplitude of exogenously 
applied 5 mM Glu in the GPT WT (9.4 ± 0.3 µM), heterozygous (9.9 ± 0.3 µM), and homozygous 
(10.5 ± 0.4 µM) mice.  B) We observed significantly (***p < 0.001; ###p < 0.001) faster Glu 
clearance in the homozygous (6.1 ± 0.3 µM/sec; yellow) mice compared to the WT (3.0 ± 0.4 
µM/sec; red) and heterozygous (3.6 ± 0.3 µM/sec; blue) mice.   
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Figure A.6:  5 mM Glu Clearance Depth Profile in the Male GPT KO Mice 
 
Average clearance rates of exogenously applied 5 mM Glu at different recording depths within the 
Str of GPT WT (n=3; +/+; red), heterozygous (n=5; +/-; blue), and homozygous (n=2; -/-; yellow) 
mice.  On average, Glu clearance was faster in the GPT homozygous mice compared to controls 
at all recording depths.  This was significant (*p < 0.05) at recording depths -2.75 and -3.75 mm 
and approached significance at recording depth -3.25 mm.  A one-way ANOVA with a Tukey’s 
post hoc was conducted at each depth for statistical analysis. 
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Figure A.7:  Resting Glu Levels in the Male GPT KO Mice 
 
A) Resting Glu levels were averaged through the entire Str and no significant (p=0.09) differences 
were found between WT (1.1 ± 0.3 µM; n=4; red), heterozygous (0.9 ± 0.1 µM; n=6; blue) and 
homozygous (0.4 ± 0.1 µM; n=2; yellow) mice.  B) Average resting Glu levels were determined for 
each depth within the Str of WT (+/+; red), heterozygous (+/-; blue), and homozygous (-/-; yellow) 
mice.  No significant difference was observed within mouse groups over the different recording 
depths. The slower clearance trend in (A) was observed at each recording depth.   A one-way 
ANOVA with a Tukey’s post hoc was conducted at each depth for statistical analysis. 
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Discussion 
 The low number of male GPT homozygous mice (n=2) studied made it 
difficult to statistically compare groups of male mice as well as compare groups 
of mice across gender.  We did, however, observe some drastic differences 
between the two genders.  Stimulus-evoked Glu release was significantly 
increased in the male GPT heterozygous mice compared to both control and 
homozygous mice.  In the female groups only the GPT homozygous mice 
showed significantly increased Glu levels compared to WT mice.  When the 
uptake of stimulus-evoked Glu release was examined, both heterozygous and 
homozygous male mice displayed faster uptake kinetics compared to controls.  
The female mice exhibited no differences in uptake kinetics across all three 
groups.   
 Comparing the clearance rates of exogenously applied 5 mM Glu is 
difficult.  The small number of available homozygous mice studied limited the 
range of maximal amplitude to 8-13 µM for analysis.  A maximal amplitude range 
of 3-13 µM was used to study stimulus-evoked Glu uptake in male and female 
mice as well as clearance of exogenously applied 5 mM Glu in female mice.  
Because of the different maximal amplitude ranges examined, direct comparison 
of uptake or clearance values is skewed.  We observed that male GPT 
homozygous mice cleared exogenously applied Glu significantly faster than WT 
and heterozygous mice, which was also seen in the uptake analysis of stimulus-
evoked Glu release in the male GPT KO mice.  When comparing gender, female 
GPT homozygous mice cleared exogenously applied 5 mM Glu significantly 
slower compared to controls.   
 Using our self-referencing recording techniques, we were able to record 
resting Glu levels in the Str of GPT KO male mice.  Resting Glu levels were 
similar in the WT, heterozygous, and homozygous mouse groups, despite the 
differences seen in stimulus-evoked Glu release as well as increases in the 
uptake and clearance rates of Glu in the homozygous mice.  We did observe a 
nonsignificant decrease in resting Glu in the homozygous male mice.  The 
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decrease in resting Glu may be due to the significantly increased Glu clearance 
in the male homozygous mice.  If Glu is cleared from the extracellular space 
faster, that may indicate an increased transporter density, which would lower 
resting Glu levels.  Further studies are needed to determine the validity of this 
hypothesis.  In the GPT KO female mice, we did not see any significant 
differences in resting Glu levels, but a nonsignificant increase was observed in 
the GPT heterozygous female mice.  Resting Glu values were similar between 
male and female GPT KO mouse groups. 
 Despite the low number of male homozygous mice studied, there are 
obvious differences in Glu regulation between the male and female GPT KO 
mice, especially when examining the uptake of stimulus-evoked Glu release and 
clearance of exogenously applied Glu.  These comparisons indicate extreme 
differences in either the number or function of EAATs in the mouse striatum.   By 
increasing the number of male GPT homozygous mice in our studies, we can 
make some direct comparisons between genders.   
 
Copyright © Kevin Nicholas Hascup 
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Appendix B: Understanding L-Glutamate Dynamics in the                           
Awake, Freely Moving BALB/C Mouse Model. 
 
Introduction 
 The C57BL/6 mouse line was used for feasibility and initial 
characterization of the freely moving recording because we anticipated studying 
the GLUD1 motor deficient mice.  However, as we progress this technology for 
behavioral research, it will be important to characterize the BALB/C mouse strain 
as well in order to provide a comparative assessment of behavior between 
different inbred strains.  Inbred strains of mice differ in their behavioral and 
neurochemical responses to stimuli.  For example, the BALB/C strain exhibits 
neophobia, especially when compared to other inbred strains, which makes them 
suitable candidates for anxiety research (Belzung and Griebel, 2001, Belzung et 
al., 2001).  This increased anxiety reduces their social behavior and increases 
aggressive behaviors, which may indicate that the BALB/C mice are a useful 
model for identifying gene and neurobiological pathways in autism-related 
diseases (Brodkin, 2007).  Studies have also shown that electric footshock 
induces a higher increase in dopamine in the PFC of BALB/C mice compared to 
C57BL/6 mice (Herve et al., 1979).  However, predator stressors such as fox 
urine elicit larger DOPAC increases in the PFC of C57BL/6 mice as compared to 
BALB/C mice further indicating that neurochemical changes due to stress or 
behavior may be situation-specific (Hayley, et al., 2001).  For these reasons it is 
useful to compare different strains of inbred mice when conducting behavioral 
research.   
Methods 
 All materials and methods for freely moving recording were thoroughly 
outlined in Chapter Two.  Male BALB/C mice between the ages of 5 and 6 
months at the time of recordings were used in these experiments.  Glu 
recordings were conducted using self-referencing, enzyme-based MEAs with a 
sampling rate of 1 Hz. A craniotomy was performed over the PFC (AP: +1.54 
mm; ML: 0.3 mm; DV: -2.45 mm vs. bregma) and MEAs were implanted using 
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the coordinates from Paxinos and Franklin (2004).  A stainless steel guide 
cannula was attached to the PCB and positioned so an internal, acute stainless 
steel cannula was positioned among the 4 Pt recording sites, resting 50-100 µm 
above the recording surface. Through this internal cannula isotonic solutions of 1 
mM Glu (in 0.9% saline; pH 7.4) or 50 µM (S)-4-Carboxyphenylglycine (CPG) 
were locally applied to the surrounding brain tissue to study glutamatergic 
neurotransmission.  Prior to connecting the mouse pedestal with the mouse hat, 
mice were allowed to freely roam around the recording chamber for at least 30 
minutes to acclimate to their environment.  Once connected to the mouse hat, 
the mice underwent a minimum 60 minute acclimation period to establish a 
stable baseline recording.  Following this acclimation period, the dummy cannula 
was removed and the internal, acute cannula (connected to a 10 µl Hamilton 
Syringe) was inserted into the guide cannula on recording sessions when 
chemicals were locally applied.  After the internal cannula was inserted, another 
acclimation period of 30 minutes was allowed to reestablish baseline.  Following 
this period, resting Glu, and the effects of locally applied Glu or CPG were 
studied for up to three additional hours.  The volumes of locally applied Glu were 
kept constant at 0.5 µl while the volume for 50 µM CPG was kept at 1.0 µl. 
 Following completion of all recording sessions (after multiple days of 
recording), mice were anesthetized with isoflurane and transcardially perfused 
with 0.9% saline followed by 4% paraformaldehyde.  The brain was removed and 
stored in 4% paraformaldehyde for three days followed by storage in 0.1 M 
phosphate buffer (10% sucrose) for sectioning and staining to confirm MEA 
placement. 
 Data analysis involved a one-way ANOVA with Tukey’s post hoc to 
examine any differences in resting Glu levels and maximal amplitude over 
multiple days post-implantation.  Since only two mice were studied, all data was 
reported as mean ± standard deviation and significance was defined as p < 0.05. 
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Results 
 Similar to our studies in the freely moving C57BL/6 mice, the FAST 16 
Mark II recording system along with our modified MEA allowed for reliable 
second-by-second recordings of Glu in the PFC of awake, freely moving BALB/C 
mice.  We implanted the pedestal assemblies and recorded Glu for one week in 
the awake BALB/C mice.  Local application of an isotonic solution of Glu (1 mM; 
0.5 µl) through the internal cannula was used to verify Glu recordings in vivo.  
Figure B.1 shows representative Glu signals in the PFC of awake, freely moving 
BALB/C mice.  Glu measures were robust and reproducible within and over 
multiple days.  Figure B.2A shows the mean maximal Glu response on days 3, 5 
and 7 post-implantation. 
 Resting Glu measures were studied in the PFC of BALB/C mice on days 3 
through 7 post-implantation using the self-referencing technique described in 
Chapter Two.  Briefly, the self-referencing site current was subtracted from the 
Glu recording site current, and divided by the Glu recording site slope obtained 
from in vitro calibration.  We observed no significant difference in resting Glu over 
days in the PFC (figure B.2B). 
 Local application of 50 µM CPG in the PFC of BALB/C mice resulted in a 
bi-phasic affect on glutamatergic neurotransmission.  Immediately following local 
application there was a rapid, robust spike (~4 µM) in extracellular Glu that 
returned to baseline after several seconds (figure B.3).  Resting Glu levels then 
decreased (~0.5 µM) for approximately 15 minutes. The inset in figure B.3 shows 
the average change in resting Glu due to administration of 50 µM CPG.   
 
Discussion 
 Similar to our freely moving studies in the C57BL/6 mice, we successfully 
adapted our enzyme-based MEAs to record Glu in the awake, freely moving 
BALB/C mouse for at least 7 days post-implantation.  We locally applied an 
isotonic solution of Glu (0.5 µl, 1mM) in the PFC of BALB/C mice on days 3, 5 
and 7 post-implantation to determine the longevity of the enzyme-based MEA in 
vivo.  We saw no significant change in MEA sensitivity for Glu on days 3 - 7 post- 
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Figure B.1:  Representative Glu Traces From Local Application of 1 mM Glu 
 
Representative traces of locally applied Glu (1 mM; 0.5 µl) in the PFC of male BALB/C mice.  Glu 
was locally applied at the time points indicated by the arrows.  A rapid, reproducible spike was 
recorded in the PFC using self-referencing MEAs. Maximal peak height shows in vivo Glu signal 
from local application of Glu (arrows), while baseline measures show resting Glu levels.  
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Figure B.2:  Local Application and Resting Glu Levels in the PFC of BALB/C Mice 
 
A. Locally applied Glu data for days 3, 5, and 7 post-implantation in the PFC (n=2).  Glu (0.5 µl, 1 
mM) was locally applied over multiple days and recorded using a self-referencing MEA.  Stable 
Glu recordings were observed over all days measured indicating reliable in vivo Glu 
measurements for at least 7 days post-implantation.  B. Resting Glu levels were assessed on 
days 3 through 7 post-implantation in the PFC (n=2) of BALB/C mice.  Self-referencing MEAs 
were used to determine resting Glu levels.  
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Figure B.3:  Local Application of CPG in the PFC of BALB/C Mice 
 
Local application of 50 µM CPG (1.0 µl; pH 7.4) resulted in a rapid increase in Glu followed by a 
prolonged decrease in resting Glu levels as shown in the trace.  The inset shows the average 
change in Glu from unstimulated resting Glu. 
  179
implantation.  The average maximum amplitude from local application of 1 mM 
Glu in the BALB/C mouse strain (30.8 ± 7.6 µM) was similar to what was 
observed in the PFC of freely moving C57BL/6 mice (30.5 ± 7.8).  Also, our self-
referencing recording technique allowed us to measure resting Glu levels in the 
PFC of BALB/C mice on days 3 through 7 post-implantation.  We saw a 
nonsignificant increase in resting Glu levels over days; however, the large 
variance made it difficult to compare these values to what was observed in the 
PFC of C57BL/6 mice.  Additional studies need to be conducted before definitive 
comparisons can be determined. 
 The cystine-Glu exchanger has been a proposed mechanism for 
regulating resting Glu levels (Baker et al., 2002; Melendez et al., 2005).   The 
cystine-Glu exchanger is located on glia cells (figure 1.1) and acts by uptake of 
cystine into glia coupled with the export of Glu into the extracellular space.  
Microdialysis studies examining the cystine-Glu exchanger has shown that 
blockade of this transporter by CPG results in a decrease in resting Glu levels 
(Baker et al., 2002; Melendez et al., 2005).  In addition, CPG has also been 
reported as a group I mGluR competitive antagonist (Brabet et al., 1995; Doherty 
et al., 1999).  Group I mGluRs are excitatory autoreceptors located on both pre- 
and post-synaptic glutamatergic neurons.  Blockade of the pre-synaptic group I 
mGluR should also cause a decrease in resting Glu levels.  Unexpectedly, 
immediately following local application of 50 µM CPG we observed a fast spike in 
Glu levels, which lasted only seconds.  This immediate increase in Glu was 
reproducible both within and between animals.  Following the spike we observed 
an expected, prolonged decrease in resting Glu levels that lasted approximately 
15 minutes.  A separate study using 50 µM CPG was conducted in the PFC of 
the Long Evans rat by our laboratory (manuscript in preparation) and a similar 
immediate increase followed by a decrease in resting Glu levels was observed.  
This initial spike in resting Glu levels has not been previously reported and was 
an unexpected finding.  The fact that the initial spike in Glu lasted on the order of 
seconds makes it difficult for microdialysis to observe this phenomenon due to 
the low temporal resolution of the technique.  Based on current literature, there is 
  180
no definitive explanation for this rapid increase in Glu, and may be due to an 
unknown interaction with a pre-synaptic Glu autoreceptor.   
 This study demonstrates the ability to successfully use the MEA freely 
moving technology in more than one strain of mice.  The present studies using 
MEAs configured for second-by-second Glu measurements were viable for at 
least 7 days post-implantation in the awake, freely moving BALB/C mouse.  We 
observed a nonsignificant increase in resting Glu levels in the PFC of awake, 
freely moving BALB/C mice over days.  Further studies are needed to decrease 
the variance across days and make comparisons between Glu regulation in the 
BALB/C PFC and the C57BL/6 PFC.  Local application of 50 µM CPG resulted in 
a currently unreported rapid spike in Glu followed by an expected decrease in 
resting Glu levels.  These findings provided evidence that the high spatial and 
low temporal resolution provided by our MEA technology was necessary to better 
understand the effects CPG has on resting Glu levels.  These studies have set 
the foundation to study behavioral differences in Glu regulation between the 
BALB/C and C57BL/6 mouse strains. 
 
Copyright © Kevin Nicholas Hascup 
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Appendix C:  Development of a Self-Referencing Microelectrode                    
Array for Detection of Hydrogen Peroxide 
 
Introduction 
 The first generation of MEAs (despite a multitude of PCB, ceramic tips, 
and recording site layout designs) all had four or five Pt recording sites 
(Burmeister and Gerhardt, 2005).  While this was revolutionary at the time, our 
lab prides itself in pushing technology further.  We have developed several new 
MEA designs with 8 and 16 Pt recording sites and eventually one with 32 
recording sites.  The advantage of additional recording sites allows us to 
simultaneously measure neurochemicals from multiple brain regions or even 
measure multiple neurochemicals within a single brain region.  With additional 
recording sites placed in a confined geometrical area, the reporter molecule, 
H2O2, can diffuse to sites other than those from which it forms leading to false 
detection of analyte on those sites.  Consider a MEA with both GluOx and 
choline oxidase enzymes placed on neighboring sites.  Some of the H2O2 
generated from a GluOx site may diffuse to the choline oxidase coated site thus 
falsely contributing to the detection of choline.  In an attempt to prevent this, we 
considered placing a layer of catalase overtop the enzyme and sentinel sites.  
This would prevent any H2O2 from being detected on sites other than those that 
enzymatically produced the reporter molecule.   
 Catalase is a tetrameric, diffusion controlled enzyme that catalyzes the 
decomposition of H2O2 into H2O and ½O2 (Eventoff et al., 1976; Dringen et al., 
2005).  We were interested in using catalase for several important reasons.  
First, catalase is endogenously expressed in peroxisomes that are located in all 
brain cells in vivo (Schad et al., 2003) so introduction of this enzyme would not 
be foreign to the microenvironment.  Second, catalase has a slightly larger 
molecular weight (250 kilodaltons) compared to that of GluOx (140 kilodaltons) 
so incorporation of this enzyme into our BSA / Glut mixture is not difficult.  
Finally, catalase requires no substrates and is considered to be “catalytically 
perfect”, with reaction rates approaching that of diffusion speeds.  This means a 
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molecule of catalase catalyzes a reaction almost every time it encounters a 
molecule of H2O2, so even large concentrations of this reporter molecule can be 
decomposed quickly.  This makes catalase a great enzyme to prevent H2O2 from 
reaching adjacent recording sites on our MEAs. 
 The interest in developing a self-referencing catalase MEA for detection of 
H2O2 is two-fold.  The first is to advance our MEA technology for measurements 
of multiple analytes.  The second has a more neurochemical basis.  Interest in 
detection of H2O2 in living brain tissues is growing.  The production of H2O2 and 
other reactive oxygen species is implicated in the etiology of neurodegenerative 
disorders such as PD (Kulagina and Michael, 2003).   Second, the laboratory of 
Dr. Margaret Rice has demonstrated that H2O2, similar to nitric oxide, plays an 
important role as a diffusible neuromodulator (Avshalumov et al., 2003; Kulagina 
and Michael, 2003; Avshalumov et al., 2007).  Dr. Rice’s group contends that 
complex I of the electron transport chain found on the inner mitochondrial 
membrane is responsible for the majority of H2O2 found in the Str (figure C.1).  
To determine if it was even possible for H2O2 to diffuse out of mitochondria, we 
enlisted the help of Dr. Patrick G. Sullivan’s laboratory to collect mitochondrial 
preparations for study.  Various electron transport chain complex inhibitors were 
added in vitro to determine if H2O2 could be generated and subsequently leave 
the mitochondria where it can be detected by our MEA.  These studies would 
help determine the factors that control the rate and concentration of H2O2 that 
can be produced in the brain. 
 To conduct these studies, we developed a self-referencing MEA for H2O2 
determination.  The concept of this MEA is similar to that of the GluOx self-
referencing MEA.  The sites coated with a mixture of BSA/Glut and Catalase was 
applied on two of the Pt recording sites to act as a sentinel sites while the other 
pair of recording sites were coated with just the BSA/Glut mixture and 
subsequently detected H2O2.  Several feasibility studies were conducted to 
determine if catalase could block exogenously applied H2O2 from being detected 
by our MEA both in vitro and in vivo.  The following section outlines the 
development and application of our catalase MEA.     
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Figure C.1:  Mitochondrial Electron Transport Chain 
 
The electron transport chain builds up a proton electrochemical gradient across the inner 
mitochondrial membrane.  For simplicity, electron flow is not shown but is transported between 
Complexes I, II, and III by the membrane soluble Coenzyme Q and between complexes III and IV 
by the membrane protein cytochrome c.  H+ is pumped out of the mitochondrion during electron 
transport (Complexes I, III, and IV) and its exergonic return powers the synthesis of ATP from 
ADP through the ATP synthase (Complex V).  Figure adapted from Mattiasson and Sullivan, 
2006). 
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Materials and Methods 
 Bovine liver catalase (aqueous solution >40,000 units/mg protein) was 
obtained from Sigma-Aldrich (Catalog #C3155).  Preparation for enzyme coating 
was similar to that of GluOx.  All proteins and enzymes were brought to room 
temperature and 0.010 g of BSA Fraction V, 99% (Sigma-Aldrich, Catalog #A-
3059) was dissolved in a 1.5 mL microcentrifuge tube containing 985 μl ddH2O 
by manual agitation.  Once dissolved, 5 μl of Glut solution, Grade I, 25% (Sigma-
Aldrich Catalog #G-6257) was added to the BSA mixture and manually mixed by 
inversion five times.  The solution was then set aside for five minutes until it 
turned a faint yellow color.  Glut crosslinked proteins that adhered to the MEA 
surface when cured.  The BSA served as a matrix to protect catalase activity 
during immobilization.   Next, 9 μl of the BSA/Glut mixture was removed and 
added to a 300 μl microcentrifuge tube.  Lastly, 1 μl of the catalase stock solution 
was added and mixed by pipette agitation. 
All MEAs were tested for their response to H2O2 to ensure Pt site 
functionality prior to enzyme coatings.  After testing, MEAs were rinsed with 
ddH2O and dried in an oven (105 – 115 ºC) for 10 minutes to remove residual 
H2O prior to coating.  Catalase solutions and the inactive protein matrix of BSA/ 
Glut were applied to the Pt recording sites by hand.  Solutions were drawn up 
into a 10 μl Gastight® Hamilton microsyringe (Hamilton Co. Catalog #80065) and 
slowly dispensed to form a small droplet of solution at the tip of the microsyringe.  
Using a dissecting microscope, the droplet was briefly applied to the Pt recording 
sites.  The solution quickly dried, leaving behind a thin, translucent layer of 
enzyme that was visible underneath a dissecting microscope.  Two additional 
coats of catalase were applied in the same manner with one minute dry times in 
between each coat.  This procedure was complete once a visible film remained 
following coating.  The advantage of using multisite MEAs was that a pair of 
recording sites was coated with the catalase mixture and the adjacent sites were 
coated with the inactive protein matrix in the same manner as applying the 
catalase mixture to create the self-referencing catalase MEA.  MEAs were 
allowed to cure at room temperature for 48-72 hours.    
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Adult, male Sprague-Dawley rat (~250g) mitochondria were isolated in the 
laboratory of Dr. Patrick Sullivan using previously published protocols (Nukula et 
al., 2006).  Rats were anesthetized using a carbon dioxide chamber and 
decapitated.   Their brains were quickly removed and the cortices dissected.  
Cortex tissue was placed in ice cold isolation buffer with 1 mM ethylene glycol 
tetraacetic acid (EGTA) (75 mM sucrose, 215 mM mannitol, 0.1% BSA, 1 mM 
EGTA, 20 mM HEPES, pH 7.2).  Tissue was put into an all glass dounce 
homogenizer with 3 mLs of isolation buffer with EGTA, homogenized, split into 
four 2 mL tubes, topped off with isolation buffer and spun at 1,300 x g for 5 
minutes at 4°C.  The supernatant was taken off and saved in separate tubes.  
The pellet was resuspended in isolation buffer and spun at 1,300 x for 5 minutes 
at 4°C.  Supernatant was discarded (by slinging off) and the pellets were 
resuspended in 500 µl of isolation buffer.  A nitrogen bomb was used to rupture 
the cell membrane in order to release the mitochondria from cells.  The samples 
were placed in a cold nitrogen bomb for 10 minutes at 1000 psi to burst 
synaptoneurosomes formed by homogenization.  After bombing, the sample was 
spun on a Percoll gradient, with fresh stocks of 30%, 24%, and 40% Percoll 
made with isolation buffer.  The gradient was made by first adding 3.5 mLs of the 
24% stock to the ultracentrifuge tube and then, using a 5 mL syringe, injecting 
3.5 mLs of the 40% stock to the bottom of the tube.  Using equal amounts of the 
30% Percoll stock and sample, a 15% Percoll solution was made and 3 mLs 
were added to the top of the gradient.  The gradient was spun in a high speed 
Sorval centrifuge for 10 minutes at 30,400 x g.  The third fraction containing the 
purified mitochondria was removed, put into clean tubes, and topped off with 
isolation buffer without EGTA.  The samples were spun at 16,700 x g for 15 
minutes.  The supernatant was removed and the pellet was resuspended in 
isolation buffer without EGTA and spun at 13,000 x g for 10 minutes.  After the 
supernatant was removed and discarded, the pellet was resuspended in 500 µl 
isolation buffer without EGTA and transferred to a microcentrifuge tube, which 
was then spun at 10,000 x g for 10 minutes.  The supernatant was removed and 
the pellet was resuspended in enough isolation buffer without EGTA to get a 
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concentration of 10-15 µg/µl.  A BCA protein assay kit was used to determine 
protein concentration by measuring absorbance at 560 nm with a BioTek 
Synergy HT treated plate (Winooskin, Vermont).     
 
Results 
 The catalase MEA was tested first in vitro to determine its ability to block 
exogenously applied H2O2.  Figure C.2 shows a representative tracing of a 
catalase coated MEA calibration.  The MEA tip was placed into a 40 mL solution 
of 0.05 M PBS.  500 µl of 20 mM AA (final beaker concentration of 250 µM) and 
3 additions of 40 µl of 8.8 mM H2O2 (final beaker concentration of 8.8, 17.6, and 
26.4 µM) were added to the beaker.  As seen in figure C.2, the sites coated with 
catalase showed minimal response to additions of H2O2, while those coated with 
just BSA and Glut showed a large change in current from baseline.  
 Next, we wanted to determine if the catalase could decompose H2O2 
before it was detected on our Pt recording sites in vivo.  To do this we 
anesthetized a C57BL/6 mouse with three subcutaneous injections of 12.5% 
urethane for a final dose of 1.25 g/kg.   100 µM H2O2 was added to the glass 
micropipette and locally applied in 30 second intervals in the mouse Str.  Figure 
C.3A shows a trace of the responses to 100 µM H2O2 (25 nl) on the catalase 
coated and inactive protein matrix coated sites.  As shown in figure, local 
application 100 µM H2O2 resulted in robust, reproducible peaks that quickly 
returned to baseline on the BSA/Glut coated sites.  The catalase coated sites 
showed minimal response to additions of H2O2.  Figure C.3B shows the trace 
after subtracting the concentration on the catalase coated sites from the 
concentration on the BSA/Glut coated sites.  This figure also indicates resting 
H2O2 levels in the extracellular space of the mouse Str, which were 
approximately 0.3 µM. 
 Since we observed a small response to H2O2 on the catalase coated sites 
in vivo we wanted to determine if this was due to H2O2 reaching the Pt recording 
sites or if this was due to pressure artifact from locally applying a solution close  
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Figure C.2:  Calibration Trace of a Catalase MEA 
 
A self-referencing catalase coated MEA for detection of H2O2.  The red trace represents a site 
coated with BSA/Glut and catalase while the blue trace represents a site coated with just the 
inactive protein matrix of BSA and Glut.  All four sites of the MEA were electroplated with 5 mM 
mPD prior to calibration.  500 µl of 20 mM AA (final beaker concentration of 250 µM) was first 
added (arrow head) and allowed to come to baseline.  Minimal change in baseline current was 
observed indicating good selectivity of the MEA.  Next, 3 additions of 40 µl of 8.8 mM (final 
beaker concentration of 8.8, 17.6, and 26.4 µM H2O2) were added.  Only the site coated with the 
inactive protein matrix showed a measurable response to H2O2 indicating the effectiveness of 
catalase degrading H2O2 before it could be detected on the Pt recording sites. 
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Figure C.3:  Local Application of 100 µM H2O2 
 
A) Local application of 100 μM H2O2 (25 nl, arrow heads) resulted in robust, reproducible peaks 
compared to baseline on the BSA/Glut (blue) coated sites.  A minimal response on the catalase 
coated site was observed.  B)  The concentration on the catalase coated site was subtracted from 
the concentration on the BSA/Glut coated site to obtain the self-referencing trace.   Baseline 
values indicate resting H2O2 levels, while peak heights indicate maximal amplitude of response. 
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to the MEA.  To do this we performed a series of recordings at two different 
potentials in the mouse Str.  The first series of recordings was taken at an 
applied potential of +0.7 V vs. a Ag/AgCl reference electrode; a potential where 
H2O2 was readily oxidizable.  Next, we dropped the potential to +0.2 V vs. a 
Ag/AgCl reference electrode; a potential where H2O2 was not as readily oxidized. 
Figure C.4 shows the responses on the catalase and BSA/Glut coated sites to 
local application of 100 µM H2O2 at an applied potential of +0.7 and +0.2 V vs. a 
Ag/AgCl reference electrode.  As shown by the graphs, the BSA/Glut coated site 
(figure C.4A) had a robust response to local application of 100 µM H2O2 that was 
attenuated when the potential was dropped to +0.2 V.  The catalase coated sites 
showed a much lower response to local application of 100 µM H2O2 at +0.7 V. 
When the potential was dropped to +0.2 V on the catalase coated sites, there 
was no longer a response, but rather a dilution artifact.  This indicates that the 
catalase was not completely degrading the locally applied H2O2, so a small 
portion was detected on the Pt recording sites.  
  Next, we wanted to determine the linearity of the catalase MEAs 
response to local application of increasing volumes of 100 µM H2O2.  To do this, 
a catalase MEA was positioned in the Str of a Fisher 344 rat and a dose 
response test was performed by increasing the volume of 100 µM H2O2 locally 
applied.  Peak responses were determined from three ejections, in thirty second 
intervals of 25, 50, 75, 125, 175, and 250 nl of 100 µM H2O2.  Figure C.5A shows 
the series of self-referenced recordings from increasing the volume of 100 µM 
H2O2 locally applied adjacent to the catalase MEA.  As shown by the trace, 
increasing the volume led to an increase in peak response.  To quantitate this, 
the three ejections at each volume were averaged as shown in figures C.5B and 
C.5C.  Peak responses were reproducible for each volume as indicated by the 
tight error bars.  Also, we reported an r2 = 0.85 for the six series of volumes 
ejected.  Finally, we noticed that resting H2O2 levels in the Fisher 344 rat Str 
were similar (~ 0.3 µM) to what was observed in the C57BL/6 mouse Str.   
 We wanted to incorporate catalase with our GluOx coated MEAs to 
determine the feasibility of coating multiple enzymes onto a single MEA.  To do  
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Figure C.4:  Potential Change for H2O2 Determination 
 
A.) A BSA/Glut coated site showing a large response to local application of 100 µM H2O2 (arrows) 
at an applied potential of +0.7 V vs a Ag/AgCl reference electrode.   When the potential was 
dropped to +0.2 V, much of the H2O2 was not oxidized resulting in smaller peaks.  The y-axis was 
split in order to see the peak response at +0.2 V   B) A BSA/Glut and catalase coated site 
showing a small response to local application of 100 µM H2O2 at +0.7 V and a dilution effect at 
+0.2 V.  Arrows indicate time points for local application.  
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Figure C.5:  Increasing Volume of Locally Applied 100 µM H2O2 
 
A) A self-referenced trace from local application of 100 μM H2O2 in the Str of Fischer 344 rats.  A 
series of three ejections were performed for each volume ejected (25, 50, 75, 125, 175, and 250 
nl), which are shown above the peaks.  Within each series of volumes, peaks heights were robust 
and reproducible.  Baseline values indicate resting H2O2 levels.   B and C) For each group of 
similar ejection volumes, peak heights were averaged into a single data set and the linear 
regression was determined with a fit of r2 = 0.85. 
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this, we applied 3 layers (as previously described in Chapter 2) of BSA/Glut and 
GluOx onto recording sites 1 and 2.  Next, we applied 3 layers of BSA/Glut and 
Catalase onto recording sites 3 and 4.  This dual enzyme MEA was allowed to 
cure for 72 hours and then mPD was electropolymerized onto all four recording 
sites.  The MEA was then  calibrated as  shown in figure  C.6  and showed  good  
response to additions of Glu on sites 1 and 2, no response to H2O2 on sites 3 and 
4, and no response to interferents such as AA and DA.  
 Our last catalase design included a self-referencing GluOx with a 
BSA/Glut and Catalase mixture placed over top of this layer.  This was an 
experiment to test whether or not catalase could be used to prevent diffusion of 
GluOx generated H2O2 to additional recording sites.  Two different MEAs were 
tested prior to coating to ensure all four sites responded to H2O2.  Sites 1 and 2 
were coated with 3 layers of BSA/Glut and GluOx while sites 3 and 4 were 
coated with just the inactive protein matrix of BSA/Glut.  This was allowed to cure 
for 48 hours.  Next, 3 layers of a mixture of BSA/Glut and catalase was applied 
onto all 4 Pt recording sites and cured for 48 hours.  A second MEA was 
prepared in the similar fashion except only 1 layer of the BSA/Glut and catalase 
mixture was applied on all four sites.  No exclusion layer was applied to either 
MEA.  Calibration consisted of final beaker concentrations of 20, 40, and 60 µM 
Glu and 8.8 and 17.6 µM H2O2.  Both MEAs showed very small responses to Glu 
(< 1 pA/ µM).  The first MEA with 3 layers of catalase showed a smaller response 
to Glu than the second MEA with 1 layer of catalase.  When examining the 
response to H2O2, the first MEA, with 3 coats of catalase, showed no response, 
but the second MEA, with 1 coat of catalase, had a small response (Data not 
shown). 
 Mitochondria were isolated as described above and 50 µg/250 µl was 
placed in a sterile 48 well cell culture plate (Corning Incorporated, Corning, NY) 
filled with 1 mL of respiration buffer.  A waterpad connected to a circulating water 
bath was placed underneath to maintain a 37°C temperature.   A miniature stir 
bar (10 mm X 3 mm) was placed in the well for faster diffusion and was 
controlled by  a  battery  operated  stirrer that  was  placed  underneath the water  
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Figure C.6:  Calibration of a Glutamate Oxidase and Catalase Coated MEA. 
 
This dual enzyme MEA was coated with BSA/Glut and GluOx on sites 1 and 2 (blue trace) and 
BSA/Glut and Catalase on sites 3 and 4 (red trace).  Final beaker concentrations of 250 µM AA; 
20, 40, and 60 µM Glu; 2 µM DA; and 8.8 and 17.6 µM H2O2 were added (arrow heads) for the 
calibration.  A trace from site 1 shows the response to both Glu and H2O2.  A trace from site 3 
shows no response to either Glu or H2O2.  Neither site responded to additions of AA or DA.   The 
MEA was tested prior to enzyme coating to ensure all sites responded to H2O2. 
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pad.  A Ag/AgCl reference electrode and a catalase coated MEA was placed into 
the well and allowed to reach baseline.  10.0 µl of pyruvate malate (PM) was 
added to start the Kreb’s Cycle and buildup the membrane potential.  This was 
allowed to reach baseline for 1 minute and then 5.0 µl of adenosine diphosphate 
(ADP) was added.  This provides the substrate for Complex V and, along with the 
membrane potential, drives the synthesis of ATP.  A byproduct of respiration was 
superoxide, however, addition of ADP did not result in formation of measurable 
levels of H2O2 as shown in figure C.7.  This reaction was allowed to occur for 2 
minutes and then 4.0 µl of oligomycin was added, which blocks Complex V 
thereby stopping respiration. Blocking Complex V allows production of reactive 
oxygen species.  During in vitro calibration of the catalase MEA, Oligomycin was 
added as a test substance and found to be electrochemically active at an applied 
potential of +0.7 V vs a Ag/AgCl reference electrode.  This explains the 
immediate increase in baseline after its addition rather than the formation of 
H2O2.  After 1 minute a new baseline was reached and, 1 µl of Antimycin-A was 
added, which is a Complex III inhibitor.  This prevents electrons from moving 
along the electron transport chain, stops oxygen consumption to water, and 
forms large levels of superoxide.  After addition of Antimycin-A, we observed a 
sustained, elevated increase in H2O2 production (~4 µM) that reached baseline 
after ~8 minutes as shown in figure C.7.  Two separate additions of 4 µl of 
carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) were added once 
H2O2 production had baselined.  FCCP is a chemical uncoupler that translocates 
H+ down its concentration gradient across the inner mitochondrial membrane 
thus shutting down respiration.  Additions of FCCP resulted in a decrease in 
H2O2 concentration that had built up from Antimycin-A (figure C.7). 
 
 Discussion 
 Catalase was successful at blocking H2O2 detection both in vitro and in 
vivo indicating that this enzyme could be used for self-referencing, amperometric 
detection of H2O2.  A pair or recording sites were coated with the BSA/Glut and 
catalase while the other pair of recording sites were coated with just the 
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Figure C.7:  Amperometric Traces of H2O2 Produced from Mitochondria Preparations 
 
A.)A self-referencing catalase MEA was used to measure H2O2 formation (blue trace) due to 
blocking specific complexes of the electron transport chain in mitochondria.  B) The self-
referenced trace of the data shown in A.  ATP synthesis was begun by adding PM and ADP.  
Respiration results in superoxide formation, but this did not cause measurable H2O2 formation.  
Next, oligomycin (O) was added, which was electrochemically active, resulting in the fast increase 
in baseline.  Antimycin-A (Anti) was added and inhibits Complex III thus driving formation of  ~ 4 
µM H2O2.  After ~8 minutes when H2O2 production had reached baseline, two additions of FCCP 
were added and a decrease in H2O2 levels were seen. 
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BSA/Glut mixture.  Without this protein coating, the H2O2 detecting sites would 
respond more quickly to analyte.  Protein layers are necessary on both recording 
sites to minimize difference between the recording properties of the different 
MEA recording sites.  
 In vivo, local application of 100 µM H2O2 (25 nl) resulted in robust, 
reproducible peaks compared to baseline in both the C57BL/6 mouse and a 
Fisher 344 rat.  Local application of 100 µM H2O2 (25 nl) in the mouse Str 
resulted in responses that were ~ 20 µM in peak height while a small (~ 1 µM) 
response was observed on the catalase coated sites.  To determine if this was 
due to pressure artifact or incomplete decomposition of H2O2 by catalase, the 
potential was dropped from +0.7 V to +0.2 V vs a Ag/AgCl reference electrode.  
At an applied potential of +0.2 V, where H2O2 is not as readily oxidized, the 
catalase coated sites showed dilution artifact after local application of 100 µM 
H2O2.  This indicates that the responses seen on the catalase coated site was 
due to incomplete decomposition of H2O2 by catalase.  It should be noted that the 
concentration of H2O2 locally applied adjacent to the recording site was 
significantly larger than the concentration of H2O2 released from the 
mitochondrial preparations.  This helps to justify that the catalase coated MEA 
works well at physiologically relevant concentrations of H2O2 in vivo.   
 Unfortunately, addition of the BSA/Glut and Catalase coating over top of 
the already cured GluOx layer resulted in minimal Glu detection during 
calibration.  When only 1 catalase layer was applied rather than 3, we observed a 
better response to Glu during calibration; however, the catalase was not capable 
of fully degrading the exogenously applied H2O2.  This indicates that the layers of 
GluOx and catalase are too thick thus preventing diffusion of molecules to the Pt 
recording sites.  It should be noted that this experiment was conducted without 
any exclusion layers.  An additional layer of either Nafion® or mPD would likely 
prevent detection of any analyte by the MEA.  This test has pushed the 
laboratory towards other MEA designs with additional Pt recording sites 
positioned among the analyte detecting sites.  These additional sites would be 
raised above the surface of the MEA to act as a physical barrier to prevent 
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diffusion of H2O2 to other recording sites.  Also, a current can be applied to these 
sites to treat them as a H2O2 scrubber, oxidizing the molecule into H2O and ½ O2.  
 With our self-referencing capabilities we were able to examine resting 
levels of extracellular H2O2.  The few studies we conducted in the Str of an 
anesthetized C57BL/6 mouse and Fisher 344 rat indicated that resting H2O2  
were ~0.3-0.4 µM.  This is slightly less than the 1-2 µM resting levels reported 
using microdialysis in the gerbil hippocampus (Lei et al., 1998) as well as the 1-3 
µM levels reported using carbon fiber amperometric microsensors in the Str of 
Sprague-Dawley rats (Kulagina and Michael, 2003).  The levels we reported may 
be lower for several reasons.  First, the damage caused by microdialysis probes 
has been thoroughly discussed already in this thesis (refer to Chapters 1 and 5).  
The damage may produce elevated levels of H2O2 and other reactive oxygen 
species which are known to form due to brain injury.  Also, the fact that the 
microdialysis study was conducted in a different rodent model (gerbil) as well as 
a different brain area may account for the differences.  But, this does not explain 
the differences in resting levels seen with our MEA and a similar dimension 
carbon fiber microsensor.  The carbon fiber microsensor does not have multiple 
recording sites which prevents the removal of interferents from the analyte signal.  
If good exclusion layers were not applied, interferents may account for the 
elevated resting levels of H2O2 observed in this study.   
  Finally, we used the self-referencing catalase MEA to measure H2O2 
formation from mitochondrial preparations in vitro.  In order to induce H2O2 we 
needed to provide substrates (PM and ADP) to start respiration.  Superoxide 
formation is a byproduct of respiration and is used to synthesize H2O2.  
Respiration did not result in measurable levels of H2O2 formation in vitro.  Next, 
we added an inhibitor of Complex V, oligomycin, which stops respiration, thus 
backing up the electron transport chain creating high levels of reactive oxygen 
species.  Oligomycin is electrochemically active, which causes the response 
seen on both sets of recording sites.  The response is much too quick to be 
attributed to the formation of H2O2, therefore blocking Complex V does not 
resulted in detectable levels of H2O2 formation.  We did observe that blocking 
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Complex III with Antimycin-A resulted in steady formation of H2O2 (~4 µM) over 
an 8 minute time period.  Blocking Complex III prevents consumption of O2 so 
none is converted to water.  This leads to formation of high levels of superoxide 
that is shown to be synthesized into H2O2.  FCCP is a chemical uncoupler that 
can carry H+ across the inner mitochondrial membrane, shutting down the 
electron transport chain and thus formation of superoxide.  Additions of this 
resulted in a decrease in the H2O2 already formed from blocking Complex III.  
This phenomenon is difficult to explain since FCCP itself should not induce 
degradation of already formed H2O2, but rather prevent additional formation of 
H2O2.  Prior to additions of FCCP, H2O2 production probably reached baseline, 
because the amount of available substrates may have been fully utilized for 
respiration.  Without available substrates, the electron transport chain would halt.  
Furthermore, adding FCCP would diminish the proton gradient and prevent 
respiration.  With no more superoxide production to generate H2O2, endogenous 
catalase present in mitochondria may begin to degrade the H2O2 formed.  This 
may explain the decrease in H2O2 observed after additions of FCCP.        
 As mentioned in the introduction, we were interested in determining if 
H2O2 was generated in the mitochondria from blocking certain electron transport 
complexes.  Dr. Margaret Rice’s group has data demonstrating that Rotenone, a 
compound that blocks electron transfer from Complex I to ubiquinone, can lead 
to H2O2 formation and release from the mitochondria.  Our laboratory performed 
several studies in vitro with the mitochondrial preparations that were similar to 
those conducted using Antimycin-A.  Substituting Rotenone for Antimycin-A we 
did not observe any H2O2 formation (data not shown).  We did however, 
determine that blocking Complex III causes a large accumulation of H2O2, most 
likely through the generation of superoxide.  We determined that this H2O2 is 
capable of leaving the mitochondria since we detected increased H2O2 levels in 
the respiration buffer using our self-referencing catalase MEA.  Additional studies 
need to be conducted to determine if any of this H2O2 can escape the 
intracellular space in vivo prior to degradation by endogenous catalase as well as 
determine if H2O2 can act as a diffusible neuromodulator. 
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